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The evidence for omega-3 polyunsaturated fatty acids (n-3 PUFA) in fish oil supplements 
being a safe therapeutic agent is steadily growing. However, there is still a lack of evidence 
around the cognitive effects of n-3 PUFAs in older adults with Mild Cognitive Impairment 
(MCI), the moderating effect of the Apolipoprotein E (APOE) ɛ4 allele on cognition and well-
being, and the popularity of fish oil supplements in New Zealand (NZ).  
The primary aim of this thesis was to conduct a clinical trial to investigate the cognitive 
effects of a high dose docosahexaenoic acid (DHA) fish oil supplement in older adults with 
MCI, and to examine how the presence of the APOE ɛ4 allele affects the efficacy of fish oil. 
The trial involved a 12-month randomised, double-blind, placebo-controlled design with 
testing sessions at baseline, 6-months, 9-months and at the end of the trial. Seventy-two 
adults with MCI between the ages of 60 and 90 were recruited from Wellington, NZ. 
Participants were either given a DHA fish oil supplement containing 1491 mg of DHA and 
351 mg of eicosapentaenoic acid (EPA) per day or a placebo supplement containing 
sunflower oil. Outcome measures included the Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS), the National Adult Reading Test (NART), the Coin 
Rotation Task (CRT), the California Older Adult Stroop Test (COAST), the Trail Making Test A 
and B (TMT), Digit Span Backwards Test (DSBT), the Geriatric Depression Scale (GDS), the 
Geriatric Anxiety Inventory (GAI), the 36-Item Short Form Health Survey Questionnaire     
(SF-36), height, weight and blood pressure as well as red blood cell (RBC) fatty acid profiles. 
ANCOVAs, t-tests and chi-square tests were used to test for differences between the DHA 
and placebo groups.  





investigate how popular fish oil supplements are within a sample population of New 
Zealanders, to determine why fish oil supplements are used, what dose fish oil users       
take, and where fish oil users store their supplements. The aim of the survey was to test   
the hypothesis that fish oil users are more likely to display healthier dietary and lifestyle 
habits.  
The final analysis (n = 60) of the trial found no evidence of a treatment effect using the 
cognitive measures, although it did find a treatment effect on systolic blood pressure           
(p = .03, ƞ2 = .08), and a treatment interaction for APOE ɛ4 carriers on depression (p = .04, 
ƞ2= .07) and anxiety (p = .02, ƞ2 = .09) scores in favour of the DHA group. The survey found 
that in a sample of 334 New Zealanders, 66.8% reported using supplements and 21.9% 
reported using fish oil supplements. The survey found that respondents who regularly eat 
oily fish are most likely to take fish oil supplements (p < .01), and that only 26% of fish oil 
users reported taking a dose that would meet dietary recommendations. Over half of fish oil 
users reported taking fish oils to ‘improve brain functioning’ and only 6.8% of fish oil users 
reported storing fish oil supplements in the refrigerator.  
The evidence from epidemiological studies suggests that fish consumption is protective 
against cognitive decline and dementia, and yet the evidence from clinical trials 
investigating the cognitive effects of n-3 PUFAs in older adults has been inconsistent and at 
times conflicting. It appears that the protective effect of fish may be more than the n-3 
PUFA content, and that fish consumption may be part of an overall healthier diet and 
lifestyle, along with regular physical activity, strong social connections and an emphasis on 
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I came to doctoral study after spending 10 years away from academic research. 
During those 10 years, I studied towards a Diploma in Herbal Medicine in an attempt to find 
alternative treatments and solutions to the disorders that I had read so much about during 
my postgraduate study in neuropsychology.  
The other major thing that happened in my life during those 10 years was the 
cognitive decline of my Nana. I was 25 years of age at the time, in the last year of the 
Diploma, and coincidentally had moved in to live with my Aunty around the same time that 
my Nana had. This was the year before she went into a specialised aged-care facility, the last 
year that she was really ever herself. That year we spent hours watching tennis, one of the 
favourite pastimes of her youth, and talking about cooking and her days as a nurse and 
missionary in the Solomon Islands. One day I went into her room to see her still lying in bed. 
She looked very confused and was holding her head as if she had a headache. I asked if she 
was okay and she told me she wasn’t. She asked me to call an ambulance. When the 
ambulance officer came, he asked her a few questions, examined her, and then eventually 
recommended that she go into hospital for a few tests. The team at the hospital found that 
she had had several small strokes – things changed from that moment on. 
After her diagnosis of Vascular dementia, the topic of treatment and medication was 
explored, and my family asked whether there was anything else, any natural supplements 
that could help. During my herbal medicine training, I had learnt about the use of Ginkgo 
biloba as a cognition enhancer with anti-platelet effects to help reduce further strokes. 
Despite a long history of use, I knew that the results from clinical trials with Ginkgo in older 
adults with Alzheimer’s disease were inconsistent – some positive, some negative. If there 





increasing number of pills she had to take each day? The answer turned out to be no. She 
made the decision to move into an aged-care facility that same year, and 3 years later, she 
moved into a specialised dementia unit. She died about a year later.  
Around the time she passed away, I began to read about the link between the n-3 
PUFAs in fish and fish oil supplementation and cognition, both prenatally and in older adults. 
I saw that this was where I could begin my research into a ‘solution’. I approached my 
supervisor and after a literature review realised that somewhere between normal ageing and 
dementia was where fish oil supplementation may have the most beneficial effect. I decided 
that the greatest contribution I could make with my knowledge and skills would be with a 
clinical trial, and so settled on using a randomised, placebo-controlled method to investigate 
the cognitive effects of fish oil supplementation in older adults. 
One of the last things my Nana said to me was “Don’t worry dear, I know who I am 
and I know who the Lord is”. She knew what was happening to her and she also knew what 
was important to her. However, she was vulnerable, and needed caring and trustworthy 
people to ensure her the dignity she deserved. She was exactly what you would want in a 
Nana – patient, caring and with biscuit tins always full. She taught me two very important 
things in my life – how to cook and how to be resilient, although she would have called it 
toughness – a quality that I believe has led me to where I am now. Researching preventive 
measures for severe cognitive decline is only a small part of the work that is needed in the 
area of dementia research, how we care for those who are already affected is also of utmost 






The treatment and prevention of dementia has become one of the most challenging 
issues facing health professionals and researchers today. Alzheimer’s Disease International 
estimated that in 2016 approximately 47 million people worldwide were living with 
dementia, with this number expected to increase to more than 131 million by 2050 (Prince, 
Comas-Herrera, Knapp, Guerchet, & Karagiannidou, 2016). The identification of a 
transitional state between normal age-related cognitive change and dementia, termed Mild 
Cognitive Impairment (MCI), has helped to shed light on the risks and likelihood of 
developing dementia in later years (Petersen et al., 2009). Focusing specifically on older 
adults with MCI provides researchers with an opportunity to investigate the effects of 
lifestyle factors such as diet on cognition at the pre-symptomatic stage of dementia.  
Nutritional research has shown that most older adults are not eating enough fish and 
seafood to reach recommended daily amounts of docosahexaenoic acid (DHA) (Bourre & 
Paquotte, 2008; Cole & Frautschy, 2010) and at the same time epidemiological research has 
shown positive associations between fish consumption and both higher scores in cognitive 
tests (e.g., Dangour et al., 2009) and a slower rate in cognitive decline (e.g., Morris, Evans, 
Tangney, Bienias, & Wilson, 2005). DHA and eicosapentaenoic acid (EPA) are n-3 PUFAs 
found in most types of fish and seafood, although in higher amounts in oily fish such as 
salmon, sardines and mackerel. These two fatty acids are commonly referred to as 
‘conditionally essential fatty acids’ because the human body cannot easily convert the plant-
derived precursor alpha-linolenic acid (ALA) to DHA, and therefore, for most people EPA and 
DHA must be consumed in the diet or taken as a supplement. As well as being important for 





neuronal cell membranes, for neuronal cell signalling, as well as providing a protective 
mechanism against neuro-toxicity (Salem, Litman, Kim, & Gawrisch, 2001).  
The extent to which lifestyle or environmental factors and genetics affect the 
progression from healthy age-related cognitive functioning to dementia remains unclear. 
The interplay between genes and nutrition in the development of dementia provides an 
interesting platform to examine the effects of a particular gene on the efficacy of a specific 
nutrient. The primary aim of this thesis was to address this issue by investigating the effects 
of a high-dose DHA fish oil supplement on cognitive performance and well-being in older 
adults with MCI, and by examining how the presence of the Apolipoprotein E (APOE) ɛ4 
allele affects the efficacy of fish oil. The APOE gene plays an important role in the transport 
of fats and cholesterol within the brain, and the presence of the APOE ɛ4 allele has been 
shown to increase the likelihood of developing Alzheimer’s disease (Barberger-Gateau, 
Samieri, Feart, & Plourde, 2011). There is enormous potential for research into gene-
nutrient interactions to help develop targeted treatments that can prevent the onset of 
dementia. 
The research presented in this thesis examines the link between fish oil 
supplementation, the APOE ɛ4 allele and cognitive performance in older adults using a 
randomised, double-blind, placebo-controlled intervention trial (RDBPC) or randomised 
controlled trial (RCT) – considered the gold standard in clinical studies. Despite the 
increasing popularity and use of complementary medicines, there is still considerable 
scepticism about the therapeutic value and use of these products. This scepticism is largely 
due to a lack of scientific research to back up the efficacy and safety of these products, but 
also a general lack of information about what products and dose are best suited to particular 





without professional advice, and some products are still manufactured outside the good 
manufacturing practices framework, which controls the manufacture and sale of food, drugs 
and pharmaceutical products in New Zealand (NZ).  
Nutritional supplements are increasingly being used by older adults, particularly fish 
oil, vitamin D, glucosamine and coenzyme Q10, as older adults search for alternatives to 
pharmaceutical drug treatments and preventative solutions to age-related conditions such 
as age-related macular degeneration, arthritis and cognitive decline (Conference on Dietary 
Supplement Use in the Elderly, 2004). With this increased use, there is a need to understand 
the pharmacology, toxicology, the benefits vs. harmful aspects of these products, as well as 
quality-related issues like sourcing of the ingredients and contraindications with 
pharmaceutical medications. The secondary aim of this thesis was to conduct an online 
cross-sectional survey to determine what percentage of a sample of New Zealanders use fish 
oil supplements, why people take fish oil supplements, where fish oil supplements are 
stored, the average daily dosage, and to examine what health behaviours are associated 
with fish oil supplement use. The survey was also used to see how willing people were to 
have a blood sample taken as part of a research study to assess this as a part of the 
exclusion criteria for the trial. 
This thesis is divided into 9 chapters. Chapter 1 begins the literature review with an 
explanation of current ageing theories, and then examines the terminology and theories 
used in cognitive ageing from normal cognitive ageing to age-related cognitive decline 
(ARCD), Cognitive impairment no dementia (CIND) and MCI through to dementia. The 
chapter ends with a brief description of the current pharmaceutical treatments available for 
dementia. Chapter 2 reviews the negative and positive risk factors for cognitive decline in 





for cognitive decline and dementia. Chapter 3 examines the chemistry, metabolism and 
pharmacological effects of n-3 PUFAs before reviewing the epidemiological evidence and 
mechanisms for the cognitive effects of EPA and DHA in older adults. A decision was made 
to exclude, as much as possible, clinical trials and reviews, which involved animals or animal 
models. The main reason why researchers are interested in the effects of EPA and DHA is 
that the human body cannot easily produce EPA and DHA, whereas most other animals can 
(Russo, 2009). It is of limited use to involve animals in research to understand human fatty 
acid metabolism, DHA homeostasis and the effects of DHA on cognition when these animals 
can convert these fatty acids while humans cannot, and especially when fish oil 
supplementation has such a good safety record.   
Chapter 4 contains the manuscript of the fish oil supplement survey, which includes 
information about current dietary recommendations for EPA and DHA as well as issues 
related to oxidised fish oil supplements. Chapter 5 reviews the most relevant RCTs that have 
investigated the effects of fish oil supplementation on cognitive performance in cognitively 
healthy older adults, older adults with MCI and older adults with dementia. Chapter 6 
introduces the objectives, research questions, and hypotheses of the current fish oil RCT, 
highlighting areas of design originality and significance. Chapter 7 outlines the method of 
the RCT in detail, in particular, the inclusion and exclusion criteria for participants, screening 
and recruitment, the cognitive and well-being measures and the blood analysis procedures. 
The trial method and a brief literature review were published in a Massey University 
Manawatu Doctoral Research Symposium – Mengelberg, A., Leathem, J., Podd, J., & Conlon, 
C. (2018). Investigating the effects of a DHA fish oil supplement on cognitive performance in 
older adults. Refereed Proceedings of Doing Psychology: Manawatū Doctoral Research 





finally, Chapter 9 discusses the results of both the RCT and survey in terms of the 
implications for the use of fish oil supplements in preventing cognitive decline as well as the 








CHAPTER 1  
 
AGEING AND COGNITION 
 
Chapter 1 begins with a description of current ageing theories, both biological and 
psychological, to understand why some older adults develop severe forms of cognitive 
decline as they age while others do not. The chapter then moves on to examine the 
terminology and theories of cognitive ageing in more depth, from age-related cognitive 
decline to severe forms of cognitive decline such as dementia, including Alzheimer’s disease 
(AD) as well as milder forms such as Mild Cognitive Impairment (MCI) in an attempt to 
understand what stage of cognitive decline may be the best time to intervene with 
preventive strategies. The chapter ends with a brief description of the current 
pharmaceutical treatments available for dementia. 
 
1.1 Ageing theories 
 Several ageing theories have been proposed to help explain the physical and 
biological changes that take place during a person’s lifetime. The first group of theories are 
based on error theory, which holds that ageing is the result of environmentally caused errors 
and damage, which accumulate over the years. The first of these, the wear and tear theory 
proposed by August Weisman in 1886, is based on the idea that the ‘wear’ and ‘tear’ from 





causes ageing (Salvi, Akhtar, & Currie, 2006). Another based on error theory, the free radical 
theory, was introduced by Rebeca Gerschman in 1954 and further developed by Denham 
Herman in 1956. It states that normal physical functioning, such as energy metabolism and 
respiration, results in a series of chain reactions that creates free radicals, causing damage 
to cells (Harman, 1992). The body’s ability to offset the oxidative damage with free radical 
agents and anti-oxidants is reflected in the extent of cellular damage over a lifespan. A third 
error-based theory, the cross-linking theory proposed by Johan Bjorksten in 1942 states that 
ageing is the result of an accumulation of large cross-linked or aggregated molecules 
(tangles) which disrupt vital processes and cause damage to cells (Bjorksten & Tenhu, 1990). 
Lastly, the DNA damage theory proposes that throughout life as DNA is copied and 
replicated within cells, errors occur resulting in mutations and eventually damage to cells 
(Jin, 2010).  
 The next group of ageing theories are based on a biological clock or programmed 
idea, that ageing is a result of programmed changes within genetic material. The first of 
these, the endocrine theory, states that ageing is the result of a reduction in 
neurotransmitter and hormone production such as insulin and thyroid-stimulating hormone, 
which causes dysfunctions in metabolism, sleep, appetite and libido (Meites, Goya, & 
Takahashi, 1987). The immune system theory proposed by Roy Walford in 1964 states that 
ageing is the result of a decline in the function of the immune system, resulting in 
autoimmune reactions, a reduction in the production of anti-bodies and increased levels of 
inflammation (Walford, 1964). The genetic or programmed longevity theories state that 
ageing is due to the stability of genes throughout the lifespan, particularly the switching on 
and off of specific genes (in some people but not others) as well as specific genetic 





divides the telomeres (the cap at the end of each DNA strand) shorten, which causes 
disruptions in homeostatic mechanisms and the lifespan of cells (Olovnikov, 1996). 
 Several psychological theories have been proposed to help explain the changes in 
mental health, emotional well-being and cognition with age. One of the earliest is the 
disengagement theory of ageing proposed by Cumming and Henry in 1961 which states that 
as people age, they withdraw from society due to a reduced capacity, as well as in order for 
the younger generations to move forward (Achenbaum & Bengtson, 1994). In contrast, 
theories such as the activity theory state that active engagement, both physically and 
socially, is what contributes to successful ageing (Havighurst, 1968), and the continuity 
theory, which asserts that older adults usually maintain the same level of activity and 
interaction in later years by using adaption strategies (Atchley, 1989). This ability to adapt 
with age has been the focus of an area of research called ‘positive and successful ageing’. 
The selection, optimization and compensation theory of successful ageing states that older 
adults ‘select’ by identifying relevant goals and prioritising them, ‘optimise’ by choosing 
strategies to successfully achieve goals and ‘compensate’ by adapting to limitations (Baltes, 
1997). In terms of social support, the convoy theory specifies that there are three key 
benefits to social support with age; firstly as ‘aid’ or for instrumental support, secondly as 
‘affect’ or for emotional support, and thirdly as ‘affirmation’ for shared goals and values 
(Antonucci & Akiyama, 1987).                                    
No single ageing theory has been able to explain all of the mechanisms or processes 
involved in ageing. It is most likely that a combination of theories is best at explaining why 
some older adults show signs of ageing earlier or develop cognitive impairments and others 
do not. Several of these ageing theories have now been supported by research, for example 





shorten) with cell division, and some studies have reported that inheriting shorter telomeres 
is associated with an increased risk of coronary artery disease (e.g., Brouilette et al., 2008). 
Understanding the role and importance of social support with age is also gaining momentum 
with recent research showing a strong link between loneliness and impaired cognition (e.g., 
Wilson et al., 2007; O’luanaigh et al., 2012). The role of oxidative stress and inflammation in 
the pathology of cognitive decline in ageing is not fully understood, although there is 
support for the role of oxidative damage, including increased free radical production and 
increased lipid peroxidation, in AD pathology (Floyd & Hensley, 2002). The role of genetics in 
cognitive decline, especially in early-onset AD, is firmly established, whereas the central 
etiological hypothesis for late-onset AD is for a genetic and environmental interaction 
(Barberger-Gateau et al., 2011).  
 
1.2 Normal ageing, the brain and cognition 
The term ‘normal ageing’ refers to patterns of cognitive change, which are commonly 
found in human ageing (Atchley, 1989). ‘Cognitive ageing’, ‘age-related cognitive change’ 
and ‘age-related cognitive decline’ (ARCD) all refer to the cognitive changes which take place 
with ageing. ARCD begins as early as in the 20s, particularly in processing speed, reasoning 
and spatial orientation (Salthouse, 2009). However, the focus here will be on the structural, 
functional and cognitive changes associated with ageing from midlife onwards. In order to 
investigate the relationship between neuroanatomical and cognitive changes with age, 
researchers have used structural and functional magnetic resonance imaging (fMRI) and 
positron emission tomography (PET), often by comparing young to older adults and by using 





structural changes cause the age-related cognitive changes is not clear, although several 
clear age-related trends have been identified (Kennedy & Raz, 2009).  
The first age-related change in the brain is the slowdown in neurotransmitter 
production and transportation, and the reduction in receptor sensitivity, particularly with 
the neurotransmitter acetylcholine and the choline receptors (Perry, 1980). Levels of 
dopamine and serotonin transportation also decrease with age, affecting cognition and 
emotional well-being (Kuikka et al., 2001; Karrer et al., 2017). Secondly, there are several 
significant structural changes in the brain. These include a shrinkage of overall brain volume 
(due to the shrinking volume of neurons), changes to white matter fibres (reduced 
myelinated axon length), and changes in regions such as temporal lobe, particularly to the 
hippocampus which can cause memory impairments and a decline in visuospatial abilities 
(Fjell & Walhovd, 2010). The hippocampus, a subcortical structure within the medial 
temporal lobe, primarily involved in the consolidation of short-term to long-term memory 
and in spatial awareness and emotion, decreases in size in normal ageing but significantly 
more so in those with dementia. The hippocampus has been shown to be vulnerable to 
internal and external influences such as levels of cortisol and inflammatory mediators, 
exercise, sleep and alcohol (Fotuhi, Do, & Jack, 2012). Changes to white matter (axons and 
glial cells) and the callosal fibres affect the connections between regions of the brain, which 
can impair the ability to function in everyday activities. As well as deficits in memory, 
particularly in episodic and spatial memory, and processing speed, there is also a decline in 
parts of executive functioning with increasing age.               
Several types of cognitive theories have been proposed to help explain these age-
related cognitive changes. Attention and processing speed theories propose that the 





underlines the deficits found in cognition functioning in the later years (Salthouse, 1996). 
Support for the processing speed theory is based on the finding that measures of processing 
speed share approximately 75% of the age-related variance with other cognitive measures 
such as memory including working memory (Salthouse, 1996; 2000). Executive function 
theories propose that components of executive functioning such as attention, inhibition and 
the role of the frontal lobe in control, coordination and compensatory mechanisms, help 
explain age-related cognitive decline (e.g., Phillips & Henry, 2008). Attention and processing 
resource capacity theories suggest that cognitive decline is due to attention deficits as a 
result of limited processing resources, whereas inhibition theories suggest that deficits in 
the ability to inhibit information increase with age resulting in forgetfulness and 
distractibility (Craik & Byrd, 1982; Hasher & Zacks, 1988). Structural and functional changes 
within the frontal lobes with increasing age have been used to explain the lower 
performance of older compared to younger adults in cognitive tasks requiring control, 
coordination, integration and goal maintenance (West, 1996).  
Support for executive functioning-based theories alone is limited, although when 
combined as a multivariate approach with processing speed theories and temporal lobe-
based memory deficits, they have been able to account for a larger percentage of age-
related variance in cognition (Albinet, Boucard, Bouquet, & Audiffren, 2012). The idea that 
multiple approaches, factors or regions contribute to age-related cognitive change forms the 
basis of compensatory theories. One such compensatory theory is the scaffolding theory of 
ageing and cognition, which states that the brain can compensate for the deterioration in 
certain areas by recruiting from brain regions that are still intact (Reuter-Lorenz & Park, 
2014). This theory is based on the idea that the changing brain is seeking a state of 





by developing new alternative connections. In a verbal vs. spatial working memory task 
using PET, young adults were shown to use predominantly the left hemisphere for the verbal 
task and the right hemisphere for the spatial task, whereas older adults were shown to 
engage both regions during both types of tasks (Reuter-Lorenz et al., 2000). The ability to 
utilise multiple regions of the brain, while younger adults typically use one or two to 
complete the same task, and to utilise the same brain regions but in different ways, also 
helps to explain why older adults typically perform better at complex tasks requiring diverse 
perspectives or contradictory information (e.g., Cabeza, Anderson, Locantore, & McIntosh, 
2002; Stern et al., 2005; Spreng, Wojtowicz, & Grady, 2010).  
 As well as structural changes within the brain, several normal age-related changes 
outside of the brain have been shown to have secondary effects on cognition. With age the 
heart muscle begins to thicken, and arteries begin to stiffen and narrow, thereby reducing 
the pumping rate and increasing blood pressure. This can result in a reduction in blood flow 
to the brain, and if combined with low clotting factors, can cause severe blockages in 
cerebral arteries, resulting in a stroke (Breteler et al., 1994). Depending on the level of 
severity and where in the brain the blockage occurs, the aftereffects can be a physical or 
cognitive weakness, a loss of sensation, difficulty speaking, talking and walking; and these 
effects can be either short or long-term. Having high systolic blood pressure, a high body 
mass index (BMI) and smoking cigarettes are risk factors for a stroke, which highlights the 
link between lifestyle choices and brain health (Asplund et al., 2009). Muscle tone and bone 
density also reduce with age, resulting in decreased mobility, an increase in the incidence of 
falls and a reduction in exercise, which impacts on well-being and cognitive health (Daley & 
Spinks, 2000). Changes to sensory systems also occur with age, particularly to vision and 





social interaction and independence (Lin et al., 2004). Further, having multiple chronic 
conditions or multi-morbidity together with the use of multiple pharmaceutical treatments, 
is increasingly common with older age, and can significantly affect cognition and quality of 
life.  
 
1.3 Severe cognitive decline and dementia  
Dementia is the syndrome most associated with a state of severe cognitive decline. 
The term dementia is used to describe a group of conditions that involve a cognitive deficit, 
usually in memory plus at least one other cognitive domain such as language, along with 
personality and sensory changes (Winblad et al., 2016). Dementia is characterised by a level 
of cognitive decline that significantly changes or interferes with a person’s ability to perform 
everyday activities (Blennow, Leon, & Zetterberg, 2006). In 2016 approximately 62,000 New 
Zealanders had a form of dementia, with a global figure of approximately 47 million set to 
reach 131 million by 2050 (Alzheimers New Zealand, 2016; Prince et al., 2016). These figures 
highlight the urgent need to understand the pathological mechanisms underlying dementia 
to develop preventative and treatment measures.  
Alzheimer’s disease (AD) is the most common cause of dementia and accounts for 
approximately 60% of all dementia cases (Winblad et al., 2016). Vascular dementia (VD), the 
second most common cause, is due to a series of strokes as a result of a blockage or the 
bursting of cerebral blood vessels (van der Flier & Scheltens, 2005). The other main causes 
and subtypes of dementia include dementia with Lewy bodies (DLB) which includes 
Parkinson’s disease dementia, Huntington’s disease (HD) and Fronto-temporal dementia 
(FTD) also known as Pick’s disease or frontal lobe dementia. The initial cognitive 





recall, with poor retrieval on recognition tests, followed by general knowledge amnesia and 
aphasia with poor category and verbal letter fluency (Salmon & Bondi, 2009). In comparison, 
the initial cognitive deficits seen in VD are in executive functioning and episodic memory. In 
DLB the impairment is in learning new information rather than in retention and recognition, 
in HD the deficit is in general retrieval and attention, and in FTD it is less of a memory deficit, 
more so a deficit in verbal fluency particularly for letter fluency alongside major personality 
and behavioural changes (Salmon & Bondi, 2009).  
Because AD is the most common cause of dementia, it has been the most intensively 
studied in terms of pathology, and causal and modifying factors. The pathology of AD 
involves the development of neurofibrillary tangles made up of hyper-phosphorylated tau 
on the microtubules of axons, and the development of senile or neuritic plaques made of 
amyloid β protein fragments between neurons (Blennow et al., 2006). Both tau and amyloid 
β are intrinsic to the brain – tau is a normal axonal protein and amyloid β is produced during 
normal cell metabolism; however, malfunctions in tau and amyloid β cause severe neuronal 
degeneration (Himmelstein, Ward, Lancia, Patterson, & Binder, 2012). The tangles from the 
hyper-phosphorylation of tau impair nutrient transport and axonal function, and the 
imbalance between the production and clearance of amyloid β causes plaques to form, 
which blocks synapse signals and causes an immune response that triggers inflammation 
(Kim & Tsai, 2009). The tangles and plaques cause disruptions in cell-to-cell communication, 
which eventually results in neuronal atrophy or neuron cell death (Blennow et al., 2006). 
This neuronal atrophy initially affects the medial temporal lobe and the hippocampus, and 
then eventually the cortical areas; this leads to a loss in functional connectivity, which 
impairs interaction between regions and systems of the brain (Salmon & Bondi, 2009).  





These include a genetic susceptibility, vascular and cardiovascular risk factors (including 
cholesterol homeostasis), lifestyle factors during midlife, and a disruption to inflammatory 
and oxidative processes (Lin, Chiu, Huang, & Su, 2012). In early-onset forms of AD, when 
pathology develops by middle age, genetic mutations account for the majority of cases 
(Prince, 2007). In contrast, late-onset sporadic AD appears to have a multifactorial etiology 
with the exact causes unknown, but most likely, is due to a combination of ageing processes 
with genetic and environmental or lifestyle factors (Winblad et al., 2016). For example, a 
large health and ageing study based in Canada involving 740 older adults over the age of 65 
found that the highest prevalence and incidence of dementia was in those who had a stroke 
and who were carriers of the APOE ɛ4 allele (Jin, Østbye, Feightner, Legge, & Hachinski, 
2008). The authors note that the effect of having a stroke was unmodified by APOE status, 
therefore implying that the two factors led to dementia byway of different mechanisms. 
The pathology and neurodegeneration behind dementia is estimated to start 
between 10 to 20 years before any clinical symptoms appear (van der Flier & Scheltens, 
2005; Dubois et al., 2016) and is termed the preclinical phase (Hubbard, Fenton, & 
Anderson, 1990). During this phase, damage caused by the disease process is thought to 
take place until a certain threshold is reached (such as a loss of a critical volume of neurons) 
and the first symptoms appear (Blennow et al., 2006). The ability to detect whether 
someone is in the preclinical stage of dementia using biological markers and with 
neuropsychological assessment has been the focus of extensive research (e.g., Elias et al., 
2000; Jack Jr et al., 2013). Researching the pathological processes involved during this 
preclinical phase has provided a deeper understanding of how cognition declines with age, 





processes has presented a significant challenge within cognitive ageing research (Fjell & 
Walhovd, 2010). 
In addition to the preclinical phase, several other stages have been identified in the 
progression from ‘normal cognition’ to dementia. Two 7-stage systems called the Global 
Deterioration scale and the Functional Assessment Staging (FAST) were developed by 
Reisberg in 1982 and 1988 to describe the stages of dementia and AD (Sclan & Reisberg, 
1992). Stage 1 is classified as ‘no impairment’ or ‘no cognitive decline’ where no detectable 
signs or symptoms of dementia or AD are evident, stage 2 as ‘very mild cognitive decline’ 
where minor subjective memory complaints are present, but with no detectable changes on 
cognitive tests or by family. Stage 3 is classified as ‘mild cognitive decline’ where friends and 
family start to notice memory and cognitive lapses, particularly with remembering names of 
newly met people and finding the right word. Stage 4 as ‘moderate cognitive decline’ where 
clear AD symptoms are present such as poor short-term memory like forgetting what the 
person had for breakfast. Stage 5 is classified as ‘moderately severe cognitive decline’ where 
the person begins to experience confusion and needs help with everyday activities. Stage 6 
is classified as ‘severe decline’ where there are personality changes, ‘problematic’ behaviour 
problems such as wandering, and when the person can no longer remember their own 
personal history. Stage 7 is ‘very severe cognitive decline’ where the person has lost the 
ability to communicate and respond to their environment, and has lost insight into their 
condition. Exactly what factors explain why a person moves from one stage to another, and 






1.4 Mild forms of cognitive impairment 
The need for an identifiable state of cognitive change or decline between normal 
ageing and dementia resulted in the development of several terms (along with diagnostic 
criteria) including Questionable Dementia (QD) based on a score of 0.5 on the Clinical 
Dementia Rating scale (CDR; Hughes, Berg, Danziger, Coben, & Martin, 1982), Age-
Associated Cognitive Decline (AACD; Levy, 1994), Mild Neurocognitive Disorder from the 
DSM-IV (APA, 1994), Cognitive impairment with no dementia (CIND; Ebly, Hogan, & Parhad, 
1995), Mild Cognitive Impairment (MCI; Flicker, Ferris, & Reisberg, 1991; Smith et al., 1996) 
and Minor Neurocognitive Disorder from the DSM-V (APA, 2013). MCI is the term most 
widely used to describe this intermediate cognitive state, and is the term that will be used in 
this thesis.  
The term MCI evolved to describe an older adult who scored 3 or had reached stage 
3 on the Global Deterioration Scale and FAST 7-stage systems (Sclan & Reisberg, 1992). 
Stage 3 in these systems specifies a level of mild cognitive decline when the earliest signs of 
a cognitive deficit appear. The term MCI was then adopted by Petersen and colleagues in 
1999 to outline criteria for the diagnosis of MCI. These criteria specified a diagnosis of MCI 
as the presence of a memory complaint, a normal ability to carry out activities of daily living, 
normal general cognitive function, but abnormal memory for age, and not demented. The 
definition of MCI was then further expanded to include selective impairments in cognitive 
domains other than memory, the differentiation between amnestic MCI (primarily a 
memory dysfunction) and non-amnestic MCI (primarily a language, attention, spatial and/or 
executive dysfunction) as well as the classification of single and multiple domains subtypes 
to correspond with the different dementia types and etiologies (Petersen, 2004; Petersen, & 





Table 1. Criteria for Mild Cognitive Impairment from Petersen (2004) and Albert et al. (2011) 
 
 
1.  Presence of a memory or cognitive complaint 
2.  An objective impairment in at least one cognitive domain 
3.  Preserved general cognitive function 
4.  A preserved ability to carry out everyday activities 
5.  No dementia 
 
Table 1 outlines the most common components of current MCI criteria. In terms of 
point 1, more recent criteria have emphasised that there needs to be a level of concern in 
regards to the recent cognitive complaint or change from the individual, which is then 
confirmed by a family member or friend (Albert et al., 2011). Point 2 has been quantified to 
be assessed as a score or scores on cognitive tests of between 1 to 1.5 standard deviations 
(SD) below the mean for age, to be used as a guideline but not necessarily as a cut-off 
(Albert et al., 2011). Point 3 is the point most likely omitted from an MCI criterion. In 2004 
Petersen added the term ‘relatively’ to ‘preserved general cognitive function’ for age, which 
reflects the ongoing problem with differentiating a ‘mild’ from a ‘very mild’ cognitive 
impairment. Other MCI criteria have stressed the need to rule out other trauma, medical 
conditions and brain diseases that could explain the cognitive decline such as a head injury 
or stroke, as well as the inclusion of diagnostic biomarkers such as cerebrospinal fluid (CSF) 
levels of amyloid β 1 (Albert et al., 2011; Petersen et al., 2018). 
The amendments made to the MCI criteria over time are the result of how MCI has 
been conceptualised and re-conceptualised over the years (Petersen et al., 2018). MCI has 
been described as the transitional stage between normal ageing and dementia, as a 





of dementia appear, as a stage distinct from the preclinical phase, as a risk factor (not a 
state or condition) of dementia, and as a benign form of the normal ageing process (e.g., 
Flicker, Ferris, & Reisberg, 1991; Tuokko & Frerichs, 2000; Ganguli et al., 2004; Albert & 
Blacker, 2006; Gauthier et al., 2006; Fischer et al., 2007; Petersen et al., 2009). The issues 
and controversy surrounding MCI are primarily the result of the criteria being implemented 
in different ways in clinical vs. research settings, and in part, due the wide range of symptom 
severity, etiologies and trajectories (Albert & Blacker, 2006; Petersen et al., 2009; Stephan et 
al., 2013). To increase the diagnostic reliability and validity of MCI, further variations have 
been proposed including ‘MCI due to AD’ along with levels of certainty (e.g., intermediate 
likelihood, high likelihood or unlikely due to AD), based on the presence or absence of 
certain biomarkers (Albert et al., 2011). Whether any of these variations have resulted in a 
clearer definition, criteria or improved predictive power is unclear. 
The concept of MCI as the earliest detectable stage of a clinical impairment has 
remained and as a research entity, has been utilised to estimate conversion rates from MCI 
to dementia, to predict clinical outcomes and to investigate risk factors and possible 
preventative treatments for dementia (Winblad et al., 2004). Research indicates that 
individuals who receive a diagnosis of MCI are at an increased risk for developing dementia 
(Petersen et al., 1999), although annual conversion rates vary from as little as 1 to 3% (Fisk, 
Merry, & Rockwood, 2003) 5 to 10% (Mitchell & Shiri‐Feshki, 2009) between 10 to 15% 
(Ganguli et al., 2004; Petersen et al., 2018) and up to 26.8% in non-amnesic MCI and 48.7% 
in amnestic MCI (Fischer et al., 2007). The variability appears to be somewhat based on the 
type of sample, for example, Farias et al. (2009) found an annual conversion rate of 3% for a 
community based sample (community health care facilities, senior and church groups), yet a 





that conversion rates varied from 9 to 42% depending on whether a 1 or 1.5 SD cut-off 
criteria was used for assessing the cognitive impairment. Studies have also differed in the 
number of older adults with MCI who improve to a normal status, from 15 to 44% (Fisk et 
al., 2003), 20% (Busse, Bischkopf, Riedel-Heller, & Angermeyer, 2003) and from 33 to 55% 
who no longer had MCI (Ganguli et al., 2004).  
Assessing the cognitive impairment component of MCI has been problematic for 
researchers both in terms of identifying the most sensitive cognitive measures and the most 
appropriate cut-off point. There is increasing evidence to support the idea that measuring 
memory deficits alone is insufficient, whereas measuring memory deficits alongside 
secondary or non-memory deficits, especially in attention, processing speed and executive 
functioning are more predictive of cognitive decline (Traykov et al., 2007; Saunders & 
Summers, 2011). The cognitive tests shown to be best at discriminating between MCI, AD 
and cognitively healthy older adults are a combination of a word list delayed recall test with 
Trail Making Test B (Chen et al., 2000), immediate and delayed free recall in combination 
with the Stroop Test (Traykov et al., 2007), and error scores particularly in executive 
functioning based tasks like the Tower of London (Rainville, Lepage, Gauthier, Kergoat, & 
Belleville, 2012), and the incongruent component of the Stroop Test (Bélanger, Belleville, & 
Gauthier, 2010).   
The cut-off point for the cognitive deficit is also an important factor, with studies 
showing that a cut-off of 1 SD results in higher sensitivity but lower specificity, while a cut-
off of 1.5 SDs results in the opposite (Busse, Bischkopf, Riedel-Heller, & Angermeyer, 2003). 
Most cognitive tasks and therefore cut-off points are assessed according to age norms, 
whereas it has been suggested that education norms or educational background are just as 





MCI research, as scores within the `normal' range could mask a decline from the individual’s 
pre-morbid ability.  The inclusion of pre-morbid functioning measures such as the National 
Adult Reading Test (NART) allows the clinican or researcher to determine whether scores on 
cognitive tasks represent a decline from the premorbid level of functioning (Ahl et al., 2013). 
Whether the cognitive deficit is in a memory or a non-memory task, and whether the 
impairment is in one or at least two tasks or domains are also decisions that need to be 
made. Considering there is currently no set way to operationalise MCI and with the many 
variations of MCI criteria and cognitive tasks used in research, particularly in clinical trials, 
comparing the results from trials can be very challenging.   
 
1.5 Current treatments for dementia 
There are four main types of pharmaceutical medications used in older adults with 
moderate to severe cognitive decline. These include symptomatic treatments, AD modifying 
treatments, anti-inflammatory treatments and cholesterol lowering treatments.  
Symptomatic treatments help provide symptomatic improvement in older adults 
with dementia at both a behavioural and cognitive level, but do not significantly alter the 
pathology or the course of the disease. The first type of symptomatic treatment involves 
acetylcholinesterase inhibitors including Donepezil or Aricept, Rivastigmine, and 
Galantamine. Acetylcholinesterase inhibitors are used to increase the availability of 
acetylcholine and enhance cholinergic neurotransmission due to the degeneration of 
cholinergic neurons in AD (Blennow et al., 2006). Clinical trials have shown that these drugs 
can improve cognition by a mean of 1.4 points on the Mini-Mental State Examination 
(MMSE), although gastrointestinal side effects such as diarrhoea, nausea and vomiting are 





cholinesterase inhibitors were not associated with any delay in the onset of AD when used 
by older adults with MCI (Raschetti, Albanese, Vanacore, & Maggini, 2007).  
The second type of symptomatic treatment is a drug called Memantine, an N-methyl-
D aspartate receptor antagonist. Memantine acts by protecting neurons from glutamate 
mediated excitotoxicity, and appears to be well tolerated with few adverse effects (Blennow 
et al., 2006). Clinical trials have shown that Memantine provides positive effects on both 
behavioural and cognitive symptoms in older adults with moderate to severe forms of AD, 
but not in early stages or milder forms. Benzodiazepines, anti-psychotic and anticonvulsant 
drugs are also used to help with anxiety, agitation and psychosis both in the early and late 
stages of dementia (Kozman, Wattis, & Curran, 2006). 
Drugs which hold hope in modifying the pathology behind the disease have so far 
been tested using ‘knockout mice’ and are still in the early stages of development. These 
drugs have been developed to help alter the pathology of AD with secretase modulators to 
reduce amyloid β concentration in the brain, with amyloid β antibodies to reduce 
deposition, with amyloid β fibrillation inhibitors to reduce amyloid β plaque changes and 
with anti-tau drugs to reduce tau phosphorylation – all so far with very limited results 
(Blennow et al., 2006). Anti-inflammatory medications including both steroidal, like as 
prednisone, and nonsteroidal anti-inflammatory (NSAID), such as the COX-2 inhibitor 
celecoxib, have been tested in clinical trials with AD but with disappointing results. Anti-
inflammatory drugs are used to reduce excess or prolonged inflammation within the brain, 
which is thought to worsen neuronal damage and loss through pathological mechanisms 
including excitotoxicity and oxidative stress (In'T Veld, Launer, Breteler, Stricker, & Hofman, 
2002; Crupi, Marino, & Cuzzocrea, 2013). The large Rotterdam study involving almost 7,000 





Veld et al., 2001). The study found that long-term (24 months or longer) use of NSAIDs, but 
not aspirin use, was associated with a reduction in risk for AD but not VD. The authors 
suggest that there may be a critical period approximately two years before the onset of 
dementia where anti-inflammatory agents may be helpful, but less so after the symptomatic 
threshold has been passed. Cholesterol-lowering medications, specifically statins, have 
shown some promise. The use of statins is based on the associations drawn between high 
cholesterol levels, cardiovascular disease and vascular dementia, as well as the link between 
cholesterol and amyloid β production (Launer et al., 2002).  
 
1.6 Summary 
Whether or not a single risk factor dictates the development of MCI and AD 
pathology, whether vascular and metabolic processes cause the pathology to pass a 
‘dementia threshold’, and exactly how genetics and environmental, lifestyle and 
psychosocial factors interact to contribute to the progression of the disease is unknown 
(Blennow et al., 2006). What is known for sure though, is that AD is a progressive, insidious, 
age-related disease and “there is an urgent need to find prevention approaches that are 
safe, effective and affordable” (Cole & Frautschy, 2010, p. 869). Given that there are limited 
treatment options available, prevention strategies should start well before or at least at the 
preclinical phase of cognitive decline such as MCI. In 2009, Petersen et al. stated in 
reference to MCI and AD that “if a disease modifying therapy or effective lifestyle 
intervention were available, one would want to intervene as soon as possible” (p. 1447). 
Identifying and understanding the negative and positive risk factors for cognitive decline and 
dementia, and then conducting RCTs with older adults with MCI could be the best way 







CHAPTER 2  
 
RISK FACTORS FOR COGNITIVE DECLINE 
 
Chapter 2 will review the major risk factors associated with cognitive decline in older 
adults in order to understand how important diet and nutrition are in preventing cognitive 
decline and dementia. 
 
2.1 Risk factors 
 The risk factors associated with cognitive decline, specifically with MCI and AD, can 
be divided into three categories; those that are non-modifiable such as age and genetics, 
those that are modifiable such as smoking and physical inactivity, and those that are 
protective such as diet. Risk factors are also classified as negative (increases risk) and 
positive or protective (reduces risk). Here ‘positive’ and ‘protective’ both refer to factors 
which reduce risk, whereas in the abovementioned, ‘protective’ refers to risk factors which 
currently have very little (but increasingly growing evidence) to support their modifying 
effect. Much of the evidence for these risk factors comes from prospective, population-
based, epidemiological and longitudinal studies, as well as systematic reviews and meta-







2.2   Non-modifiable risk factors 
Age is the single biggest non-modifiable risk factor for cognitive decline, MCI and 
late-onset AD (Dubois et al., 2016). The prevalence of dementia is approximately 1% in older 
adults between 60 and 64 years of age, whereas it is between 24 to 33% in older adults over 
the age of 85 (Blennow et al., 2006). The incidence of AD doubles in rate with every five 
years of life (Plassman et al., 2010). Age is also a significant risk factor for MCI, with 
prevalence rates for MCI of 6.7% for 60 to 64 years olds, 8.4% for 65 to 69 year olds, 10.1% 
for 70 to 74 year olds, 14.8% for 75 to 79 year olds and 25.2% for 80 to 84 year olds 
(Petersen et al., 2018). The number of older adults with dementia will continue to increase 
with the world’s ageing population. 
The second non-modifiable risk factor for cognitive decline, particularly for AD, is 
genetics. Mutations in the genes for amyloid β precursor proteins, presenilin 1 and 
presenilin 2 account for approximately 40% of early-onset AD, whereas a variant of the 
Apolipoprotein E (APOE) gene, APOE ɛ4, has been identified as the primary genetic risk 
factor for sporadic late-onset AD (Farrer et al., 1997; Puglielli, Tanzi, & Kovacs, 2003; Coon et 
al., 2007; Barberger-Gateau et al., 2011). The APOE gene is a glycoprotein, a protein 
attached to a sugar molecule, made up of 299 amino acids on chromosome 19 (Kim, Basak, 
& Holtzman, 2009). The APOE gene is expressed mainly in the liver and the brain, mostly in 
astrocytes and microglia, and to a lesser extent in neurons (Kim et al., 2009). One of the 
main roles of APOE is as a ligand or a binding molecule to receptors on lipoproteins. 
Lipoproteins are protein complexes that allow the body to transport hydrophilic substances, 
such as fats and lipids, within water-based fluids like blood. There are five main types of 
lipoproteins – high-density lipoproteins (HDL), intermediate-density lipoproteins (IDL), low-





lipoproteins (ULDL) (Mora et al., 2007). HDL is often referred to as a ‘good’ lipoprotein 
because it transports fats and cholesterol from the cells back to the liver, whereas LDL is 
‘bad’ as it transports fats and cholesterol from the liver to cells, and has been implicated in 
depositing fats and cholesterol within atherosclerosis plaques (Mora et al., 2007).  
One of the roles of APOE is to help transport and clear LDL, VLDL and ULDL from 
circulation by acting via receptors on the liver and peripheral cells (Thakkinstian, Bowe, 
McEvoy, Smith, & Attia, 2006). Within the brain, APOE is the main carrier of cholesterol to 
neurons, and plays a role in stabilising the structure of lipoproteins as well as repairing and 
maintaining neuronal cell membranes (Puglielli et al., 2003; Thakkinstian et al., 2006). There 
are three alleles or variants of the APOE gene labelled as APOE ɛ2, APOE ɛ3 and APOE ɛ4. 
Humans carry two APOE alleles; one allele has been passed on from each parent. Individuals 
can be homozygous (carry two of the same alleles) or heterozygous (carry two different 
alleles) for the APOE gene, resulting in six variants or genotypes – ɛ2/ɛ2, ɛ2/ɛ3, ɛ2/ɛ4, ɛ3/ ɛ3, 
ɛ3/ɛ4 and ɛ4/ɛ4 (Barberger-Gateau et al., 2011). The most common variant is ɛ3, which is 
carried by approximately 75% of Caucasians, followed by ɛ4 which is carried by 
approximately 15% of Caucasians and ɛ2 by approximately 10% (St George-Hyslop, 2000). 
Approximately 0.9% of Caucasians carry ɛ2/ɛ2, 12% carry ɛ2/ɛ3, 60.6% carry ɛ3/ɛ3, 2.1% 
carry ɛ2/ɛ4, 22.4% carry ɛ3/ɛ4 and 2% carry ɛ4/ɛ4 (Alzheimer Research Forum, 2010). 
Research has shown variations in the prevalence of APOE allele carriers within different 
ethnic groups. For example, a meta-analysis by Thakkinstian et al. (2006) found no 
difference between Caucasians and Asians in the prevalence of ɛ2 carriers, but a higher 
prevalence of ɛ4 carriers in Caucasians than in Asian populations.  
Farrer et al. (1997) computed odds ratios (OR) for risk of AD in Caucasians according 





significant increase in risk for AD in the three ɛ4 genotypes, ɛ2/ɛ4 (OR = 2.6), ɛ3/ɛ4 (OR = 
3.2) and ɛ4/ɛ4 (OR = 14.9), as well as a significant decrease in risk for ɛ2/ɛ2 (OR = 0.6) and 
ɛ2/ɛ3 (OR = 0.6) compared to ɛ3/ɛ3 carriers. Results from this study and several others 
indicate that carrying one ɛ4 allele results in a 2 to 3-fold increased risk for developing AD, 
whereas carrying two ɛ4 allele results in a 12 to 15-fold increased risk in developing AD 
compared to carrying two ɛ3 alleles (Coon et al., 2007; Barberger-Gateau et al., 2011). The 
relationship between the APOE ɛ4 allele and the onset of AD appears to be dose-dependent, 
in that homozygous ɛ4 carriers (ɛ4/ ɛ4) tend to develop AD before 70 years of age, whereas 
heterozygous carriers develop AD later than 70 (St George-Hyslop, 2000). Carrying ɛ2 has 
been shown to have a protective role on cognition, and if carriers of ɛ2 develop AD, it tends 
to be after 90 years of age. For example, in 85 older adults over the age of 90, ɛ2 carriers 
were found to be less likely to be diagnosed with dementia but along with ɛ4 carriers to be 
more likely to meet the neuro-pathological criteria for AD than ɛ3 carriers (Berlau, Corrada, 
Head, & Kawas, 2009). These authors suggest that ɛ2 may contribute to maintaining healthy 
cognition in the oldest old independently of AD pathology.  
Several mechanisms have been proposed to explain the roles that APOE and the ɛ2, 
ɛ3 and ɛ4 alleles play within the brain. Research shows that plasma APOE levels decrease as 
a function of the progression from normal cognition through to MCI and AD (Soares et al. 
2012) and that ɛ4 carriers have lower APOE levels in the blood, brain and CSF than ɛ2 and ɛ3 
(Poirier et al., 2014). APOE is the main carrier of cholesterol within the brain and plays an 
important role in cholesterol homeostasis. A large study of 1089 men aged between 65 and 
84 found that APOE status was associated with serum total and LDL cholesterol levels, 
specifically that the genotypes ɛ2/ɛ2, ɛ2/ɛ3, ɛ2/ɛ4, ɛ3/ ɛ3, ɛ3/ɛ4 and ɛ4/ɛ4 were associated 





Research also indicates that ɛ4 binds more readily to amyloid β peptide than ɛ2, that 
amyloid β deposition may start earlier in ɛ4 carriers than non-ɛ4 carriers and that ɛ2 may be 
more effective at clearing soluble amyloid than ɛ4 (St George-Hyslop, 2000; Kim et al., 2009). 
Berlau et al. (2009) suggested that ɛ2 might provide a protective effect by maintaining 
synaptic integrity via higher levels of synaptophysin in the frontal cortex and by modifying 
the formation of tangles based on the finding that ɛ2 carriers had increased plaque but not 
tangle pathology. Drzezga et al. (2009) found that ɛ4 carriers had significantly higher amyloid 
β deposits particularly in the left temporal lobe, but also in both hemispheres in the 
temporoparietal and pre-frontal regions, than non-ɛ4 carriers.   
A large meta-analysis that included 77 studies involving 40,942 cognitively healthy 
older adults found that ɛ4 carriers performed significantly worse on measures of episodic 
memory, global cognitive ability, executive functioning, and perceptual speed than non-ɛ4 
carriers, with homozygous ɛ4 carriers performing significantly worse than heterozygous ɛ4 
carriers on episodic memory when compared to homozygous ɛ3 carriers (Wisdom, Callahan, 
& Hawkins, 2011). Wang, Hong, Lin, Liu, and Chen (2011) found that ɛ4 carriers had a higher 
MCI to AD conversion rate than non-ɛ4 carriers, and that normal ageing subjects who were 
ɛ4 carriers also progressed to AD faster than non-ɛ4 carriers. Another study found an 
interaction between age and ɛ4 carrier status (Filippini et al., 2011). Older (mid-sixties) ɛ4 
carriers were found to have decreased activation in the frontal and temporal lobes, 
cerebellum and hippocampi as well as reduced cerebral blood flow whereas young (mid-
twenties) ɛ4 carriers showed increased brain activity. A much earlier study by Tierney et al. 
(1996) found that ɛ4 carrier status was only a reliable indicator of developing AD when 
performance on a memory test (e.g., Rey Auditory Verbal Learning Test (RAVLT)) was 





and although APOE ɛ4 has been identified as the main genetic risk factor for late-onset AD, it 
seems that it is neither required nor sufficient on its own to cause AD (Tanzi & Bertram, 
2001; Puglielli et al., 2003). 
 
2.3 Modifiable risk factors 
Researchers have identified several modifiable risk factors that have ‘sufficient’, 
‘consistent’ or at least ‘moderate to strong’ evidence for increasing the risk of cognitive 
decline and dementia. These factors include diabetes, midlife obesity and hypertension, 
smoking, depression, low educational attainment or cognitive inactivity, physical inactivity 
and traumatic brain injury (Plassman et al., 2010; Barnes & Yaffe, 2011; Deckers et al., 2015; 
Baumgart et al., 2015). In addition, several other risk factors such as sleep disturbances, 
alcohol intake and cholesterol levels have also been linked to an increased risk of dementia, 
although low to moderate alcohol consumption is also associated with a decreased risk 
(Anstey, Mack, & Cherbuin, 2009). These modifiable risk factors work directly or indirectly 
and several show significant overlap in terms of the mechanisms by which they increase the 
risk of dementia. 
The evidence linking diabetes with an increased risk for dementia and lower 
cognitive performance is considered to be very strong (Baumgart et al., 2015). For example, 
a meta-analysis of longitudinal studies found that diabetes was a risk factor for MCI, AD and 
VD, and those with diabetes have more than double the risk for developing VD (Cheng, 
Huang, Deng, & Wang, 2012). A meta-analysis of prospective observational studies found 
that older adults with a history of diabetes compared to those without showed a 73% 
increased risk of all types of dementia, a 56% increased risk for AD alone and a 127% 





were more likely to convert to dementia than those without diabetes (Cooper, Sommerlad, 
Lyketsos, & Livingston, 2015). The mechanisms by which diabetes increases dementia risk is 
via vascular pathways (diabetes increases the risk for strokes and infarctions), and directly 
through glucose mediated toxicity and reduced insulin receptor activation (Cooper et al., 
2015).  
A strong link has also been found between midlife obesity and an increased risk for 
dementia (Baumgart et al., 2015). A meta-analysis of longitudinal, epidemiological studies 
found that obesity significantly increased the risk for AD (Profenno, Porsteinsson, & Faraone, 
2010). Another meta-analysis found that midlife underweight BMI, overweight BMI and 
obese BMI were all associated with increased risk of dementia, implying a U-shaped 
relationship where both being underweight and overweight increase the risk of dementia 
(Beydoun, Beydoun, & Wang, 2008). Adiposity or being severely overweight is thought to 
affect the brain through different biological mechanisms including by altering energy 
metabolism and by increasing inflammation via cytokines (Gustafson, 2006). Calorie 
restricting or fasting programs have been shown to improve cognition in healthy older 
adults, which may be due to improved insulin sensitivity and reduced inflammatory activity 
(Witte, Fobker, Gellner, Knecht, & Flöel, 2009). A meta-analysis by Loef and Walach (2013) 
also found a relationship between midlife obesity and dementia risk, as well as a lower risk 
of dementia in those who were overweight compared to those with a normal weight in later 
life. The authors suggest this result may be due to low BMI being a marker for dementia, due 
to dementia-related brain atrophy affecting brain regions implicated in appetite control and 
energy balance (Loef & Walach, 2013).  
 The evidence linking midlife hypertension with dementia is strong, yet 





review of longitudinal and cross-sectional prospective studies found that hypertension 
significantly increased the risk for VD (Sharp, Aarsland, Day, Sønnesyn, & Ballard, 2011), and 
a large (11,151 adults between 46 and 70 years) population-based prospective study found 
that diabetes, hypertension and smoking were all strongly associated with a higher risk of 
hospitalisation with dementia, particularly in middle-aged participants (Alonso et al., 2009). 
Two meta-analyses found no association between hypertension and risk of AD (Guan et al., 
2011; Power et al., 2011), although some have suggested that these results may be due to 
combining mid and late life hypertension (Qiu, 2012). The use of hypertension medications 
for reducing the risk for cognitive decline has also been extensively studied, but again, with 
mixed results (Chang‐Quan et al., 2011; Rouch et al., 2015). Long term or chronic high blood 
pressure leads to a thickening of the vessel walls, which narrows arteries resulting in 
infarctions (obstruction of the blood supply) including within the cerebral areas. Exactly why 
hypertension in later life is not associated with an increased risk for AD or VD (in fact has a 
protective effect against cognitive decline) whereas hypotension in late life is associated 
with an increased risk of dementia, is unclear, although it is likely due to the reduced 
regulatory capabilities of cerebral arteries (Kennelly, Lawlor, & Kenny, 2009).  
There is strong evidence linking smoking with cognitive decline and dementia 
(Baumgart et al., 2015). A meta-analysis of prospective cohort studies found that current 
smokers had an increased risk for AD, VD and all-cause dementia, and that ceasing smoking 
decreased the risk to that of those who had never smoked (Zhong, Wang, Zhang, Guo, & 
Zhao, 2015). Another meta-analysis found that current smokers, compared to those who 
had never smoked, had a 40 to 80% increased risk of dementia and cognitive decline 
(Anstey, von Sanden, Salim, & O'Kearney, 2007). In a large cohort study, smoking in midlife 





(more than two packs per day) with the greatest risk (Rusanen, Kivipelto, Quesenberry, 
Zhou, & Whitmer, 2011). Smoking is thought to affect brain health in several indirect ways 
via vascular, inflammatory, and degenerative (e.g., oxidative stress from the free radicals in 
cigarette smoke) processes (Collins, Sachs-Ericsson, Preacher, Sheffield, & Markides, 2009).  
A Delphi consensus study rated depression as the most important risk factor for 
dementia, whereas a population-based report concluded that the link between depression 
and cognitive decline is unclear (Deckers et al., 2015; Baumgart et al., 2015). Two systematic 
reviews and meta-analyses found that older adults with a history of depression were more 
likely to have AD in later life (Ownby, Crocco, Acevedo, John, & Loewenstein, 2006), and that 
a history of depression was associated with a significant risk for all-cause dementia and AD, 
and was the highest for VD (Diniz, Butters, Albert, Dew, & Reynolds, 2013). Studies also 
indicate that high levels of depression increase the risk of MCI progressing to dementia 
(Modrego & Ferrández, 2004). It is still unclear whether depression is a symptom or early 
marker of dementia, whether depression is a risk factor for dementia or whether depression 
is triggered by a diagnosis of dementia, with some suggesting that depression is part of the 
cognitive decline continuum in specific subsets of older adults (Panza et al., 2010). Multiple 
factors contribute to the etiology of depression, from neurobiological factors such as gender 
(being female), dysregulation of the limbic, serotonergic and immune systems, to family and 
precipitating factors such as childhood adversity or trauma, high levels of stress, low 
sunlight, life events and transitions including retirement, along with personality and social 
factors such as neuroticism, pessimism and a lack of social support and loneliness (Carr & 
McNulty, 2016). Several hypotheses such as poor vascular health, neuronal damage 
(particularly in the frontostriatal circuit) and long-term inflammation have been proposed to 





There is strong evidence for the link between low educational attainment (the 
number of years spent in formal education) and risk for dementia (Baumgart et al., 2015). A 
large systematic review and meta-analysis involving 437,477 older adults found that those 
with a low education had a higher risk for dementia (Meng & D’Arcy, 2012), and another 
meta-analysis found low level of education to be an independent risk factor for AD 
(Caamaño-Isorna, Corral, Montes-Martínez, & Takkouche, 2006). A large study found 
education had a protective effect on the risk for developing AD in a dose-dependent 
manner, in that the protection increased with the number of years of education (Sando et 
al., 2008). This study also found carriers of the APOE ɛ4 allele had an increased odds ratio for 
developing AD, and that males had a lower risk for AD than females, which the authors 
suggest was possibly related to years of education. Analysis of 470 Catholic sisters from a 
large Nun study found that age, educational attainment and carrying the APOE ɛ4 allele 
influenced the odds for developing dementia, and that all three were significant predictors 
for the transition from normal cognition to mild cognitive impairments (Tyas et al., 2007).   
The construct or hypothesis of cognitive reserve has been proposed to explain why 
higher educational attainment might reduce the risk of dementia (Stern, 2012). Cognitive 
reserve is the ability to use compensation mechanisms, to draw upon multiple regions of the 
brain or to utilise the regions of the brain that are working in a more efficient way, when 
other regions are affected by neuronal degeneration (Meng & D’Arcy, 2012). Cognitive 
reserve is used to describe a state of discrepancy found in the brain function of older adults, 
where in some older adults a greater level of disease pathology needs to occur before 
clinical symptoms appear (Stern, 2012). The capacity to develop compensatory mechanisms 
or neural scaffolding (Park & Reuter-Lorenz, 2009) has been shown to be strongly related to 





adults and 809 older adults with MCI) found that older adults with MCI showed less 
employment of these compensatory mechanisms and that greater participation in cognitive 
activities (reading books, using a computer, operating a video or DVD player, using a bus or a 
train and management of finances) was associated with lower odd ratios of MCI (Doi et al., 
2013). A systematic review of seven RCTs found that cognitive training produced a strong 
and persistent protective effect on cognitive performance in cognitively healthy older adults 
(Valenzuela & Sachdev, 2009). A systematic review of 13 cohort observational studies found 
an association between participating in cognitive leisure activities and a reduced risk for 
developing AD (Stern & Munn, 2010). Together with education and cognitive activity, 
occupational attainment, physical exercise and life experiences have also been shown to 
increase cognitive reserve and neural scaffolding capacity.   
Physical inactivity has been shown to be strongly linked to an increased risk of 
dementia and cognitive decline (Baumgart et al., 2015). A systematic review of 16 
prospective studies found that physical activity was inversely associated with risk for 
dementia, and overall reduced risk for dementia by 28% and AD by 45% (Hamer & Chida, 
2009). A meta-analytic review of 29 RCTs undertaken by Smith et al. (2010) found the 
aerobic exercise training was associated with ‘modest’ improvements in cognitive 
performance particularly in attention, processing speed, executive functioning and memory, 
with moderator analysis finding that combining aerobic exercise with strength training 
improved cognitive performance to an even greater extent. Smith et al. also found 
preliminary evidence to suggest that participants with MCI showed a greater improvement 
in memory from exercise than participants who were non-cognitively impaired.  
A RCT involving 120 older adults found that moderate-intensity aerobic exercise 





anterior hippocampus by 2%, which is equivalent to an age-related loss in volume of 
between 1 to 2 years (Erickson et al., 2011). The RCT also found that the increase in 
hippocampal size was associated with higher serum levels of brain-derived neurotrophic 
factor (BDNF). The mechanisms by which physical activity influences cognitive decline is via 
vascular factors such as lowering blood pressure and improving cerebral circulation (blood 
flow and oxygen supply), by enhancing growth factors such as BDNF and by lowering anti-
inflammatory markers (Hamer & Chida, 2009). It is still unclear what type and intensity of 
exercise are required, and how long the physical activity needs to be in order to maximise 
the protective effects of exercise (Baumgart et al., 2015).   
There is now solid evidence that moderate to severe traumatic head or brain injury 
(TBI) increases the risk for dementia (Baumgart et al., 2015). A large study involving 188,764 
US veterans over 55 years of age found that TBI was associated with a 60% increased risk for 
developing dementia (Barnes et al., 2014). Another study involving 2,552 retired 
professional US football players found that those players who had sustained three or more 
concussions had a 5-fold prevalence of MCI and 3-fold prevalence in memory problems 
(Guskiewicz et al., 2005). Another military-based study with 811,622 Swedish men found a 
strong association between risk for early-onset dementia of non-AD forms and TBIs of 
different levels of severity (Nordström, Michaëlsson, Gustafson, & Nordström, 2014). 
Explanations for why TBI increases risk for dementia include that a head injury might trigger 
the pathological development of tangles and plaques, white matter degradation, general 
neuronal loss and cerebral atrophy and chronic neuro-inflammation. Other factors such as 
carrying the APOE ɛ4 allele also seem important, as the APOE gene plays an important role 
in the response of the brain to injury (Guskiewicz et al., 2005; Blennow et al., 2006; Smith, 





Several cohort and observational studies have indicated that sleep disturbances 
increase the risk of cognitive decline (Baumgart et al., 2015). A prospective study found that 
women with sleep-disordered breathing had an increased risk of developing cognitive 
impairment (Yaffe et al., 2011). A five-year follow-up population-based study found that 
sleep apnoea participants had a higher risk of developing dementia (Chang et al., 2013), and 
a large population-based study with 30,038 older adults found that sleep disturbances were 
associated with an increased risk of developing AD and dementia (Sterniczuk, Theou, Rusak, 
& Rockwood, 2013). A study involving 101 older adults with AD found that poor subjective 
sleep quality, sleep problems and daytime sleepiness were associated with greater AD 
pathology such as CSF plaques (Sprecher et al., 2017). Sleep affects cognition by disrupting 
long-term memory consolidation, by way of hypoxia and reducing cerebral blood flow and 
grey matter (Yaffe et al., 2011). Yet again, it is unclear whether sleep disturbances are a 
cause of or are a precursor to dementia (Baumgart et al., 2015). 
Alcohol consumption and cholesterol levels are both negative and positive risk 
factors for dementia, in that low to moderate levels of alcohol show a protective effect and 
yet high levels are associated with brain damage, and cholesterol levels can be a positive or 
negative risk factor depending on the type of cholesterol measured. For example a meta-
analysis of 15 prospective studies found that low to moderate alcohol consumption was 
associated with a 25 to 28% reduction in risk for dementia compared to those who did not 
drink, although several studies have found this reduction in risk for wine only (Anstey et al., 
2009; Luchsinger Tang, Siddiqui, Shea, & Mayeux, 2004). A systematic review of 18 
prospective studies found that high midlife total serum cholesterol increases the risk of 
dementia (Anstey, Lipnicki, & Low, 2008) whereas in a large population-based cohort late‐





prospective cohort study found that high levels of HDL were associated with a decreased risk 
of AD (Reitz et al., 2010). Low to moderate alcohol consumption may reduce dementia risk 
by increasing HDL levels which lowers cardiovascular risk, increasing cerebral blood flow, 
decreasing coagulation and reducing inflammation, whereas heavy consumption is a risk 
factor for most stroke subtypes and causes alcohol-related brain damage such as cortical 
volume deficits, cerebral shrinkage, neurotoxicity, neuro-inflammation and changes in 
neurotransmitter production (Anstey et al., 2009; Zahr, Kaufman, & Harper, 2011).           
    While the evidence for these modifiable risk factors is strong, all epidemiological 
evidence suffers from the inability to infer causality. It is difficult to be sure, for example, 
whether low physical activity levels result in accelerated cognitive decline or a cognitive 
deficit causes a reduction in physical activity. What is more apparent, is that these risk 
factors have very similar mechanisms, in that most risk factors affect cognition via vascular, 
inflammatory or insulin receptor pathways. Educational attainment and cognitive activity is 
the exception, where it is thought to protect via an increased brain reserve capacity; 
although again it is uncertain as to whether low levels of cognitive engagement contribute 
to the development of MCI and AD or whether those with MCI are less likely to engage in 
cognitive activities due to their declining cognition. These modifiable risk factors are also 
highly interrelated; for example, obesity and physical inactivity are related to socioeconomic 
status, which is related to education and occupation (Cerin & Leslie, 2008).   
 
2.4 Protective factors 
 Researchers have identified several other modifiable risk factors which have been 





decline and dementia. The two risk factors that will be discussed here are social connection 
or engagement, and the effects of diet and nutrition.  
Several studies have shown that social connection or social engagement, including 
having regular social activities, larger social networks, and a history of social contact, are 
associated with better cognitive function and reduced risk of cognitive decline (Baumgart et 
al., 2015). A prospective study of 2,249 women over 78 years of age found that women with 
larger social networks had a lower risk for dementia (Crooks, Lubben, women, Little & Chiu, 
2008) and another study with 1,138 older adults without dementia found more social 
activity was associated with less cognitive decline during average follow-up of 5.2 years 
(James, Wilson, Barnes, & Bennett, 2011). A study involving 6,102 older adults found that 
greater social networks and social engagement was associated with reduced cognitive 
decline (Barnes, De Leon, Wilson, Bienias, & Evans, 2004). Another study assessing the 
effects of physical, social and mental components of leisure activities in 2,368 older adults 
from Sweden found that the social element of activities was just as beneficial as the physical 
and mental components for reducing the risk of dementia (Karp et al., 2006). In contrast, a 
coordinated analysis of four longitudinal studies did not find an association between social 
activity and cognitive functioning (Brown et al., 2012). Social engagement is thought to 
provide a protective effect on cognition by reducing stress, depression and loneliness, by 
enhancing resilience and by building scaffolding or cognitive reserve due to the complexities 
and challenges involved in communication (Barnes et al., 2004; Crooks et al., 2008; James et 
al., 2011). 
The evidence for the direct effects of diet and nutrition on reducing the risk for 
cognitive decline and dementia is considered to be inconsistent and limited (Baumgart et al., 





by a Delphi consensus study (Deckers et al., 2015). Research investigating the link between 
food, diet and cognition can be divided into four areas – micronutrients (a substance needed 
in a small quantity, but which is necessary for normal metabolism and growth) such as 
vitamin E and flavonoids, macronutrients (a type of nutrient required in large amounts) such 
as fats and carbohydrates, specific foods or food groups such as fish or fruit and vegetables, 
and diets or whole dietary patterns such as the Mediterranean diet. Several micronutrients 
have been studied in terms of reducing the risk for dementia (by reducing atrophy in MCI 
and improving cognition) including vitamin E, D and B12, folate (vitamin B9) and 
homocysteine (a by-product of amino acid metabolism) but with inconsistencies and limited 
support (e.g., Petersen et al., 2005; Ford & Almeida, 2012; Douaud et al., 2013).  
Research indicates that the damage caused by AD pathology is associated with 
damage from oxidative stress, a term used to describe the damage caused to cells from free 
radicals as a result of a series of chain reactions involving oxygen (Launer et al., 2002). Free 
radical agents or anti-oxidants interact with free radicals (by donating or accepting 
electrons) to interrupt and terminate this chain reaction (Opara & Rockway, 2006). There 
are many different types of anti-oxidants found in food from vitamins and minerals such as 
the vitamin C in citrus fruit and selenium in Brazil nuts, certain types of acids (e.g., benzoic 
and cinnamic acid) found in onions and coffee, and pigments such as carotenes and 
flavonoids. Carotenes and flavonoids are found in plants as brightly coloured pigments and 
have been shown to have potent anti-oxidant and anti-inflammatory effects (Gillette-
Guyonnet et al., 2007). Plants with particularly high levels of carotenes and flavonoids 
include orange and yellow fruits and vegetables such as carrots and mangoes, berries 
especially blueberries and blackcurrants, black and green tea from the camellia plant, dark 





grapes (Opara & Rockway, 2006). The Rotterdam study found the use of anti-oxidant 
supplements such as beta-carotene and flavonoids as well as intake of vitamin C and E was 
associated with a lower risk for AD (Engelhart et al., 2002).  
Several macronutrients and food groups have been linked to both improvements and 
impairments in cognition through the lifespan. These include fats or fatty acids, particularly 
n-3 PUFAs found in oily fish and the saturated fatty acids found in meat and dairy, also 
simple and complex carbohydrates (the link between cognition and insulin insensitivity) as 
well as fruit and vegetables, and water. Along with fish consumption, fruit and vegetable 
consumption has been shown to play a protective role in reducing the risk of dementia. A 
large cohort study involving 8,085 healthy older adults over 65 years of age found that daily 
consumption of fruits and vegetables was associated with a decreased risk for dementia 
(Barberger-Gateau et al., 2007), and a systematic review of nine cohort studies found 
increased vegetable, but not fruit intake, was associated with a lower risk of dementia and a 
slower rate of decline (Loef & Walach, 2012). Reasons why vegetable consumption may be 
more protective than fruit could be due to the lower sugar and higher fibre (which reduces 
total serum cholesterol levels) content along with the higher level of flavonoids and 
micronutrients. 
Research investigating the protective effects of the Mediterranean diet has also been 
very promising. The Mediterranean diet is characterised by a diet high in fruit and 
vegetables, whole grains, legumes and nuts, moderate in dairy, low in red meat, with fish 
and olive oil as alternative sources of protein and fat, and with a moderate level of wine 
consumption. Evidence suggests that people who maintain diets like those which proliferate 
in the Mediterranean (Italy, Spain and Greece) as well as in North East Asia (without olive oil, 





have lower rates of chronic disease, coronary health disease, cancer, neuro-degenerative 
conditions such as Parkinson’s disease and AD, a reduced risk of progressing from MCI to AD 
as well as a higher life expectancy (Willett et al., 1995; Trichopoulou, Costacou, Bamia, & 
Trichopoulos, 2003; Knoops et al., 2004; Scarmeas, Stern, Tang, Mayeux, & Luchsinger, 2006; 
Sofi, Cesari, Abbate, Gensini, & Casini, 2008; Estruch et al., 2013; Singh et al., 2014). Possible 
mechanisms underlying the protective effects of the Mediterranean diet include via 
vascular, oxidative and anti-inflammatory pathways, quite possibly from the interaction of 
components and nutrients of the diet (Frisardi et al., 2010). The Mediterranean diet is also 
characterised by a minimal level of food processing, the use of fresh and seasonal fruits and 
vegetables which further increases the fibre, anti-oxidant and micronutrient content (Willett 
et al., 1995). Recently a large study involving 2,796 adults in France aged between 45 and 60 
years found that a pro-inflammatory diet was associated with a decreased likelihood of 
healthy ageing, indicating that the anti-inflammatory effect of a diet maybe the significant 
factor (Assmann et al., 2018).   
Support for a diet, social and lifestyle interaction comes from demographic work into 
regions of the world coined ‘Blue zones’ (Sardinia in Italy, Okinawa in Japan, Loma Linda in 
California, the Nicoya Peninsula in Costa Rica and Icaria in Greece) with particularly high 
rates of longevity. Researchers found that the people who lived in these areas shared 
several characteristics including a moderate calorie, plant-based (semi-vegetarian with high 
legume consumption) diet along with regular physical activity, moderate alcohol 
consumption, strong social and family connections, a life purpose and an emphasis on stress 
reduction (Poulain, Herm, & Pes, 2013). A recent 3-year RCT called the Multi-domain 
Alzheimer Preventive Trial aimed to investigate the effects of a multi-domain intervention 





adults with memory complaints over 70 years of age. The trial did not find any significant 
effects on cognitive decline, except in executive functioning in the n-3 PUFA group with low 
baseline levels of n-3 PUFAs (Andrieu et al., 2017; Hooper et al., 2017). An earlier 2-year 
multi-domain (diet, exercise, cognitive training and vascular risk monitoring) RCT with 1,260 
older adults between 60 and 77 years of age did find a significant intervention effect on 
overall cognition (composite score from 14 tests), secondary cognition (executive 
functioning and processing speed), but not memory (Ngandu et al., 2015). The authors note 
that considering the multifactorial nature of cognitive decline and dementia, “a one-size-fits-
all solution is unlikely to be found” and that “tailoring interventions to risk profiles and 
different geographical and cultural settings should be the focus of future research” 
(Kivipelto, Mangialasche, & Ngandu, 2017, pg. 339). 
 
2.5 Summary 
Given that most risk factors for cognitive decline are interrelated and cumulative, the 
best prevention approaches are likely to be multifactorial or ‘pleiotropic’ with multiple 
benefits such as a healthy lifestyle with regular exercise and a balanced diet (Baumgart et 
al., 2015). In terms of diet, components of the Mediterranean diet such as the consumption 
of oily fish and vegetables alongside physical exercise and cognitive training shows promise 
and deserves further exploration. Exactly how and why the typical Western-style diet has 
veered so far away from the Mediterranean or ‘blue zone’ way of eating is unclear, although 
the large scale production and advertising of food high in refined sugar and certain types of 
fats is a likely culprit. The type of nutrient that has received the most attention in reducing 
cognitive decline are the n-3 PUFAs found in oily fish, and are the focus of Chapter 3 and 5, 





cognition in older adults. Evidence from RCTs provides the best support for prevention 
strategies, although variation from person to person in terms of the latent time period 
between the beginning of pathological mechanisms and the onset of clinical symptoms 
confounds results. Important considerations for prevention trials are an adequate sample 
size, an appropriate age range, including specific risk profiles, the strength of the 








CHAPTER 3  
 
OMEGA-3 FATTY ACIDS AND COGNITION 
 
This chapter will examine the chemistry, metabolism and pharmacological effects of 
omega-3 polyunsaturated fatty acids (n-3 PUFA) before reviewing the epidemiological 
evidence and mechanisms for the cognitive effects of n-3 PUFAs in older adults.  
 
3.1 Fatty acids  
Fats or fatty acids have received a bad name, mainly because of the high energy 
density (37 kilojoules per gram compared to 17 kilojoules per gram for protein and 
carbohydrates), but also because of the link between certain types of fatty acids such as 
saturated fatty acids and trans-fatty acids with coronary heart disease and cholesterol levels 
(Capra et al., 2006; Kromhout et al., 1995). However, it was not until quite recently that the 
detrimental effects of a low-fat diet, particularly a diet low in n-3 PUFAs on growth and 
cognition have become known. Nutritional research shows that most older adults who eat a 
Western-style diet have insufficient dietary intake and blood levels of n-3 PUFAs, possibly 
due to increased acute and chronic illnesses, impaired digestion, changes in taste and smell 
as well as the difficulties associated with living, shopping and eating alone (Bourre & 
Paquotte, 2008; Cole & Frautschy, 2010). Symptoms of a deficiency in n-3 PUFAs include 





Whether the low intake of n-3 PUFAs in older adults can also explain the high incidence of 
conditions such as AD is unclear.  
 
3.2. Chemistry and metabolism of fatty acids 
Most fatty acids in the human body are in the form of triglycerides, phospholipids 
and cholesterol (Capra et al., 2006). Triglycerides are found in the blood, adipose tissue and 
in sebum secreted by sebaceous glands in the skin, whereas most phospholipids are found 
within cell membranes (Yehuda, Rabinovitz, Carasso & Mostofsky, 2002). A phospholipid is 
made up of two fatty acids joined by a phosphate group head. The phosphate head end is 
hydrophilic or water attracting, whereas the tail end is hydrophobic or water repelling. Two 
phospholipids join up tail to tail (as both tails are water repelling) to form a phospholipid 
bilayer with the phosphate heads on the inside and outside of the cell membrane. This 
important structure provides the cell membrane with a barrier to control the movement of 
substances in and out of the cell (Yehuda et al., 2002). 
A fatty acid is made up of a carbon atom chain with a methyl end and a carboxyl or 
acid end. The number of carbon atoms in a fatty acid can be anywhere between 3 and 38, or 
more. Fatty acids can be further divided into saturated, monounsaturated or 
polyunsaturated based on whether the carbon chain contains a double bond or not (White, 
2009). If a fatty acid contains no double bonds (i.e., contains only single bonds) between the 
carbons, it is called a saturated fatty acid (SFA). If the fatty acid contains one double bond in 
the carbon chain it is called a monounsaturated fatty acid (MUFA), and if it contains two or 
more double bonds it is called a polyunsaturated fatty acid (PUFA) (White, 2009). The three 
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Figure 1. Fatty acid carbon chains derived from White (2009) 
Note. C = Carbon, H = Hydrogen, O = Oxygen 
 
for example, one SFA and two PUFAs. PUFAs typically contain between 2 to 6 double bonds 
and are referred to as omega-3, omega-6 (n-6 PUFA) or omega-9 (n-9 PUFA) 
polyunsaturated fatty acids depending on whether the first double bond is at the 3rd, 6th or 
9th carbon atom. The double bond in a MUFA is usually on the 7th or 9th carbon. In this 
system, the number of the first carbon in the chain is determined by counting the carbon 
atoms from the methyl end. See Figure 1.      
SFAs are found in animal meats and various types of milks, palm kernel and coconut, 
MUFAs in olives, avocados, nuts and plant oils, and PUFAs in seeds, meat and oily fish (Capra 
et al., 2006). See Table 2 for the most common fatty acids, along with the lipid number and 






Table 2. The most common types of fatty acids derived from White (2009) 
FA Common name Lipid number Food sources 
S Butyric acid C4 Animal milk – butter, cheese 
S Caprylic acid C8 Animal milk, coconut, palm kernel oil 
S Lauric acid C12 Animal milk, coconut, palm kernel oil 
S Palmitic acid  C16 Dairy, meat, palm oil, cocoa butter 
M Palmitoleic acid C16:1n-7 Macadamia, coconut, palm oil 
S Stearic acid  C18 Meat, cocoa butter, shea butter 
M Oleic acid  C18:1n-9 Olive oil, avocado, pecans, canola oil 
P Linoleic acid  C18:2n-6 Safflower, sunflower oil, corn oil 
P Alpha-linolenic acid C18:3n-3 Flax/chia seeds, leafy green vegetables 
P Stearidonic acid C18:4n-3 Hemp, blackcurrant seeds, spirilina 
M Eicosenoic acid  C20:1n-9 Jojoba oil 
P Dihomogamma linolenic  C20:3n-6 Evening primrose oil, borage oil 
P Mead acid C20:3n-9 Cartilage 
P Arachidonic acid  C20:4n-6 Meat, eggs, dairy 
P Eicosapentaenoic acid C20:5n-3 Oily fish, seaweed/algae, eggs 
P Docosapentaenoic acid  C22:5n-6 Oily fish, beef, seal, maternal milk 
M Nervonic acid  C24:1n-9 Oily fish, flaxseeds, sesame seeds 
P Docosahexaenoic acid  C22:6n-3 Oily fish, maternal milk 
P Nisinic acid C24:6n-3 Fish 
Note. FA = Fatty acid: S = Saturated, M = Monounsaturated, P = Polyunsaturated 
 
chain, how many double-bonds, if any, are in the carbon chain, and which carbon the first 
double bond is on. For example, a lipid number of ‘C16’ indicates that the fatty acid has 16 
carbons in the carbon chain, with no double bonds and is therefore a SFA. A lipid number of 
‘C22:6n-3’ indicates that the fatty acid has 22 carbons in the chain, with six double bonds 
with the first double bond on the 3rd carbon and is therefore an n-3 PUFA. PUFAs tend to be 
long-chained, that is contain at least 13 carbon atoms as opposed to SFAs which tend to be 
short chained and MUFAs which are often medium chained.  
 The properties and functions of a fatty acid largely depend on the number of 
carbons and the number of double bonds in the carbon chain (Bradbury, 2011). SFAs contain 
no double bonds and therefore are ‘saturated’ with hydrogen because the ratio of hydrogen 





charge (are stable), are slow to react with other chemicals, and mostly provide energy, 
insulation and fat-soluble vitamin absorption. Long-chained SFAs, that is a fatty acid with 
more than 13 carbons, are found in cell membranes but because SFAs tend to aggregate, 
they lend a rigid structure to cell membranes. MUFAs contain one double bond which causes 
a bend or kink to form in the carbon chain (not shown in Figure 1). This kink is caused by the 
negative charge of the double bond, causing the fatty acids to repel each other, and 
therefore disperse as opposed to aggregate. This dispersing action means these fatty acids 
tend to be liquid at room temperature, and when found in cell membranes they lend more 
fluidity to the structure.  
PUFAs contain multiple double bonds and are always liquid at room temperature. 
With every double bond the fatty acid has, the more kinks it has and the more dispersed it 
becomes. The human body uses PUFAs for hormone-like functions, to produce anti-
inflammatory agents, to generate electrical currents (especially nerve impulses) and to 
create membranes that are very fluid which make it easier for substances to move in and 
out of cells.  The human body will use long-chained PUFAs as an energy source, but only if 
other requirements have been met. Humans need a certain balance of the three types of 
fatty acids for optimal health. If there is insufficient PUFA in the diet, SFAs and MUFAs are 
used in replacement, but because these fatty acids do not have the same properties as 
PUFAs, the cell becomes less able to perform certain functions (Yehuda et al., 2002; Hulbert, 
2003). Humans also need a certain ratio of n-3 PUFAs to n-6 PUFAs, ideally a ratio of 1:3, 
which is uncommon in Western-style diets due to the high consumption of foods deep fried 
in n-6 PUFA vegetable oils and the low consumption of oily fish, seaweed or algae and n-3 
PUFA containing seeds (Yehuda et al., 2002). Western-style diets typically contain a ratio of 





inflammatory diseases, heart disease and neurological disorders in Western countries 
(Simopoulos, 2002; Denis, Potier, Vancassel, Heberden & Lavialle, 2013). 
Humans are able to produce or synthesise SFAs from excess glucose from 
carbohydrates, and MUFAs from excess SFAs (Capra et al., 2006). However, animals 
(including humans) and plants differ in their ability to insert double bonds into fatty acid 
carbon chains to produce PUFAs. Humans can modify SFAs and MUFAs to synthesise PUFAs, 
but are the only mammals that cannot insert a double bond closer than seven carbons from 
the methyl end, and therefore cannot synthesise the longer chained n-3 and n-6 PUFAs 
(Russo, 2009). The conversion from one fatty acid to another requires three main types of 
enzymes – desaturase, which removes two hydrogen atoms from a carbon in the chain 
resulting in the insertion of a double bond, elongases, which adds two carbons to the chain, 
and beta oxidase, which removes two carbons from the chain. Desaturase are numbered 
with a delta number that refers to which carbon on the chain (this time counting from the 
carboxyl or acid end) the hydrogen atoms were removed from. Plants can insert double 
bonds at the 3rd, 6th and 9th carbon, e.g., at the 9th carbon in stearic acid (C18) with delta-9 
desaturase to produce oleic acid (C18:1n-9), then a double bond at the 6th carbon in oleic 
acid with delta-12 desaturase to produce linoleic acid (LA; C18:2n-6), and then a double 
bond at the 3rd carbon with delta-15 desaturase to produce alpha-linolenic acid (ALA; 
C18:3n-3). Humans do not have delta-12 or 15 desaturase enzymes, which means they 
cannot convert the SFA stearic acid (C18) to LA or ALA, nor LA directly to ALA (Simopoulos, 
2002).  
The two most important or ‘essential fatty acids’ for human health are the long-
chained LA and ALA. ‘Essential’ refers to the fact that the human body cannot produce these 





human health (Crupi, Marino, & Cuzzocrea, 2013). LA is found in seed oils such as safflower, 
sunflower and corn oil, whereas ALA is found in flaxseeds/linseeds, chia seeds, kiwifruit 
seeds, walnuts and some leafy green vegetables. LA is the precursor to three important n-6 
PUFAs – dihomogamma linolenic acid (DGLA), arachidonic acid (ARA) and docosapentaenoic 
acid (DPAn-6). ALA is the precursor to three important n-3 PUFAs – docosapentaenoic acid 
(DPAn-3), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).  DGLA and EPA play 
important roles in producing eicosanoids (hormone-like signal lipids) which have anti-
inflammatory and anti-thrombotic effects, whereas ARA produces eicosanoids, which have 
vaso-constriction, platelet aggregation, and pro-inflammatory effects (Brenna, Salem, 
Sinclair, & Cunnane, 2009). DPAn-3 and DHA play important roles in reducing inflammation 
and platelet aggregation, and DHA in vision and the function of the neuronal membrane 
(Dyall, 2015).   
The conversion from LA and ALA to these six important PUFAs requires delta-5 and 6 
desaturase as well as vitamins B3, B6, C and the minerals magnesium and zinc, which means 
that deficiencies in any of these nutrients can inhibit conversion. Humans have delta-5 and 6 
desaturase, but the conversion rates vary from person to person due to genetics, sex and 
dietary factors. Stress levels and reduced digestive capacity, due to certain medical 
conditions or age, also play a role (e.g., Tully et al., 2003; Burdge, 2006; Denis et al., 2013). In 
terms of dietary factors, this conversion can depend on the availability of the starting fatty 
acid, on any competing fatty acids as well as whether there are high or low levels of the end-
product fatty acid (Brenna et al., 2009). Competing fatty acids here refers to n-3 PUFAs and 
n-6 PUFAs competing for the use of desaturase enzymes, and therefore, if a higher amount 
of n-6 PUFAs are consumed in the diet than n-3 PUFAs, then the n-3 PUFAs will get 





3.3 Long-chain omega-3 polyunsaturated fatty acids  
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are very long chain n-3 
PUFAs; EPA (C20:5n-3) has 20 carbon atoms in the carbon chain with five double bonds and 
DHA (C22:6n-3) has 22 carbon atoms with six double bonds. Both EPA and DHA are found in 
high amounts in oily fish such as salmon, mackerel and sardines, shellfish like mussels, fish 
eggs or roe, and certain types of marine algae (Capra et al., 2006). Fish can synthesise LA but 
not ALA, and obtain ALA from marine algae, plankton and krill which is then converted to 
EPA and DHA. EPA is also found in grass-fed beef and free-range eggs, and DHA is found in 
maternal milk. Both EPA and DHA can also be synthesised from ALA so neither are 
considered to be essential fatty acids, although due to the limited conversion rates of ALA to 
DHA, EPA and DHA are sometimes referred to as a ‘conditionally essential fatty acids’ 
(Arterburn, Hall, & Oken, 2006).   
The process of converting the fatty acids from ALA to EPA through to DHA is shown 
in Figure 2. ALA (C18:3n-3) is first converted to stearidonic acid (C18:4n-3) by delta-6 
desaturase (adds a double bond), then to eicosatetraenoic acid (C20:4n-3) by elongase (adds 
two carbons), then to EPA (C20:5n-3) by delta-5 desaturase. EPA is then converted to 
docosapentaenoic acid (DPAn-3) (C22:5n-3) and then to tetracosapentaenoic acid (C24:5n-3) 
using elongases, then to nisinic acid (C24:6n-3) using delta-6 desaturase, and finally to DHA 
(C22:6n-3) using beta oxidase. Only microalgae have shown the ability to convert DPAn-3 
(C22:5n-3) directly to DHA (C22:6n-3) using delta-4 desaturase (Russo, 2009). The conversion 
from ALA to EPA to nisinic acid takes place in the liver within a cellular organelle called the 
endoplasmic reticulum, and the last steps to form DHA takes place within a peroxisome 
(Hulbert, 2003). Using isotope tracer studies, the conversion from ALA to EPA has been 






Figure 2. Conversion of alpha-linolenic acid (ALA) to docosahexaenoic acid (DHA)      
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from ALA to DHA is less than 4% in men (in some cases results in no change or a negative 
change), and up to 9% in women (Arterburn et al., 2006). The higher conversion rate in 
women is due to the influence of oestrogen (which increases desaturation), the lower 
amount used for energy production in women (via beta-oxidation), and the overall higher 
percentage of adipose tissue in women than in men – 15% vs. 23% in males (Burdge & 
Calder, 2005). The conversion from ALA to EPA and DHA is much less efficient in humans 
than in other animals, which is the main reason why the use of animals models is not useful 
is investigating the effects of these nutrients in human health-related outcomes. 
Direct dietary or supplement intake of ALA has been shown to result in increases in 
EPA but not DHA, although several studies have shown increased DHA levels when LA levels 
are low (Burdge & Calder, 2005; Arterburn et al., 2006). In contrast, direct dietary or 
supplement intake of EPA and DHA results in correspondingly significant increases in EPA 
and DHA. Dietary EPA intake results in a linear response increase in EPA plasma 
phospholipid concentration, whereas dietary DHA intake results in a dose-dependent 
increase in DHA plasma phospholipid concentration up to 2 g per day, which reflects that 
DHA is the end product of the fatty acid metabolism. EPA supplementation does not always 
result in increased DHA levels; usually in an increase in EPA and DPAn-3 only, yet DHA intake 
does result in a linear response increase in EPA concentrations due to retro conversion at a 
rate of 0.4 g/100 g fatty acid per 1 g of DHA (Arterburn et al., 2006).  
DHA exceeds EPA by 5 to 30-fold in most tissue types, and up to 700-fold in brain and 
retina tissue (Lin et al., 2012). EPA and DHA are found in the highest amounts in human 
tissue within the brain, retina, adrenal glands and sperm (Stillwell & Wassall, 2003). EPA is 
found in smaller quantities than DHA, but in more tissue types. EPA is found in cholesterol, 





membranes (Simopoulos 1991; Kuratko, & Salem, 2009; Lin et al., 2012). In contrast, the 
amount of ALA in phospholipids is less than 0.5% of the total fatty acids, which suggests that 
ALA has very minimal effect on the function of cell membranes (Burdge & Calder, 2005). 
Between 25 to 60% of ALA is oxidised for energy production, whereas DHA is quickly 
incorporated into plasma and phospholipid cell membranes (Brenna, 2002; Stillwell & 
Wassall, 2003). Both EPA and DHA are highly susceptible to peroxidation due to the multiple 
double bonds, which has both advantages and disadvantages for human health. For 
example, by attracting oxygen EPA and DHA allows oxygen to be captured and incorporated 
into haemoglobin within the blood; however, it results in the production of free-radicals due 
to the oxidation reaction at the double bond (Cole & Frautschy, 2010). The fact that housing 
these two fatty acids results in oxidative stress, and that converting ALA to DHA is very 
energy and resource taxing process, is taken as an indication of how important these two 
PUFAs are to the functioning of the biological system (Olbrich, Rawicz, Needham, & Evans, 
2000; Stillwell & Wassall, 2003). 
 
3.4 Eicosapentaenoic acid (EPA)  
One of the main roles of EPA is in producing eicosanoids, which are a group of 
hormone-like signalling molecules. Eicosanoids are made from fatty acids with 18 and 20 
carbons, including both ARA and DGLA, taken from the phospholipid cell membrane. EPA 
produces several types of eicosanoids including resolvins and hydroxyl fatty acids, which 
have anti-inflammatory, anti-thrombotic and vaso-dilatory effects. In contrast, ARA 
produces types of eicosanoids called prostaglandins (series 2) and leukotrienes, which have 
inflammatory, vaso-constricting, and coagulation effects. The picture is not this simple 





anti-inflammatory agents, and EPA contributes to producing prostaglandins (series 3) and 
leukotrienes which have inflammatory and smooth muscle contracting effects (Calder, 
2009). The difference between the two types of prostaglandins is that those produced from 
EPA are much slower to react than the prostaglandins created from ARA, which are very 
potent and fast acting (Bradbury, 2011). The opposing effects of these two different types of 
eicosanoids are crucial in helping the body to regulate and modify immune and 
inflammatory processes (Calder, 2009).  
EPA has been shown to reduce inflammation in a dose dependent manner. For 
example, Rees et al. (2006) showed that doses of EPA from 1.35 g to 2.70 g to 4.05 g per day 
resulted in incremental decreases in the production of the inflammatory prostaglandin 
series 2, particularly in relation to high EPA to ARA ratios. The study also found that the 
production of prostaglandins series 2 was significantly negatively associated with EPA 
content in phospholipids (r = -.23, p = .01). Rees et al. also found that older men 
incorporated EPA into plasma more readily than younger men, irrespective of n-6 PUFA 
intake, which the authors suggest reflects changes due to age in the ways fatty acids are 
used and stored. ALA, ARA, EPA and DHA all compete for positioning within cell membranes, 
therefore EPA’s role in regulating ARA levels (especially when dietary intake of n-6 PUFAs 
are high) by competing for the same desaturase is crucial (Arterburn et al., 2006; Huang, 
2010).  
EPA and DHA also decrease inflammation by decreasing several types of cytokines, in 
particular interleukin 1 β (IL-1β) and tumour necrosis factor α (TNF-α) (James, Gibson, & 
Cleland, 2000). Cytokines are signalling proteins that are released from immune cells and 
result in increased inflammation. IL-1β and TNF-α have been implicated in several chronic 





disease (Calder, 2006). A meta-analysis by Goldberg and Katz (2007) of 17 n-3 PUFA RCTs in 
patients with RA found that n-3 PUFAs significantly reduced duration of morning stiffness, 
the number of painful/tender joints and consumption of nonsteroidal anti-inflammatory 
drugs (NSAID) after three months of supplementation. Another meta-analysis by Lee, Bae 
and Song (2012) did not find a significant reduction in pain-related symptoms in patients 
with RA, but found that 2.7 g of EPA + DHA per day for at least three months significantly 
reduced the use of NSAIDs. The authors note the significance of this finding is based on 
concerns around the adverse effects of NSAID such as increased cardiovascular risk and 
gastrointestinal damage (Lee, Bae, & Song, 2012). 
 
3.5 Docosahexaenoic acid (DHA) 
DHA has two more carbons and one more double bond than EPA, making it more 
unsaturated and therefore more dispersed and flexible in its structure and function (Feller, 
Gawrisch, & MacKerell, 2002; Valenzuela, 2009). DHA is involved in producing several very 
important intra and extracellular signalling molecules (Hamilton, Hillard, Spector, & Watkins, 
2007). Where EPA produces eicosanoid signalling molecules such as prostaglandins, 
resolvins and leukotrienes, DHA produces docosanoids and docosatrienes such as maresins 
and a particular type of resolvin that generates neuroprotectins (Calon, 2011). Maresins and 
neuroprotectins have potent anti-inflammatory, neuro-protective and tissue regeneration 
effects (Valenzuela, 2009). DHA-derived neuroprotectin D1 has been shown to mediate 
apoptosis proteins and induce cell survival against oxidative stress in human retinal pigment 
cells, while maresin 1 has been shown to stimulate tissue regeneration and reduce pain 





DHA makes up between 30 to 50% of the fatty acids in the synaptosomal membrane, 
mostly in the form of ethanolamine head groups within phospholipid membranes (Conquer, 
Tierney, Zecevic, Bettger, & Fisher, 2000; Tully et al., 2003). These ethanolamine head 
groups are a major constituent of synaptic vesicles, which store neurotransmitters, and play 
an important role in membrane fusion events within the synaptic cleft (Teague, Fuller, Rand, 
& Gawrisch, 2002). DHA influences the structure and function of the neuronal membrane in 
several different ways, namely by forcing cholesterol out of the membrane structure and by 
increasing membrane permeability to water and other substances (Olbrich et al., 2000; 
Stillwell & Wassall, 2003; Freemantle et al., 2006). Cholesterol levels increase within the cell 
membrane with age, and where cholesterol reduces membrane fluidity within the cell 
membrane structure, DHA increases fluidity (Yehuda et al., 2002). This ability to alter the 
movement of cholesterol in and out of the cell membrane may help to explain the important 
role of DHA in the brain with age. By increasing membrane fluidity and permeability, DHA 
also contributes to increasing the rate of protein to protein interaction within the cell 
membrane, and influences signal transduction and transmission from neuron to neuron 
(Valenzuela, 2009; Cunnane et al., 2009).  
 
3.6 Evidence for the cognitive effects of EPA and DHA 
The ability to assess EPA and DHA intake with the use of Food Frequency 
Questionnaires (FFQ) and to accurately measure levels of EPA and DHA within the body has 
been crucial to understanding the cognitive effects of n-3 PUFAs. The main issue with using 
FFQs as a measure of fatty acid levels is that they rely on the accuracy, memory and 
willingness of participants to report dietary intake, although a study involving 273 older 





can increase the validity of FFQs (Sun, Ma, Campos, Hankinson, & Hu, 2007; Arsenault et al., 
2009). The accuracy of food composition databases and age-related differences in how n-3 
PUFAs are digested and metabolised also pose problems for using FFQs. Adipose tissue 
levels of DHA are considered the most accurate reflection of dietary and supplement intake; 
however accessing this type of tissue can be difficult, whereas accessing blood is much 
easier. Blood is composed mostly of serum (non-cell component of blood without the 
clotting factors), plasma (serum plus the clotting factors), white blood cells and erythrocytes 
or red blood cells (RBC), with serum, plasma and RBCs the most commonly used to measure 
levels of EPA and DHA (Tan et al., 2012). Both plasma and RBC levels of DHA correlate well 
with dietary intake and brain tissue levels, the difference being that plasma and serum levels 
reflect recent intake (weeks) and RBC levels reflect long term intake (months) (Katan et al., 
1997; Kuratko & Salem, 2009). A large study with 306 women aged 43 to 69 found that both 
plasma and RBC levels were associated with EPA and DHA intake, with RBC fatty acid levels 
being better than plasma (Sun et al., 2007).  
The omega-3 index has been used an n-3 PUFA biomarker for assessing health risks 
associated with low levels of n-3 PUFAs, and as a way to quantify a low vs. high or deficient 
vs. sufficient level of n-3 PUFAs. The omega-3 index is calculated by taking the sum of EPA 
and DHA concentrations then dividing by total % fatty acid levels. The omega-3 index has 
been primarily used as a biomarker for coronary health disease risk (where an index score 
above eight is associated with the greatest cardio protection and an index score below four 
the least protection), but it is increasingly being used for assessing risk for dementia and 
cognitive decline (Harris & von Schacky, 2004). For example, Pottala et al. (2014) found that 
higher omega-3 index scores correlated with larger total brain and hippocampal volume in 





3.6.1 Brain and blood levels of EPA and DHA 
The levels of fatty acids in brain tissue are made up of approximately 50% PUFAs, in a 
roughly 1:1 DHA to ARA ratio (Denis et al., 2013). The amount of DHA to ARA is higher in 
grey matter but lower in white matter, although the ratio of these two fatty acids appears to 
change with age (Bradbury, 2011). For example, a study comparing the brain tissue of 2 year 
olds through to healthy 80+ year olds found that both DHA and LA increase with age, 
whereas ARA and all other PUFAs decrease with age (Carver, Benford, Han, & Cantor, 2001). 
Despite the increase in LA, the study found that LA metabolites such as DGLA (C20:3n-6), 
ARA (C20:4n-6) and DPAn-6 (C22:5n-6) decreased with age, which the authors suggest may 
reflect a reduced conversion rate possibly due to a lack of desaturase enzymes. This study 
also investigated the relationship between cerebral cortex fatty acid levels and RBC fatty 
acid levels, and found a significant relationship in those over 18 years of age particularly for 
palmitic acid (C16) but also for DHA. In contrast to the increase in DHA with age in healthy 
brain tissue, several plasma, RBC and brain analysis studies of older adults with AD and MCI 
have shown a decrease in DHA levels. 
Conquer et al. (2000) tested plasma fatty acid levels in 19 older adults with AD, 10 
older adults with other forms of dementia (OD), 36 with CIND and 19 controls, and found 
decreased levels of DHA, total n-3 PUFAs and n-3:n-6 ratio in older adults with AD, OD and 
CIND. Tully et al. (2003) found that 139 older adults with AD (otherwise well-nourished and 
generally physically healthy) had approximately half the amount of serum DHA than the 
control group, as well as lower levels of EPA and n-3 PUFAs and higher levels of SFAs. Tully et 
al. also found higher ALA:DHA ratios in older adults with AD compared to controls indicating 
a lower conversion rate, perhaps due to a lack of enzymes or co-factors. Roberts et al. 





significant dose-dependent decrease in risk for those with a high dietary intake of n-3 PUFAs 
(OR = 0.62) and total PUFAs (OR = 0.44) as well as a high ratio of combined PUFAs + 
MUFAs:SFAs (OR = 0.56) compared to those in the lowest tertiles for dietary intake. Lopez, 
Kritz-Silverstein, and Barrett-Connor (2011) found that higher levels of plasma and dietary 
DHA were significantly associated with reduced odds of AD and all other causes of dementia 
in 266 older adults including 72 with dementia. Milte et al. (2011) found lower EPA levels as 
well as higher DGLA, ARA and DPA n-6 levels in older adults with MCI compared to healthy 
controls. Tan et al. (2012) found that lower RBC levels of DHA and EPA in late middle age 
were associated with smaller brain volumes (equivalent to 2 years of brain ageing) and 
vascular patterns of cognitive impairment.  
A meta-analysis by Lin et al. (2012) of 10 studies involving healthy controls, 481 older 
adults with dementia and 363 older adults with pre-dementia syndrome (MCI and CIND) 
found a significant decrease in EPA, DHA and total n-3 PUFAs in older adults with dementia, 
and a significant decrease in EPA but not DHA or total n-3 PUFAs in older adults with pre-
dementia. The authors suggest the lower EPA levels but not DHA in MCI and CIND indicates 
a possible link between EPA and risk for early cognitive decline, and may even indicate the 
use of EPA levels as a biomarker for cognitive decline (Lin et al., 2012). Several studies have 
not found significantly lower DHA or n-3 PUFAs levels in older adults with AD, CIND, ARCD or 
MCI compared to healthy older adults (e.g., Cherubini et al., 2007; Castellano, Chouinard-
Watkins, Brenna, Meyer, & Cunnane, 2011). One study even found higher EPA levels in older 
adults with CIND or MCI and higher levels of DHA, n-3 PUFA and total PUFA levels in those 
with dementia (Laurin, Verreault, Lindsay, Dewailly, & Holub, 2003). Whether low EPA and 





DHA could be due to low dietary intake, reduced conversion or synthesis due to reduced 
desaturation or due to the disease process itself (Tully et al., 2003). 
 
3.6.2 Epidemiological evidence  
Numerous prospective studies have shown an association between fish consumption 
and a lower risk of or slower rate of cognitive decline. The Rotterdam study with 5,386 non-
demented older adults found that fish consumption was inversely associated with an 
incidence of dementia, whereas SFAs and cholesterol levels were associated with an 
increased risk for dementia (Kalmijn et al., 1997). A 10-year follow-up analysis however, 
found that there was no longer an association between consumption of fish and n-3 PUFAs 
and long-term dementia risk (Devore et al., 2009).  A prospective cohort with 1,674 older 
adults aged 68 and over without dementia found a significant trend between eating fish and 
seafood and a decreased incidence of dementia (Barberger-Gateau et al., 2002). A 
prospective study involving 815 older adults without AD found that those who ate fish at 
least once a week had 60% less risk of AD, and that both DHA and n-3 PUFA intake were 
associated with a reduced risk of AD (Morris et al., 2003). A large epidemiological study 
involving 2,950 non-demented older adults in France found that those who ate fish or 
seafood once a week had a significantly reduced risk of dementia as did moderate alcohol 
drinkers (Larrieu, Letenneur, Helmer, Dartigues, & Barberger-Gateau, 2004).  
A prospective cohort study with 6,158 older adults over the age of 65 found that fish 
consumption, but not n-3 PUFA intake, was associated with slower cognitive decline with 
age (Morris et al., 2005). Another prospective follow-up study with 899 older adults as part 
of the Framingham Heart Study found that high plasma DHA levels (equivalent to three 





risk (Schaefer et al., 2006). A prospective cohort of older men found that fish consumers had 
less cognitive decline after the 5 and 10-year follow up, and a dose-dependent relationship 
between intake of n-3 PUFAs, EPA and DHA and cognitive decline (van Gelder, Tijhuis, 
Kalmijn, & Kromhout, 2007). A large US based prospective diet pattern analysis study 
involving 2,148 older adults found that a diet high in n-3 PUFAs, n-6 PUFAs, vitamin E, and 
folate, but with lower SFA levels, was significantly associated with reduced AD risk, whereas 
the nutrients individually were not (Gu, Nieves, Stern, Luchsinger, & Scarmeas, 2010). The 
study also found that older adults who were current smokers and less educated were less 
likely to adhere to a diet high in these nutrients, and that men were less likely to adhere 
than women.   
Several cross-sectional studies have shown an association between fish consumption 
and better cognitive performance. A cross-sectional, population-based study with 1,613 
older adults from 45 to 70 years found that fatty fish consumption was associated with a 
reduced risk of impaired cognitive function, whereas intake of cholesterol and saturated 
fatty acids was associated with an increased risk of impaired cognitive function (Kalmijn et 
al., 2004). A large cross-sectional study with 2,031 older adults between 70 and 74 years of 
age found that a diet high in fish and fish products was associated with better cognitive 
performance in a dose dependent manner, particularly for non-processed lean and fatty fish 
(Nurk et al., 2007). Baseline data from a large study with 867 non-demented older adults 
between 70 and 79 years of age also found a positive association between high levels of fish 
consumption, particularly for oily fish, and higher scores in cognitive tests (Dangour et al., 
2009). In contrast, a study with 1,025 older men from the Veterans Affairs Normative Aging 
study did not find an association (the model was adjusted for age, educational level, BMI, 





nor n-3 PUFA intake with cognitive performance (van de Rest et al., 2009).  
It appears the presence or absence of the APOE ɛ4 allele may be a modulating factor 
between fish consumption and cognitive decline. A longitudinal epidemiologic study with 
915 older adults found that one meal of fish or seafood per week was associated with a 
slower decline in semantic memory, with slower rates of decline in global cognition, episodic 
memory and perceptual speed in APOE ɛ4 carriers, but not in non-ɛ4 carriers (van de Rest et 
al., 2016). van de Rest et al. also found that higher intake of ALA was associated with slower 
global cognitive decline in ε4 carriers. In contrast an observational follow-up study with 120 
older adults found that DHA and total n-3 PUFA concentrations were associated with 
cognitive benefits, but only significantly in non-ɛ4 carriers when controlled for sex and IQ at 
age 11 (Whalley et al., 2008). Two other studies found that consumption of fatty fish twice a 
week (but not fried lean fish) was associated with a reduced risk for dementia for non-ɛ4 
carriers but not ε4 carriers (Huang et al., 2005), and that daily consumption fish and n-3 
PUFA oils was associated with a decreased risk for dementia among non-ε4 carriers 
(Barberger-Gateau et al., 2007). A possible explanation for these findings comes from a 
study by Plourde et al. (2009) who found that while ɛ4 carriers had significantly higher 
baseline EPA and DHA levels in plasma, the incorporation of EPA and DHA from a fish oil 
supplement was decreased in ɛ4 carriers, and in fact EPA plasma levels did not increase in ɛ4 
carriers despite a very high dose of 1900 mg of EPA per day for six weeks.  
The discrepancies between the evidence for fish consumption, for n-3 PUFA, EPA and  
DHA intake and n-3 PUFA levels suggests that the protective effect of fish consumption may 
be from more than the n-3 PUFA content. For instance, fish may provide a preventative 
effect via the vitamin E and D content of oily fish, as a form of easily digested protein or as 





of cognitive decline as well as genetic, demographic, cultural and lifestyle factors are also 
likely to play a part (Dacks, Shineman, & Fillit, 2013). For example, Barberger-Gateau et al. 
(2002) found that fish consumption was higher in participants with higher education, and 
that the protective effect of weekly fish and seafood consumption was partly explained by 
higher education. 
 
3.7 Mechanisms for preventing cognitive decline 
There are several proposed explanations for how DHA, EPA and n-3 PUFAs work to 
decrease or prevent cognitive decline pathology. Firstly, n-3 PUFAs may work by decreasing 
amyloid β deposits and the effects of these deposits on oxidative stress, inflammation and 
apoptotic cell death. Secondly, they could work by providing protective vascular and 
cardiovascular effects. Thirdly, n-3 PUFAs may benefit by directly reducing inflammation by 
inhibiting pro-inflammatory mediators. Fourthly, by the specific role of DHA within the 
neuronal cell membrane (Lin et al., 2012), and lastly via the APOE gene.  
To date there have been no human studies specifically looking at the effects of n-3 
PUFAs on amyloid β deposits. The majority of evidence used to support the mechanisms by 
which n-3 PUFAs prevent cognitive decline comes from animal studies. However, there is 
some human-based research, including studies that show that n-3 PUFAs can help to reduce 
the effects of oxidative stress and protect human neural cells. The brain is particularly prone 
to oxidative stress due to a high content of multiple-bond PUFAs, in particular DHA and ARA, 
and because of the high production of free radicals due to the brain’s requirement for high 
amounts of oxygen and high consumption of glucose and low anti-oxidant protective 
defences (Floyd & Hensley, 2002). A RCT involving 59 type 2 diabetic adults between 40 and 





significantly decreased by a 6-week course of EPA or DHA supplement (Mori et al., 2003). 
Another trial involving 162 adults found that 3-months of an EPA + DHA supplement 
significantly decreased plasma 8-isoPGF2a, which is a biomarker of lipid peroxidation and 
oxidative stress (Nälsén et al., 2006). Another study by Lukiw et al. (2005) found that DHA-
derived lipid mediator neuroprotectin reduced amyloid β secretion in cytokine-stressed 
human neural cells. 
 The protective vascular and cardiovascular effects of n-3 PUFAs are thought to be 
primarily via the anti-thrombotic and vaso-dilatory effects of eicosanoids and docosanoids 
(Lin et al., 2012). EPA and DHA have been shown to reduce blood platelet reactivity, reduce 
plasma viscosity, reduce triglycerides and VLDL levels by increasing HDL cholesterol and to 
have an inhibitory effect on atherosclerosis and inflammation via inhibition of smooth 
muscle cell proliferation and altered eicosanoid synthesis (Holub & Holub, 2004). A RCT in 
adults with hypercholesterolemia (high cholesterol) found that an EPA + DHA supplement 
significantly improved brachial artery flow-mediated dilation and significantly reduced 
triglycerides (Goodfellow, Bellamy, Ramsey, Jones, & Lewis, 2000). In a RCT involving adults 
awaiting carotid endarterectomy surgery (to remove arterial plaque build-up) showed that 
those given the EPA + DHA supplement compared to the sunflower oil and control groups 
had plaques with well-formed, thick fibrous caps (less likely to rupture) indicating an 
enhanced stability of the atherosclerotic plaques (Thies et al., 2003). Thies et al. also found 
those given the EPA + DHA supplement had a reduced number of macrophages in the 
plaques (indicating less infection) and no signs of inflammation. By way of inhibiting platelet 
aggregation, EPA and DHA are also thought to increase blood flow and supply of nutrients to 
the brain as well as increase the removal of toxic metabolites and proteins from the brain 





 EPA, DHA and n-3 PUFAs have been shown to directly reduce inflammation by 
inhibiting pro-inflammatory mediators such as inflammatory cytokines including 
interleukins, tumour necrosis factor and mitogens and by inhibiting the production of ARA-
derived pro-inflammatory eicosanoids (Holub & Holub, 2004). For example, the OmegAD 
trial involving 174 older adults with AD found that higher plasma levels of EPA and DHA 
were associated with a decrease in the pro-inflammatory factors interleukin-1b, interleukin-
6 and granulocyte-stimulating factor by immune cells (Vedin et al., 2008). Another study 
involving dialysis patients found that a supplement containing DHA + gamma tocopherol 
(vitamin E) significantly decreased plasma interleukin-6 concentrations and total white blood 
cell count including neutrophils – all of which are signs of infection and inflammation 
(Himmelfarb et al., 2007). 
DHA plays a significant role within the neuronal cell membrane where it affects nerve 
conduction, neurotransmitter release and neurotransmitter reuptake (Morris et al., 2003). 
DHA is also an important regulator of brain glucose uptake, possibly by selectively affecting 
the activity of glucose transporters (Freemantle et al., 2006). EPA and DHA are also involved 
in the regulation of gene expression of cells via peroxisome proliferator activated receptors 
and sterol regulatory element binding protein, allowing the cell to metabolize fuel according 
to the availability in the external environment (Pégorier, May, & Girard, 2004). There is 
evidence to support a homeostatic mechanism that controls how DHA is used, stored and 
conserved within the body, especially when dietary intake is low. For example, Rosell et al. 
(2005) compared plasma proportions of dietary fatty acids, including LA, ALA, EPA and DHA 
in meat-eating, vegetarian and vegan men, and found lower EPA and DHA levels in 
vegetarians than meat-eaters, and even lower levels in vegans. The authors noted that the 





a source of EPA and DHA. Rosell et al. found that the vegan group showed stable DHA 
concentrations, regardless of whether it had been one or 20 years since becoming a vegan, 
indicating that humans can convert ALA to DHA when there is a deficiency or a diet low in n-
6 PUFAs, as the ratio of LA:ALA was inversely correlated with EPA and DHA. 
As of yet, it is not clear how n-3 PUFAs interact with the APOE ɛ4 allele in cognitive 
decline. The first possibility is via cholesterol homeostasis as APOE is one of the main 
carriers of cholesterol within the brain. Research shows that ɛ4 carriers have the lowest 
levels of APOE in the blood, brain and CSF as well as the highest levels of plasma and LDL 
cholesterol, most probably because the ɛ4 allele is the least effective in lipid membrane 
turnover and the most inefficient at delivering PUFAs, particularly DHA, to glia, neurons and 
membranes (Lane & Farlow, 2005; Barberger-Gateau et al., 2011; Poirier et al., 2014). 
Minihane et al. (2000) investigated the effects of a fish oil supplement (equivalent to 3000 
mg of EPA and DHA per day) on cholesterol levels in ɛ2, ɛ3 and ɛ4 carriers and found that 
both ɛ3 and ɛ4 carriers showed a decrease in fasting circulating triglycerides, but not as 
much as ɛ2 carriers who also showed a substantial decrease in lipoprotein lipase (a 
lipoprotein that breaks down fats) and postprandial (after food) circulating triglycerides.  
The other possibility is via neurodegenerative processes, where ɛ4 has been associated 
with faster myelin breakdown, greater hippocampal atrophy and reduced neuroplasticity 
capacity along with greater inflammation and oxidative stress (Blennow et al., 2006; Fjell & 
Walhovd, 2010; Barberger-Gateau et al., 2011). APOE is involved in the binding, clearance 
and metabolism of the amyloid β peptide and in tau protein metabolism, where ɛ4 appears 
to have the lowest affinity and therefore be the least effective of the three alleles thereby 
“acting as a pathological chaperone” (Lane & Farlow, 2005, pg. 962). The fact that ɛ4 carriers 





suggests that at best n-3 PUFAs may only provide a neuro-protective effect to prevent 




The pharmacological and epidemiological evidence for the role of n-3 PUFAs in 
cognition in the mid to late stages of life is relatively strong, however some inconsistencies 
mean that no conclusive links can be drawn. Despite these inconsistencies, it is clear that 
humans require LA, ALA, ARA, EPA and DHA for optimal health, and that there is a need to 
understand which foods best provide these nutrients in a way that maximises the brain’s 
ability to perform and protect itself. It is also clear that the main issue with fatty acids is not 
so much the quantity that is consumed, but more so the ratio of different types of fatty acids 
consumed, with the Western-style diet having far too much saturated fatty acids and n-6 
PUFAs compared to n-3 PUFAs. There has been an increase in interest in the use of n-3 PUFA 
supplementation for the treatment of cognitive and behavioural conditions; however, it is 
still unclear at what stages it is most efficacious. Measuring the cognitive effects of n-3 
PUFAs may be difficult in older adults particularly those with a high cognitive reserve and 
those who are carriers of the APOE ɛ4 allele, and because of age-related changes in 
digestion and metabolism, and the homeostatic mechanisms by which DHA is used and 









FISH OIL SUPPLEMENT USE IN NEW ZEALAND 
 
This chapter has been published by Complimentary Therapies in Clinical Practice: 
Mengelberg, A., Leathem, J., & Podd, J. (2018). Fish oil supplement use in New Zealand: A 
cross-sectional survey. Complementary Therapies in Clinical Practice, 33, 118-123. 
 
Note.  This manuscript does not include the results from Section 2, Question 12 (see Appendix 
C) which asked whether respondents would be willing to have a blood sample taken as 








Objective: The aims of the survey were to determine: (i) the percentage of fish oil 
supplement users in a sample population; (ii) why people take fish oil supplements; (iii) 
where fish oil supplements are stored as well as the average daily dosage; (iv) what dietary 
and lifestyle behaviours are associated with fish oil supplement use  
Design: An online cross-sectional survey. 
Setting: New Zealand. 
Respondents: A total of 334 New Zealand residents over the age of 18. 
Results: Fish oil supplements were taken by 21.9% of respondents. Reasons for taking fish oil 
supplements were - 72.6% for ‘general well-being’, 54.8% to ‘improve brain function’, 31.5% 
for ‘pain/inflammation’, 12.3% to ‘lower cholesterol levels’ and 11% for ‘a dietary 
insufficiency’. Approximately 26% of fish oil users reported taking a dose of fish oil 
supplements that would meet the recommended daily intake of 400-600 mg combined 
docosahexaenoic acid and eicosapentaenoic acid, and only 6.8% of fish oil users reported 
storing their fish oil supplements in the refrigerator. After controlling for other 
characteristics including age, gender, ethnicity and body mass index, fish oil 
supplementation use was most likely among respondents who already eat oily fish and least 
likely in respondents who regularly eat nuts and seeds. 
Conclusions: Fish oil supplements are a commonly used supplement in New Zealand, yet 
questions remain about the role of these supplements in improving health outcomes. Safety 
issues related to manufacturing and storage conditions indicate that there is an urgency in 








Supplement use surveys indicate that there has been an increase in the use of fish oil 
supplementation over the last 10-20 years (Kantor et al., 2016; Fish oil, multivitamins still 
most used supplements, 2015). This popularity may be due to a number of studies showing 
the beneficial effects of omega-3, polyunsaturated fatty acids (n-3 PUFA) on learning 
difficulties and developmental conditions in school age children (Richardson et al., 2012; 
Portillo-Reyes et al., 2014; Bloch & Qawasmi, 2011), on mood and cognition (Sublette, Ellis,  
Geant, & Mann, 2011; Grosso et al., 2014; Stonehouse et al., 2013; Yurko-Mauro et al., 
2010), as well as cardiovascular and arthritic conditions (Delgado-Lista et al., 2012; Miller, 
Van Elswyk, & Alexander, 2014; Lee, Bae, & Song, 2012) in young, middle-aged and older 
adults. Despite these positive results, the majority of n-3 PUFA clinical trials have not found 
a significant improvement in outcomes, and several design issues have been proposed such 
as an insufficient dose, an insufficient duration, unknown baseline n-3 PUFA status, and the 
lack of a uniform biomarker to explain these negative and at times contradictory results 
(Stonehouse, 2014).  
Fish oil supplements contain two types of n-3 PUFAs – docosahexaenoic acid (DHA) 
and eicosapentaenoic acid (EPA). DHA and EPA are found in oily fish such as salmon, tuna, 
anchovies and sardines as well as krill and some shellfish. DHA and EPA and the plant 
derived alpha-linolenic acid (ALA) which is found in seeds and nuts, are important nutrients 
for bodily functioning, particularly brain functioning, due to their anti-inflammatory, anti-
thrombotic and vaso-dilatory properties (Parletta, Milte, & Meyer, 2013). DHA is one of the 
most dominant structural lipids in the brain, where it plays a protective role, and improves 
the fluidity of the neuronal cell membrane thereby influencing neuronal cell signalling 





therapeutic agents is steadily growing, it is still unclear what role they play in maintaining 
brain function from childhood to older age (Karr, Alexander, & Winningham, 2011). 
 In New Zealand (NZ), the Ministry of Health recommends an ‘adequate intake’ (AI) 
of 800 mg of ALA and 90 mg of combined DHA+EPA for women over 19 years of age and an 
AI of 1300 mg of ALA and 160 mg of combined DHA+EPA for men over 19 years of age, 
whereas the upper level at the 90th percentile, which provides a ‘potential benefit while still 
at a safe level’, is set at 430 mg/day combined DHA+EPA for women and 610 mg/day for 
men (Capra, 2006). This upper level is consistent with recommendations by the National 
Heart foundation to eat fish twice a week which would provide between 400 and 600 mg of 
combined DHA+EPA per day (Heart foundation, 2016). Most fish oil supplements in NZ 
contain between 1000-1500 mg of fish oil per capsule, equivalent to between 300-700 mg of 
n-3 PUFAs with the amount of DHA and EPA varying between 100-360 mg of DHA and 100-
540 mg of EPA.  
There has been considerable media attention in NZ regarding fish oil supplements 
after a study showed that of the 32 fish oil supplements tested from retail and online stores 
within NZ, 69% of the products contained less than 67% of the EPA and DHA content 
specified on the label, and that oxidation levels were higher than recommended 
international standards (Albert et al., 2015). Both DHA and EPA consist of long carbon chains 
with multiple double bonds which makes them very sensitive to light and heat, and 
therefore depending on manufacturing and storage conditions they can easily become 
oxidised and rancid. The New Zealand Institute for Plant and Food Research state that 
temperature is the number one contributing factor to the oxidation of oils (Miller, n.d.) and 
even though it is difficult for consumers to control or even access information about 





recommended that n-3 PUFA products including fish oils and ALA containing oils such as 
flaxseed and hemp seed oils are stored in opaque containers in a cool dark place such as a 
refrigerator.  
The 2008/2009 New Zealand Adult Nutrition Survey contains the most recent 
information about fish oil supplementation use in NZ (New Zealand Adult Nutrition Survey, 
2011). This survey showed that 30.7 % of the respondents (25.5% of males, 35.5% of 
females) were ‘regular’ users of supplements (‘regular’ meaning consumed a supplement at 
least once a week). The most frequently consumed supplements were ‘oils’ (fish oils, omega 
3, 6 and/or 9, flax/linseed oils and evening primrose) at 16.4% (13.7% of males, 18.9% of 
females), followed by multi-vitamins/minerals at 14.8%. In terms of ‘oils’ users, age was a 
significant factor for female ‘oils’ users, where 6.9 % of females aged 15-18 took oils, 
compared to 14.3% of females aged 19-30, 17.9% of females aged 31-50 and 24.8% of 
females aged 51 plus. The 2011-12 Australian Health Survey showed that 29% of 
respondents (33% of females, 24% of males) reported taking at least one dietary 
supplement on the previous day (Australian Health Survey, 2012). Multi-vitamin/multi-
mineral supplements were the most common dietary supplement at 16%, followed by fish 
oil supplements by 12% of the population. The highest percentage of fish oil users were in 
the 51+ age groups.  
The associations between supplementation use and demographics or other health 
behaviours have been extensively studied (Lyle, Mares-Perlman, Klein, Klein, & Greger, 1998; 
Kirk, Cade, Barrett, & Conner, 1999; Satia-Abouta et al., 2003; Archer et al., 2005; Rock, 
2007; Nahin et al., 2007). These studies have consistently found that supplement use is 
more common among women, older and more educated respondents, and in respondents 





activity, who drink low to moderate amounts of alcohol and who are less likely to be a 
current smoker of cigarettes. When studies have included dietary measures they have 
shown that supplement users generally report higher levels of dietary nutrient intakes and 
in some cases exceed the recommended daily allowances. The ‘inverse supplement 
hypothesis’ was proposed to explain why people who are most likely to take supplements 
were often the people that need them the least. In support of this hypothesis a study found 
that 43% of a sample of Australians over the age of 51 consumed fish oil supplements, and 
that these fish oil consumers had a higher daily intake of finfish or seafood than those who 
were non-supplement consumers (Grieger, Miller, & Cobiac, 2013). Reasons for why people 
take supplements vary, generally either to ‘improve overall health’ or for ‘general well-
being’ as a preventive measure or to treat a medical condition or a symptom such as cancer 
or pain. Respondents from the National Health and Nutrition Examination Survey indicated 
that they were most likely to use fish oil supplements for ‘heart health or to lower 
cholesterol’ (Bailey et al., 2013).  
The current survey was designed to provide an update on the use of fish oil 
supplementation in a sample population of New Zealanders, and to determine why people 
use fish oil supplements. To date very few surveys have specifically asked fish oil users what 
dose they take and where the fish oils are stored. These questions were addressed as well as 
testing the hypothesis that fish oil users are likely to be more health conscious and therefore 









Survey population  
This online survey was a cross-sectional analysis of a sample of the general 
population in New Zealand over the age of 18. The survey was advertised for a 6-month 
period from June until November 2015 on the Massey University School of Psychology 
mailing lists, the Massey University Facebook page, as well as through posters placed in 
public libraries, community centres and hospitals in main cities within New Zealand. All 
advertisements explained the purpose of the study and specified that anyone over 18 years 
of age could complete the survey. Respondents were instructed to click on a link or enter a 




The survey consisted of five sections; section 1 contained an information page with a 
consent question, section 2 contained demographic and general health questions, section 3 
questions about fish oil supplement use, section 4 about general supplementation use and 
section 5 contained questions about dietary habits and exercise. The demographic questions 
in section 2 included age, gender, city/town of residence, ethnicity, highest qualification 
achieved and annual salary. The general health questions included self-reported health 
status, whether a current tobacco smoker or not, and current height and current weight, 
which were used to calculate body mass index (BMI). Section 3 began with the question “Do 
you take fish oil supplements?”. If respondents answered ‘yes’ they were classified as a ‘fish 
oil user’ and completed section 3 which included questions regarding frequency of fish oil 





respondents used and where respondents stored their fish oil supplements. Once 
completed, ‘fish oil users’ were directed to section 4 which began with the question “Do you 
take any other types of supplements?”. If respondents had answered ‘no’ to taking fish oil 
supplements, they were classified as a ‘non-fish oil user’ and were automatically directed to 
section 4. 
Section 4 of the survey asked respondents to specify what type of other supplements 
they took along with questions regarding frequency, reasons for supplement use, where the 
supplements were purchased, how much is spent per month on supplements, what 
influenced the decision to select a supplement and whether respondents told their GPs that 
they took supplements. Respondents were able to select ‘I don’t take any supplements’ at 
the beginning of section 4 and were then directed to Section 5 which asked how often 
respondents ate oily fish, white fish, nuts and seeds, free range eggs/chicken/grass fed 
meat, as well as how many portions of fruit and vegetables respondents ate per day and 
how often respondents engaged in exercise for longer than 30 minutes at a time.  
 
Statistical analysis 
Statistical analysis of the data was conducted using SPSS version 24. Chi-square tests 
including Fisher’s exact test were performed to assess demographic differences between 
supplement users and non-supplement users, and between fish oil users and non-fish oil 
users. Logistic regression was used adjusted for age, gender, ethnicity, BMI, qualifications, 
smoking status, salary, self-reported health status, dietary intake of oily fish and nuts/seeds 
to assess what factors predict fish oil supplement use. P values equal to or less than 0.05 







A total of 346 New Zealand residents completed the survey, 12 (3.5%) respondents 
were omitted because they did not complete section 3, resulting in 334 being included in the 
analysis. More than a half of respondents, 223 (66.8%) reported taking at least one type of 
supplement and 73 (21.9%) of respondents reported taking a fish oil supplement.  
 
General demographics and supplement use 
Table 3 shows the demographics of the respondents, as well as the supplement and 
fish oil users by demographic factors. Using a chi-square test for independence, there were 
no significant differences between supplement users and non-supplement users in any of 
the demographic characteristics. The only significant difference between fish oil users and 
non-fish oil users was for the salary category $150,000 plus per year, χ2(7, p = 0.02). The 
sample was skewed in the demographic variables of age, gender and highest qualification 
gained – 194 (58.1%) of respondents were between 18-39 years of age, 262 (78.4%) of 
respondents were ‘female’ and 133 (39.8%) of respondents held a ‘post-graduate 
qualification’. This is probably due to the survey being posted on a psychology graduate 
email list The most common supplement used was a ‘multi-vitamin/mineral’ supplement 
(28.1 %), followed by ‘fish oil’ (21.9%), ‘Single mineral’- Magnesium (16.5%) and ‘Probiotics’ 
and ‘Single vitamin’- Vitamin C (15%).  
In terms of cost, 31.7% of respondents spent between ‘0-$19’ (NZD) on supplements 
per month, although over 38.6% of respondents did not respond to the question. 
Supplements were purchased from a supermarket (29.9%), at a pharmacy (28.1%), at a 
health shop (17.7%) and online (12.9%). Factors influencing respondents’ decisions to 










 Fish oil users  
Background factors    n %       n   %      n    % χ2 
Gender          Male 59 17.7  37 16.6  12 16.4  
                       Female 262 78.4  177 79.4  57 78.1  
                       Other 13 3.9  9 4  4 5.5  
Age                18-29 years 111 33.2  67 30  22 30.1  
                       30-39 years 83 24.9  59 26.5  17 23.3  
                       40-49 years 49 14.7  35 15.7  11 15.1  
                       50-64 years 74 22.2  51 22.9  18 24.7  
                       65-85 years  17 5.1  11 4.9  5 6.8  
Ethnicity       NZ Euro/Pak 252 75.4  174 78  56 76.7  
                       NZ Maori 23 6.9  12 5.4  3 4.1  
                       Pacific Islander 4 1.2  1 0.4  0 0  
                       Chinese 13 3.9  7 3.1  2 2.7  
                       Indian 4 1.2  2 0.9  0 0  
                       Other 38 11.4  27 12.1  12 16.4  
Education     HS attendance 11 3.3  8 3.6  4 5.5  
                       HS completed 19 5.7  14 6.3  3 4.1  
                       University Entry 26 7.8  16 7.2  4 5.5  
                       Trade/Polytechnic 22 6.6  17 7.6  7 9.6  
                       Diploma/Cert 27 8.1  21 9.4  7 9.6  
                       Bachelor’s degree 95 28.4  60 26.9  17 23.3  
                       Postgraduate  133 39.8  86 38.6  31 42.5  
Salary             0-$14,999 83 24.9  56 25.1  21 30  
(per annum) $15,000-$24,999 26 7.8  20 9  9 12.8  
                       $25,000-$ 44,999 60 18  40 17.9  12 16.4  
                       $45,000-$64,999 61 18.3  34 15.2   9 12.8  
                       $65,000-$84,999 57 17.1  38 17  9 12.8  
                       $85,000-$104,999 17 5.1  14 6.3  6 8.5  
                       $105,000-$149,999 12 3.6  7 3.1  0 0  
                       $150,000 plus 7 2.1  5 2.2  4 5.7 P < .05 
BMI               Underweight 5 1.5  4 1.8  2 2.7  
                       Healthy 183 54.8  118 52.9  41 56.2  
                       Overweight 81 24.3  52 23.3  15 20.5  
                       Obese 59 17.7  45 20.2  12 16.4  
Exercise        Never/Rarely 44 13.2  31 14  12 17.3  
                       Monthly/fortnightly 17 5.1  7 3.1      2     2.9  
                       1-2 times per week 97 29  67 30  16 23.1  
                       3-4 times per week 95 28.4  59 26.5  23 33.3  
                       5-6 times per week 45 13.5  35 15.6  9 13  
                       Every day 30 9  19 8.5  7 10.1  
Smoker         Yes 31 9.3  17 7.6  4 5.5  
                       No 303 90.7  206 92.4  69 94.5  





Table 4. Characteristics of fish oil supplement users 
 
                                           n                %          
How often           Every day 39 53.4 
                              4-6 times per week 11 15.1 
                              1-3 times per week 7 9.6 
                              Several times per month 11 15.1 
                              About once a month 1 1.4 
                              Less than once a month 4 5.5 
Length of time    Less than 3 months 14 19.2 
                              Between 3 to 6 months 12 16.4 
                              Between 6 to 12 months 8 11 
                              More than 12 months 39 53.4 
 Reason                General well-being 53 72.6 
                              To improve brain functioning 40 54.8 
                              For joint pain/inflammation          23 31.5 
                              Recommended by a health professional 





                              To lower cholesterol levels 9 12.3 
                              Dietary insufficiency 8 11 
                              Read about them on internet 8 11 
                              Other 





                              For skin health 3 4.1 
                              Read about them in a magazine 3 4.1 
Daily dosage        0 – 499 mg 1 1.4 
 of fish oil             500 – 999 mg 2 2.7 
                              1000 – 1499 mg 18 24.7 
                              1500 – 1999 mg 23 31.5 
                              > 2000 mg 19 26 
                              No idea 2 2.7 
                              No response 8 11 
Storage                In the pantry/food cupboard 





                              In the refrigerator 5 6.8 
                              No response 5 6.8 
                              Bedroom 4 5.5 







and brand (21.9%). Forty-one percent said they take supplements for ‘general well-being’, 
16.8% because they were prescribed by a health professional and 15.9% for a specific  
‘medical condition’. Ninety-five percent of supplement users take supplements at least once  
a month and 48.1% every day. Most respondents (62.8%) told their GP that they take 
supplements and 43.5% reported currently taking medications prescribed by a GP.   
 
Fish oil supplement users 
Table 4 shows that of the 21.9% of respondents who took fish oil supplements, 
53.4% reported taking them every day and 53.4% reported having taken them for longer 
than 12 months. Reasons for taking fish oils were – 72.6% for ‘general well-being’, 54.8% to 
‘improve brain function’, 31.5% for ‘pain/inflammation’, 12.3% to ‘lower cholesterol levels’ 
and 11% for a ‘dietary insufficiency’. Around 26% of fish oil users are taking a dose of fish oil  
that would meet the daily recommendations for DHA and EPA, and 6.8% of fish oil users 
store their fish oil supplements in the refrigerator. After controlling for other characteristics 
(age, gender, ethnicity, BMI, self-reported health status, highest qualification, annual salary, 
smoking status, exercise, consumption of oily fish, and consumption of nuts and seeds) fish 
oil supplement use was most likely among respondents who eat oily fish (p<0.01), in 
respondents who identify as ‘Other’ in terms of gender (p<0.01) and who report an annual 
salary of ‘$150,000 plus’ (p<0.01). Table 5 also shows that when controlling for all of these 
characteristics, fish oil supplement use was least likely in respondents with a highest 
qualification of ‘university entrance’ and ‘diploma/certificate’ (p<0.05), in respondents who 
eat nuts (p< 0.01), and in respondents with an annual salary of ‘$45,000-$64,999’ and 





Table 5. Logistic regression model describing the relative probabilities of taking fish oil 
Variable P value OR (95 % CI) 
Gender                  Male <.001 1.00 
                               Female  1.66 (0.58, 4.79) 
                               Other  23.13 (2.74, 195.21) 
Eats oily fish         Never <.001 1.00 
                               Rarely  10.10 (1.33, 76.82) 
                               Once a month  19.45 (2.49, 152.12) 
                               Once a fortnight  9.06 (1.28, 64.16) 
                               1-2 times per week  15.16 (2.17, 105.98) 
                               > 2 times per week  5.67 (0.56, 57.26) 
Qualification        HS attendance <.05 1.00 
                               HS completed  0.09 (0.007, 1.09) 
                               University Entrance  0.08 (0.007, 0.85) 
                               Trade/Polytechnic  1.36 (0.13, 13.96) 
                               Diploma/Certificate  0.08 (0.007, 0.99) 
                               Bachelor’s degree  0.20 (0.03, 1.51) 
                               Postgraduate degree  0.27 (0.37, 1.87) 
Salary                     0-$14,999 <.001 1.00 
(per annum)         $15,000-$24,999  0.87 (0.24, 3.07) 
                               $25,000-$ 44,999  0.47 (0.17, 1.29) 
                               $45,000-$64,999  0.15 (0.04, 0.53) 
                               $65,000-$84,999  0.17 (0.05, 0.61) 
                               $85,000-$104,999  0.25 (0.04, 1.43) 
                               $105,000-$149,999  0 
                               $150,000 plus  46.88 (3.83, 573.62) 
Eats nuts/seeds   Never <.05 1.00 
                               Rarely  0.41 (0.02, 7.4) 
                               Once a month  0.04 (0.002, 0.86) 
                               Once a fortnight  0.02 (0.001, 0.41) 
                               1-2 times per week  0.15 (0.01, 2.1) 
                               > 2 times per week  0.33 (0.02, 4.42) 




In this sample of 334 New Zealanders, 66.8% reported using supplements. This figure 
is more than double the number of supplement users in both the 2008/2009 New Zealand 
Adult Nutrition Survey and the 2011-12 Australian Health Survey. This figure is also higher 
than three NZ based supplement surveys, which showed 16.6%, 38.1% and 47% of 





Almost 30% of respondents in the current survey purchased their supplements from a 
supermarket, compared to only 2.5% of respondents from a 2006 NZ survey (Bacon, 2011). 
This may represent a change in shopping habits, where the convenience and lower prices of 
a supermarket may be deciding factors. 
Fish oil supplements were used by 21.9% of respondents in the current survey, 
second only to multi-vitamin/mineral supplements at 28.1%. This finding is consistent with 
the 2011-12 Australian Health Survey, although in lower numbers in this survey at 12% and 
16% respectively. In the 2008/2009 New Zealand Adult Nutrition Survey, ‘oils’ were the most 
commonly used supplement at 16.4%, where ‘oils’ included fish oil supplements as well as 
evening primrose and flaxseed oils. Again this figure is lower than in the current survey with 
an equivalent total of approximately 25% (n = 83) of respondents using fish, evening 
primrose or flaxseed oils. The higher percentage of fish oil users in the current survey 
compared to the 2008/2009 New Zealand Adult Nutrition survey indicates that fish 
supplement use is increasing in NZ.  Fish oil users in the current study reported taking fish oil 
supplements for ‘general well-being’(72.6%), to ‘improve brain functioning’ (54.8%), for 
‘pain/inflammation’(31.5%), to ‘lower cholesterol levels’(12.3%) and for ‘dietary 
insufficiency’(11%), indicating that fish oils are used to both prevent and treat health 
conditions. 
The 2008/2009 New Zealand Adult Nutrition Survey showed that 24.8% of females 
aged 51 plus took ‘oils’ compared to 31.5% of fish oil users over the age of 50 in the current 
study, indicating an increase in use in older adults. A large US survey showed that 65+year 
olds were more likely to be fish oil users than 20-39 and 40-64 age groups, and that the 65+ 
age group showed the biggest increase in fish oil supplement use from the 1999-2000 to the 





Kingdom (UK) showed that ‘oils’, in particular fish liver oil, are the most commonly used 
supplement in older adults in the UK, and that ‘oils’ are more commonly used by older men 
with the highest BMI and in lower social classes, and in older women with the least healthy 
diets (Denison et al., 2012). The authors suggest that this high prevalence maybe due to the 
widespread use of fish liver oil in childhood, indicating a habitual pattern of use, possibly 
related to dietary insufficiency and socio-economic status. The current survey showed that 
43% of fish oil users over 50 years of age take fish oils to ‘improve brain functioning’ and 
65% for ‘general well-being’, whereas only 17% take fish oils to ‘lower cholesterol levels’. 
The fact that 60% of fish oil users under the age of 50 years of age also reported using fish 
oil to ‘improve brain functioning’ indicates that both young and older adults believe fish oil 
supplementation can provide some benefit here.  
The increase in fish oil supplement use over the last two decades may be due to the 
link drawn between fish consumption and fish oil supplementation use, and improvements 
in cognition and memory. In older adults, epidemiological research has shown positive 
associations between fish consumption and both higher scores in cognitive tests (Dangour et 
al., 2009) and a slower rate in cognitive decline (Morris et al., 2005) in older adults, and yet 
clinical trials have shown mixed results in healthy older adults (van de Rest et al., 2008; 
Dangour et al., 2010; Nilsson, Radeborg, Salo, and Bjorck, 2012). The findings from the 
current survey highlight the need for more well-designed intervention trials in both young 
and older adults with particular emphasis on the replication of design elements such as 
dose, duration and cognitive measures to help shed light on the conflicting results. 
The current survey showed that respondents who eat oily fish are most likely to take 
fish oil supplements. This result supports the inverse supplement hypothesis that 





well. This finding is consistent with an Australian survey which found that fish oil consumers 
had a higher daily intake of finfish or seafood than non-supplement consumers despite 
being no different in gender, education or BMI (Grieger et al., 2013). The current survey also 
showed that fish oil supplement use was least likely in respondents who eat nuts and seeds. 
Nuts and seeds such as walnuts, flaxseeds, chia seeds and pumpkin seeds are all sources of 
ALA which can be converted to DHA and EPA. It is likely that this group may represent 
vegetarians and vegans who do not consume fish, and therefore eat nuts and seeds as a 
source of n-3 PUFAs. 
The majority of fish oil users in the current survey reported taking a fish oil 
supplement that contained 1000 mg of fish oil equivalent to 120 mg of DHA and 180 mg of 
EPA per capsule. This means that a dose of at least 2000 mg of fish oil per day would be 
required to meet the National Heart foundation recommendations of 400-600 mg DHA and 
EPA. Around 26% of fish oil users would meet these recommendations, although exactly 
how much n-3 PUFAs fish oil users were also getting from their diet is unclear. With huge 
variation in dietary recommendations for n-3 PUFAs, DHA and EPA, and very limited 
information regarding dosing requirements for specific conditions, there is a need for 
further research in this area. 
Contraindications between fish oil supplements and other medications particularly 
with anti-coagulants like warfarin can be potentially serious due to the blood thinning action 
of n-3 PUFAs. The current study showed that 62.8% of supplement users tell their GPs of 
their use. Over 40% of supplement users reported that they are currently taking medications 
prescribed by a GP and over a half (51.4%) of supplement users who take medications tell 





up” or “I wasn’t asked”. This highlights the need for GPs to ask patients about their 
supplementation use.  
In terms of the harmful effects of oxidised supplements, the current survey showed 
that only 6.8% of fish oil users reported storing their capsules in the refrigerator and 29.9% 
of supplement users reported purchasing their supplements at the supermarket, where 
supplements are typically displayed under bright florescent lights. It appears more can be 
done in terms of educating manufacturers, retailers and consumers in the appropriate 
storage conditions for this type of supplement.  
Levels of the toxic mineral mercury and the sustainability of fish stocks are major 
concerns for consumers of fish oil supplements. Higher levels of mercury are typically found 
in larger predator, deep sea fish such as tuna and swordfish, but not in smaller short-lived 
fish such as sardines, anchovies and salmon (Mozaffarian & Rimm, 2006). Several species of 
fish high in n-3 PUFAs such as bluefin tuna are currently classified as endangered. More 
recently the New Zealand Institute for Plant and Food Research Plant and the 
Commonwealth Scientific Industrial Research Organization in Australia have begun looking 
at sustainable sources of n-3 PUFAs such as marine algae, shown to be a viable and 
sustainable source of DHA for vegetarians and vegans, where there are no issues with toxic 
mercury levels (Nichols, McManus, Krail, Sinclair, & Miller, 2014; Ryan & Symington, 2015). 
There are several limitations with the current survey, largely to do with the 
unrepresentative sample which was mostly youngish, highly-educated females. Several 
questions had a high number of ‘no response’ which limited analysis.  Respondents of the 
survey may have had more of an interest in supplementation, and this may be reflected in 







Fish oil supplementation was used by 21.9% of a sample of 334 New Zealanders. 
Over half of these fish oil users had been taking a fish oil supplement for longer than 12 
months, and it appears that those who eat oily fish are most likely to take fish oil 
supplements. Fish oil supplementation use has increased over the last two decades both 
worldwide and in NZ, yet questions remain about the role of DHA and EPA in brain health, 
what exactly is a ‘sufficient’ daily dose and which health conditions show the most 
improvement from taking n-3 PUFAs. Safety issues related to manufacturing and storage 
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DHA SUPPLEMENT TRIALS IN OLDER ADULTS 
 
This chapter will review 23 randomised controlled trials (RCTs) that have investigated 
the cognitive effects of DHA supplements in older adults. For the purpose of this thesis, this 
review was limited to RCTs that used a capsulated DHA supplement, and which included 
participants within an age range or a mean age extending past the age of 60 to allow 
comparison with the current RCT. Details of the design and cognitive outcomes of each trial 
are summarised in Tables 6, 7 and 8. The chapter ends with a summary of all 23 RCTs. 
 
5.1 Cognitively healthy older adults 
Four large-scale intervention trials found no effect of DHA fish oil supplementation 
on cognitive performance in cognitively healthy older adults (see Table 6, studies 1-4). The 
first trial by van de Rest et al. (2008a) compared a high and low dose fish oil supplement 
with a placebo in 299 older adults, where the low dose was comparable to the Netherlands 
recommended intake of two fish portions per week with one oily and one non-oily fish. No 
main significant differences were found between the three groups on any of the cognitive 
tests, although there was a treatment effect in the attention domain (Digit Span Forwards 
Task) for APOE ɛ4 carriers indicating that ɛ4 carriers in both the low (p = .03) and high          





differences between the three groups on four depression scales including the short version 
of the Geriatric Depression Scale (GDS-15) (van de Rest et al., 2008b). In the second large    
(n = 728) trial by Dangour et al. (2010), a specific dose of n-3 PUFAs was used as it could be 
achieved by eating 250 g of oily fish per week (equivalent to 1.75 portions), and was based 
on UK recommendations for oily fish consumption. The results showed no differences 
between the fish oil group and placebo group in the cognitive measures over the two years 
of supplementation.  
In the third trial by Chew et al. (2015), 3024 older adults with drusens (yellow 
deposits under the eye) or late age-related macular degeneration (AMD) were allocated to 
one of four groups: DHA/EPA fish oil group, lutein/zeaxanthin group, DHA/EPA and 
lutein/zeaxanthin mix group and placebo group. Lutein is a carotenoid, typically found in 
red, orange and yellow fruits and vegetables that have anti-oxidant actions, particularly 
related to age-related decline, and zeaxanthin is one of the main carotenoids found within 
the retina (Craft, Haitema, Garnett, Fitch, & Dorey 2004). At the 5-year mark, neither the fish 
oil nor the lutein/zeaxanthin treatments had a statistically significant effect on cognitive 
function. The results showed that lower cognitive function at baseline was associated with 
increasing age, lower education level, and the male sex, as well as hypertension and other 
cardiovascular diseases including stroke. The fourth trial by Danthiir et al. (2018) used a high 
dose DHA fish oil supplement (1720 mg DHA + 600 mg EPA per day) in a final sample of 390 
older adults for 18 months. Again, there were no main significant differences between the 
fish and placebo groups on the cognitive measures, although a negative treatment effect 
was found for simple and choice reaction time (p < .01) and psychomotor speed (p < .01) in 





a significant improvement on reasoning (p = .02), whereas non-ɛ4 carriers performed worse 
on simple and choice reaction time (p = .01). 
Two smaller trials also found no treatment effect on cognitive performance in 
cognitively healthy older adults (see Table 6, studies 5 & 6). Stough et al. (2012) gave healthy 
older adults fish oil or a placebo for 90 days. The results showed no differences between the 
two groups in the cognitive measures as measured by a cognitive drug research 
computerised assessment system, including 11 tasks used to calculate five factor scores – 
speed of attention, speed of memory, accuracy of attention, secondary memory and 
working memory. The authors found that for participants with corrected vision, the fish oil 
group had significantly improved right eye visual acuity at the 90-day mark. Pase et al. 
(2015) conducted a 16-week trial combining fish oil supplementation with multi-vitamin 
(MV) supplements – high dose fish oil + MV, low dose fish oil + MV, high dose fish oil, 
placebo fish oil and placebo MV groups. There were no cognitive differences between the 
groups at the 16-week mark, although there was an association between the n-3:n-6 ratio 
and faster spatial working memory (r = -.17, p < .01). Compared to the placebo fish 
oil/placebo MV groups, there were no changes in DHA levels in the three groups. The study 
found that levels of n-6 PUFAs decreased in the high fish oil group, and that decreases in n-6 
PUFA were associated with decreases in brachial (r = .23, p < .01) and aortic pulse (r = .21,    
p < .01) pressure, and that increases in DHA were associated with decreases in diastolic 
aortic pressure (r = -.18, p < .01).  
Several smaller trials however, found positive results in cognitively healthy older 
adults (see Table 6, studies 7-11). Johnson et al. (2008) conducted a 4-month trial where 
participants were divided into four groups: DHA, lutein + zeaxanthin, DHA + lutein and a 





on cognition, without and in combination with n-3 PUFAs. At the 4-month mark women in 
the DHA (p = .03, d = 0.68), lutein (p < .01, d = 0.79) and DHA + lutein groups (p < .01,              
d = 1.54) scored better in a verbal fluency task compared to baseline. The DHA + lutein 
group showed a faster rate of learning on the shopping list task (p = .03, d = 0.74), recalled 
more items in a memory apartment test (p = .02, d = 0.58) and were more efficient at 
learning a word list (p = .07, d = 0.78) after 4-months of supplementation. After adjusting for 
age, higher DHA serum levels were associated with higher verbal fluency scores (r = .24,        
p = .04). Nilsson et al. (2012) conducted a 5-week crossover design trial in order to relate 
cognitive outcomes to cardiovascular parameters. The trial found significant treatments 
effects on working memory at 60-minutes (p = .04, d = 0.26), working memory test with 
nonsensical sentences (p = .01, d = 0.34) and working memory at 60 + 160-minutes (p = .02, 
d = 0.31). The study also showed that systolic blood pressure (p = .04, d = 0.46) and serum 
triglycerides (p = .05, d = 0.59) were significantly reduced after fish oil supplementation 
compared to after the placebo period, and that systolic blood pressure was inversely related 
to cognitive performance.  
Witte et al. (2013) found a fish oil treatment effect using an executive composite 
score (included z-scores of fluency tests, Trail Making Test versions B-A and Stroop), 
compared to the placebo group (p = .01, d = 0.75). The fish oil supplement group showed a 
significant increase in EPA proportions (p < .01, d = 1.49), and the results showed that letter 
fluency scores were correlated with these increases in EPA (r = .46, p = .01). There was a 
trend for memory consolidation according to a change in the omega-3 index, with the fish oil 
group showing more improvement than the placebo group (p = .09). The fish oil supplement 
resulted in significant increases in white matter structural integrity and increases in grey 





parietal and postcentral gyri, and right middle temporal gyrus. The authors also noted that 
improvements in executive functions in the fish oil group were associated with relative 
increases in brain-derived neuro-trophic factor (BDNF) (r = .46, p = .02), and that the fish oil 
group had a significant decrease in both diastolic blood pressure (p = .05, d = 0.34) and 
fasting triacylglycerides (p = .01, d = 0.39).  
 Strike, Carlisle, Gibson, and Dyall (2015) tested a DHA + EPA + Ginkgo biloba 
supplement and found significantly shorter psychomotor latencies (information processing 
speed)(p = .04, ƞp2 = .13), significantly more words remembered (verbal recognition 
memory)(p = .03, ƞp2 = .15) and an improvement in habitual walking speed (a measure of 
overall health and function) in the treatment group (p = .03, ƞp2 = .14). There were positive 
associations between DHA levels and habitual walking speed (r = .46, p < .05), fast walking 
speed (r = .55, p < .01) and vertical height jump (r = .49, p < .01). Külzow et al. (2016) used a 
visuospatial object location memory task (LOCATO) to assess cognitive performance with 
both learning and recall components. LOCATO was designed to be a meaningful and 
ecological assessment for older adults, as it assesses the ability to remember the location of 
objects, an ability that declines with age. Recall performance was significantly better in the 
fish oil group (p = .05, ƞp2 = .09) than the placebo group after controlling for dietary habits 
and APOE ɛ4 carrier status (p = .01, ƞp2 = .17) but not in the learning component of the 
LOCATO or in a German version of the RAVLT.  
 The results from the DHA supplement trials in cognitively healthy older adults are 
conflicting. The four large RCTs found no treatment effects except for a positive effect in 
attention and reasoning for APOE ɛ4 carriers. However, several of the smaller studies found 
positive treatment effects on memory (recall and working memory), and positive 





Table 6. Summary of fish oil trials in cognitively healthy older adults              




Placebo Cognitive Results Sampling 
tissue/change 
1. van de Rest 
et al. 2008 






Rx1: 847 DHA            
+ 1093 EPA      
Rx2: 176 DHA + 
226 EPA                





there was a treatment 
effect in APOE ɛ4 
carriers and in men in 
the digit span 
forwards task 
Plasma – Fatty acid 
profiles and APOE 
genotyping. 
EPA+DHA increased 
by 236% in Rx1 and 
51% in Rx2 
2. Dangour et 
al. 2010 
UK 24-months Rx: 434/13.4%   
Pb: 433/14.1% 
Total: 748 
70-79   
M=75 
Rx: 500 DHA + 
200 EPA                
2 capsules/day 
Olive oil No significant 
differences on any of 
the cognitive 
measures 
Serum – Fatty acid 
profiles at 24-
months. Rx showed 
higher DHA and EPA, 
and lower ARA  




USA 5-years Rx1: 1069/0.6%   
Rx2: 1044/0.6%    
Rx3: 1079/0.9%      




Rx1: 350 DHA + 
650 EPA           
Rx2: 10 lutein + 
2 zeaxanthin       
Rx3: 350 DHA + 
650 EPA + 10 
lutein + 2 
zeaxanthin   
Not specified Fish oil showed no 
statistically significant 
effect on cognitive 





Serum   
4. Danthiir et 
al. 2018 
Australia 18-months Rx: 203/4.4%           




Rx: 1720 DHA + 
600 EPA             
4 capsules/day 
Olive oil + 10 
mg fish oil 
equivalent to 
1.2 mg DHA + 
1.8 mg EPA 
No significant 
differences on the 
cognitive measures, 
except for a positive 
effect for APOE ɛ4 
carriers in reasoning  
RBC – Fatty acid levels 
and APOE. EPA levels 
increased by 212.4 %    
and DHA increased by 
84.9 % in Rx group 
Note. APOE = Apolipoprotein genotype, ARA = Arachidonic acid, DHA = Docosahexaenoic acid, EPA = Eicosapentaenoic acid, M = Mean, Pb = Placebo,                       





Table 6. (continued) 




Placebo Cognitive results Sampling 
tissue/change 
5. Stough et al. 
2012 
Australia 90-days Rx: 38               
Pb: 36              
No attrition 
information 
45-77    
M=57 
Rx: 252 DHA + 60 
EPA                        
1 capsule/day 
Soybean oil No significant 
cognitive differences 




Plasma – Levels 
of Phospholipid 
DHA. Rx showed 
1.79%   raised 
plasma 
phospholipid DHA  
levels           
6. Pase et al. 
2015 
Australia 16-weeks Rx1: 43/11.6%          
Rx2: 39/7.6%            
Rx3: 41/7.3%             




Rx1: 240 DHA+ 
240 EPA + MV                 
3 capsules/day   
Rx2: 480 DHA+ 
480 EPA + MV                 
6 capsules/day  
Rx3: 480 DHA+ 















although increases in 





RBC – Fatty acid 
levels. EPA 
increased by 96% 
in Rx2, 57% in Rx3 
but not in Rx1. No 
changes in DHA 
levels in all three 
Rx groups 
 
7. Johnson et al. 
2008 
USA 4-month 57/86%    
Total: 49    
Rx1: 14       
Rx2: 11        




Rx1: 800 DHA   
Rx2: 12 lutein  
Rx3: 800 DHA+ 12 




DHA, lutein and 
DHA+lutein groups 




rate of learning and 
recall compared to 
placebo  
Serum – DHA and         
lutein levels    





Table 6. (continued) 




Placebo Cognitive results Sampling 
tissue/change 
















Rx1: 1050 DHA + 
1500 EPA →Pb             
Rx2: Pb →1050 






salts of fatty 




between the fish 
oil and placebo 
intervention 
periods in several 
working memory 
measurements 
Serum – free                    
fatty acids 
9. Witte et al. 
2013 
Germany 26-weeks Rx: 40/20%    




Rx: 880 DHA + 1320 
EPA                           
4 capsules/day 
 
Sunflower oil Improved 
executive score 
(included fluency 
tests, TMT versions 
B-A and Stroop) in 
fish oil group 
compared to 
placebo  
RBC – fatty acid 
levels, BDNF. 
Increase in EPA 
10. Strike et al. 
2015 
UK 6-months Rx: 15/0%      
Pb: 13/7.7%     
Total: 27   
60-84 
M=67 
Rx: 1000 DHA + 160 
EPA + 240 Ginkgo 
biloba + 
phosphatidylserine 
+ Vitamin E + folic 











Whole blood – 
fatty acid levels.                  
Rx showed a 17% 
increase in DHA, a 
71% increase in 
EPA and an 18% 
decrease in ARA 
11. Külzow et al. 
2016 
 
Germany 26-weeks Rx: 40/45%    




  Rx: 880 DHA + 
1320 EPA                           
4 capsules/day 
 
Sunflower oil Recall of object 
location was 
significantly better 
in the fish oil group 
than the placebo 
group 
RBC/DNA – total 
fatty acid levels + 
APOE genotyping. 
Significant increase 
in the omega-3 
index in Rx group 





5.2 Older adults with cognitive impairment and dementia 
In older adults with dementia, the results from n-3 PUFA trials are also very mixed. The 
first of these trials by Quinn et al. (2010) gave participants with mild to moderate Alzheimer’s 
disease (AD) an algal derived DHA supplement for 18 months (contained no EPA) (see Table 7, 
study 12). DHA supplementation did not slow the rate cognitive or functional decline as 
measured by changes in the cognitive subscale of the Alzheimer’s Disease Assessment Scale 
(ADAS-cog) and the Clinical Dementia Rating (CDR) sum of boxes. There were also no differences 
in the changes in total brain volume using MRI between the two groups. Quinn et al. found a 
significantly lower decline in mean change in the ADAS-cog for APOE non-ɛ4 carriers in the fish 
oil group (p = .03, d = 0.76) than for non-ɛ4 carriers in the placebo group. 
More promising results have been found in milder forms of dementia (see Table 7, 
studies 13 & 14). Freund-Levi et al. (2006) found no differences between two treatment groups 
of AD using the MMSE and ADAS-cog, although there was a significant difference in the change 
in mean MMSE scores in a subgroup of patients with a MMSE score > 27 points (classified as 
‘mild AD’) (p < .01, d = 0.68). There were also significant treatment effects for two MMSE sub-
items, delayed word recall (p < .01, d = 0.31) and attention (p < .01, d = 0.58). Using the 
Neuropsychiatric Inventory, Freund-Levi et al. (2008) found significant differences in 
hallucination (p = .04) scores changes in favour of the fish oil group, in irritation (p = .01) scores 
changes in favour of the placebo and a significant positive treatment effect in the agitation 
domain scores for APOE ɛ4 carriers (p = .01). Using the Montgomery Asberg Depression Scale the 
authors also found that non-ɛ4 carriers in the fish oil group showed a significant positive effect 
on scores (p = .01) compared to non-ɛ4 carriers in the placebo group. A pilot study by Terano et 
al. (1999) found that in a group of older adults with dementia from thrombotic cerebrovascular 





three months (p < .05, d = 0.57) and six months (p < .05, d = 0.48) and on the MMSE after six 
months (p < .05, d = 0.39) but not after 12 months. The authors found that red blood cell (RBC) 
deformability significantly improved in the DHA group (p < .01), and that DHA:ARA ratio was 
positively correlated with scores on the HDS-R (r = .44, p < .05).  
Three clinical trials included both older adults with dementia and older adults with mild 
cognitive deficits, and two found a significant cognitive effect but only in the mild cognitively 
impaired older adults (see Table 7, studies 15-17). The first trial by Kotani et al. (2006) used a 
Japanese version of the Repeatable Battery for the Assessment of Neuropsychological Status 
(RBANS) in older adults with MCI, AD and organic brain lesions. Kotani et al. found that older 
adults with MCI showed significant improvements in both immediate memory (p < .01) and 
attention (p < .05) from a DHA + ARA supplement compared to the placebo, and that the 
participants with organic brain lesions showed improvement from the baseline scores in 
immediate (p < .01) and delayed memory (p < .01) from the DHA + ARA supplement.  
The second trial by Chiu et al. (2008) with AD and MCI participants found a significant 
improvement in disease severity as measured by the Clinician’s Interview-Based Impression of 
Change scale in those who took the fish oil supplement (p = .01). After adjusting for age, gender 
and education, MCI participants in the fish oil group showed greater improvement in the ADAS-
cog than the placebo group (p = .03), whereas the change in ADAS-cog scores in AD participants 
was the same for the fish oil and placebo groups. The trial also found that better ADAS-cog 
scores were associated with higher levels of EPA (p < .01). The third trial by Phillips, Childs, 
Calder, and Rogers (2015) involved older adults with Cognitive impairment no dementia (CIND) 
and AD, and found no significant treatment effects for any of the cognitive or mood measures, 
although there was a trend for improved visual memory (p = .09) from the Rivermead 





Two trials have specifically focused on older adults with subjective memory complaints 
and MMSE scores below 26 (see Table 7, studies 18 & 19). The first trial by Yurko-Mauro et al. 
(2010) used an algal supplement in older adults with age-related cognitive decline (ARCD). 
Participants were further excluded if they had a raw score of ≥ 1 SD below the mean for younger 
adults in the logical memory subtest from the Wechsler Memory Scale (WMS-III). The DHA group 
had significantly fewer errors on the Cambridge Neuropsychological Test Automated Battery 
Paired Associate Learning (PAL) Test (p = .03), and improved immediate (p = .02) and delayed 
verbal memory (p = .01) compared to participants in the placebo group at the 24-week mark. 
Plasma DHA levels significantly increased in the DHA group (p < .01) and were correlated with 
improved PAL scores (r = -.11, p < .02). The DHA group also showed a significant decrease in 
heart rate (p < .03) at the 24-week mark.  
The second trial by Vakhapova, Cohen, Richter, Herzog, and Korczyn (2010) investigated 
the effects of a phosphatidylserine (PS) and DHA combination (PS-DHA) vs. a placebo in non-
demented elderly participants with memory complaints for 15-weeks. The study showed that 
the PS-DHA group had significantly improved immediate recall in the RAVLT (p = .04) at the 15-
week mark compared to the placebo group. The authors found that participants in PS-DHA group 
with a higher cognitive status at baseline (n =78) showed the most improvement in RAVLT 
immediate recall (p = .01), total learning (p < .01) and delayed recall (p = .04).  
The DHA supplement trials in older adults with cognitive impairments and dementia have 





Table 7. Summary of fish oil trials in older adults with cognitive impairment and dementia 
 




Placebo Cognitive results Sampling 
tissue/change 
12. Quinn et al. 
2010 
 
USA 18-months Rx: 238/28.1%            
Pb: 164/24.4%     
Total: 295  
M=76 Rx: Algal – 
approx. equiv. 
to 1000 DHA                  
2 capsules/day 
Either corn 
or soya oil 
DHA supplementation did 
not slow the rate of decline 
as measured by changes in 
the ADAS-cog and CDR sum 
of boxes 
Plasma, CSF –  
phospholipid fatty 
acid levels, APOE. 
DHA levels 
increased by 207% 
in the Rx group 
13. Freund-Levi  







Rx fish oil) 
Rx: 103/13.6%  
Pb: 101/15.8%           
Total: 174 
M=73 Rx: 1720 DHA + 
600 EPA                 
4 capsules/day 
4000 mg of 
corn oil 
equivalent to 
2400 mg of 
LA 
No differences were found 
between the two groups 
using the ADAS-cog; fish oil 
group with a MMSE score > 
27 showed significantly 
different change in MMSE 
scores from baseline to 6-
months  
Serum – fatty acid 
levels, APOE.                  
Rx group showed a 
2.4-fold increase in 
DHA and a 3.6-fold 
increase in EPA 
14. Terano et al. 
1999 
 
Japan  12-months Rx: 10           
Pb: 10      
Total: 20 
M=83 Rx: 720 DHA         
6 capsules/day 
Not specified DHA group scores 
improved on the HDS-R 
and MMSE compared to 
the placebo after 3 and 6-
months 
Serum – fatty acid 
levels. In the RX 
group DHA levels 
increased by 79% 
and EPA by 70%  




Japan 90-days MCI-Rx: 12  
MCI-Pb: 9     
AD-Rx: 8             
OBL-Rx: 10 
Total: 39 
M=64 Rx: 240 DHA + 
240 ARA                  
6 capsules/day 
240 mg of 
Olive oil 
MCI-Rx showed significant 
improvements in 
immediate memory and 
attention; OBL showed 
significant improvement in 
immediate and delayed 
memory 
Serum – fatty acid 
levels. No serum                   
changes were 
found 
Note. ADAS-cog = Cognitive subscale of the Alzheimer’s Disease Assessment Scale, AD = Alzheimer’s disease, CDR = Clinical Dementia Rating,                    






Table 7. (continued)         
 




Placebo Cognitive results Sampling 
tissue/change 




Taiwan 24-weeks MCI: 23       
AD: 23                 
Rx: 24/29.1%     
Pb: 22/45.5% 
Total: 29     
70-82 
M=75 
Rx: 720 DHA + 
1080 EPA           
3 capsules/day 
Olive oil          
3 caps/day 
MCI-Rx group showed a 
significant improvement in 
ADAS-cog score than placebo 
group; no change in ADAS-
cog scores in AD-Rx   
RBC and plasma –   
fatty acid levels 
17. Phillips et al. 
2015 
 
UK 4-months CIND:57      
AD:19    
Rx:37/2.7%           
Pb:39/7.7%       
Total: 72 
M=71 Rx: 625 DHA + 
600 EPA             
2 capsules/day 
Olive oil No significant treatment 
effects were found for the 
cognitive or mood measures 
Plasma –  
phospholipid fatty 
acid levels. DHA 
levels increased by 
38.1% and EPA by 
137.5% in Rx group  
18. Yurko-Mauro 
et al. 2010 
 
 
USA 24-weeks Rx: 242/9.5%  
Pb: 243/10.3  
Total: 437 
M=70 Rx: 900 DHA      
3 capsules/day 
50% corn 
oil + 50% 
soy oil 
DHA group had significantly 
fewer CANTAB PAL errors as 
well as improved immediate 
and delayed verbal memory 
scores compared to the 
placebo group 
Plasma –  
phospholipid fatty 
acid levels. Plasma 
DHA levels 
significantly 
increased in the Rx 
group 
19. Vakhapova 
et al. 2010 
 
 
Israel 15-weeks Rx: 79/24%   
Pb: 78/20.5%  
Total: 122 
M=73 Rx: 79 as 3:1 
DHA:EPA +  
300 PS                        
3 capsules/day 
Cellulose PS-DHA group had 
significantly improved 
immediate recall; Ps with 
higher cognitive status at 
baseline showed the most 
improvement in immediate 
recall, total learning and 
delayed recall  
 
Note. CANTAB PAL = Cambridge Neuropsychological Test Automated Battery Paired Associate Learning, CIND = Cognitive impairment no dementia,                              





5.3 Older adults with Mild Cognitive Impairment  
The first trial to specifically investigate the cognitive effects of a DHA supplement in 
older adults with MCI was by Sinn et al. (2012) who compared an EPA group, a DHA group and 
a placebo group (see Table 8, study 20). MCI was defined as a subjective complaint of memory 
loss with otherwise normal daily functioning and cognitive assessment scores of ≤ 1.5 SD 
below the population age mean. Scores improved significantly on the GDS in both the DHA    
(p = .01) and EPA (p = .04) groups compared to the placebo group. There was also a significant 
improvement in Initial Letter Fluency for the DHA group (p = .04), and an improvement in the 
DHA group in the Digit Span Backwards Test, though not significant (p = .10). Increased RBC 
levels of DHA and EPA were associated with improvements on the GDS (r = .39, p = .02), and 
increased RBC levels of DHA were associated with improved physical health (r = .39, p < .05) 
and physical functioning (r = .37, p < .05) from the 36-Item Short Form Health Survey 
Questionnaire (SF-36), in particular reduced bodily pain (r = .35, p < .05). A reduced ARA:EPA 
ratio was associated with improvements on the GDS (r = .34, p < .05) as well as improvements 
in both mental health (r = .50, p < .01) and vitality (r = .34, p < .05) scores from the SF-36.  
In the same year, Rondanelli et al. (2012) investigated a combination supplement 
containing DHA and EPA (see Table 8, study 21). Of note is that the supplement and placebo 
groups differed significantly at baseline on the GDS (Msupplement = 21.5, Mplacebo = 12.7,    
p = .00), with a trend for years of education (Msupplement =5.4, Mplacebo = 7.3, p = .07). MCI 
was defined as a memory complaint referred by the participant or a family member, a 
cognitive impairment in more than one domain (executive function, memory, language, or 
visuospatial), normal functional activities and not having dementia. At the 12-week mark the 
supplement group showed a significant treatment effect on the MMSE (p < .01) and a trend in 





the Mini Nutritional Assessment tool (includes anthropometric measures, medication use and 
mobility) was also found. This trial also used an olfactory sensitivity assessment called the 12-
item Sniffin’ Sticks Screening Test based on research which suggested it could be a useful 
measure in predicting the progression from amnesic MCI to AD (Eibenstein et al., 2005). The 
results found that the supplement groups’ (p < .01) scores significantly improved on the 
Sniffin’ Sticks Screening Test compared to the placebo group. 
The following year Lee, Shahar, Chin, and Yusoff (2013) published a fish trial in older 
adults with MCI (Table 8, study 22). MCI was defined as the presence of a memory complaint 
(either self-reported or by family members or caregivers), preserved normal cognitive 
function (assessed by the MMSE), intact activities of daily living (1.5 SD from mean), not 
demented (1 SD from norm on the Dementia Rating Scale), not depressed (4 points on the 
GDS short version) and abnormal cognitive impairments for age (>1 SD from norm). At the end 
of the 12-month trial and after controlling for age, education and baseline blood pressure the 
DHA + EPA treatment group showed a significant improvement in three of the four memory 
tasks – Digit Span Backwards (p < .01), Visual Reproduction I (p < .05) and RAVLT delayed recall 
(p < 0.05), which test short-term memory, working memory, immediate verbal memory and 
delayed recall. Scores did not significantly differ between the two groups on the GDS at either 
the 6-month or 12-month mark.   
A fourth MCI trial was published by Yacong et al. (2017) and was designed to test an 
EPA:DHA ratio of 3:2, and to investigate the link between cognition and inflammation (see 
Table 8, study 23). MCI was defined based on the criteria by Petersen et al. (1999) with the 
inclusion criteria of a memory or cognitive disorder for at least three months and an MMSE 
score of 24 to 26 for individuals who had >6 years of education, 20 to 22 for <6 years, and 17 





the n-3 PUFA group had a significant improvement in the total Basic Cognitive Aptitude Test 
score (p < .01), perceptual speed (p < .01), space imagery efficiency (p < .01), working memory 
(p < .05), with a trend for mental arithmetic efficiency (p = .06) but not recognition memory  
(p = .58). The authors found that the n-3 PUFA supplement resulted in significant decreases in 
interleukin IL-6, tumour necrosis factor TNF-α, sPLA2 (p < .05), all of which are signals of 
inflammation.  
The results from the DHA supplement trials in older adults with MCI have been very 
promising. Overall, these four trials have found positive effects for fluency, short-term 






Table 8. Summary of fish oil trials in Mild Cognitive Impairment (MCI)  
 




Placebo Cognitive Results Sampling 
tissue/change 






Rx1: 18/27.7%   
Rx2: 18/11.1%    




Rx1: 160 DHA 
+ 1670 EPA       
Rx2: 1550 DHA 








letter fluency for the 
DHA group 
compared to the ALA 
group; scores 
improved 
significantly on the 
GDS in both the DHA 
and EPA groups; 
increased RBC levels 




health and physical 
functioning  
RBC – fatty acid 
levels. Over a 4-fold 
increase in EPA in 
Rx1 and a 2-fold 
increase in both EPA 
and DHA in Rx2 
21. Rondanelli et 
al. 2012 
Italy 12-weeks Rx: 11/0%                 




Rx: 720 DHA + 
286 EPA + 160 
PLP + 95 TRP + 
5 MEL                    
2 capsules/day 
Non-fish oils Found a significant 
treatment effect in 
the MMSE, MNA and 
in olfactory 
sensitivity in the 
supplement group, 
as well as a trend in 
semantic fluency in 




Note. GDS = Geriatric Depression Scale, PLP = Phospholipids, MEL = Melatonin, MMSE = Mini-Mental State Examination, MNA = Mini Nutritional  





Table 8. (continued)                                                                                                                                                                                                                                                                                                                                                                                                                




Placebo Cognitive Results Sampling 
tissue/change 







Rx: 18/5.5%   




Rx: 1290 DHA 




1800 mg of LA 
per day 
The DHA+EPA group 





memory and delayed 
recall after controlling 
for age, education and 
baseline blood 
pressure 
Plasma – fatty acid 
levels. Plasma                
levels of DHA and 
EPA increased by 
83.7% and 121.6% in 
Rx group 






Rx: 44/27%        




Rx: 480 DHA + 




2200 mg of 
oleic acid                     
4 caps/day 
DHA+EPA group had a 
significant 
improvement in total 
BCAT score, as well as 
sub-items perceptual 
speed, space imagery 






Plasma –  
phosphatidyl-choline 
fatty acid levels, 
cytokines, enzymes. 
Increased levels of 
plasma DHA and EPA 





5.4 Meta-analysis of DHA trials in older adults 
In 2012, Mazereeuw, Lanctot, Chau, Swardfager, and Herrmann performed a meta-
analysis of three n-3 PUFAs trials with cognitively healthy older adults (studies 1, 2 & 7) and 
seven trials involving older adults with memory complaints, CIND, MCI and dementia 
(studies 12, 13, 15, 16, 18, 19 & 20). The inclusion criteria for the meta-analysis required 
that studies were RCTs with measurable neuropsychological results, used a supplement 
form of n-3 PUFAs, and included participants aged 50 years and older without psychiatric 
comorbidity.  Results from the neuropsychological tests were classified into five cognitive 
domains – immediate recall, delayed recall, recognition, working memory/executive 
function and attention/processing speed, in addition to composite memory (pooled 
memory outcomes) and global cognitive functioning as measured by MMSE and ADAS-cog.  
When all participants were combined, the results of the meta-analysis found that n-3 
PUFAs did not provide a significant benefit in any of the cognitive domains. However, 
Mazereeuw et al. (2012) found a significant effect in the subgroup of older adults with CIND 
in the cognitive domains of immediate recall (p = .03, g = 0.16) and attention/processing 
speed (p = .04, g = 0.32). There was also a significant treatment effect in delayed verbal 
recall (p = .02, g = 0.30) in a subgroup analysis of high-functioning CIND and AD participants 
(MMSE ≥ 26). The meta-analysis also compared safety and tolerability of n-3 PUFA vs. 
placebo supplements and found no differences in drop-outs and adverse effects, implying 
that n-3 PUFA supplements are safe and well tolerated. The authors noted that dose, 
duration and baseline MMSE scores were not related to treatment effect in any of the 
cognitive domains. In the case of dose, the authors suggest this finding indicates that n-3 
PUFA supplementation may work by surpassing a DHA threshold level rather than by a 





for assessing n-3 PUFAs, DHA or EPA levels, exactly what a ‘low’ or a ‘high’ baseline level is 
or where this DHA threshold level may sit, is not clear.  
 
5.4 Summary of DHA trials  
The difficult task for researchers in the area of DHA and n-3 PUFA interventional 
trials is trying to make sense of the conflicting results. The results of the meta-analysis 
suggest that n-3 PUFAs may provide the most benefit for older adults with mild forms of 
cognitive impairment, specifically in the areas of verbal recall and attention. Defining 
participant groups is a major challenge within this area of research, particularly in milder 
forms of cognitive impairment. It is comparatively easy to define and measure dementia, 
although to show that an intervention prevents or improves dementia is difficult as any 
improvements in AD may be overcome by the progression of the disease. As a result, the 
rate of decline is often used as an outcome measure in AD as opposed to an improvement in 
cognition. The need for universal measures of both global and specific cognitive domains is 
controversial, and results in most clinical trials opting to use the MMSE. Both van de Rest et 
al. (2008) and Dangour et al. (2010) used the MMSE to assess whether participants were 
cognitively healthy at baseline, where van de Rest et al. used the cut-off of scores above 23, 
and Dangour et al. scores above 25. Several of these trials relied on global cognitive 
measures or memory tasks only, even though it is quite clear that the best type of cognitive 
assessment involves a battery of memory along with executive functioning and language 
tasks. 
The main issue with the MMSE as a cognitive measure is that, especially in high 
functioning or highly educated older adults, it often results in a ceiling effect. In constrast, 





semantic fluency tasks show no ceiling, and in some cases, no practice effects after three 
months making them particularly useful for longer trials (e.g., Bartels et al., 2010). van de 
Rest et al. chose to select participants who were ‘cognitively still intact’ by way of an MMSE 
score above 23 based on the idea that it may be ‘too late’ for fish oil supplementation to 
counteract the process of decline in participants who have mild to severe cognitive 
impairment. The authors also noted though that the participants in their study may have 
been ‘too good’ for fish oil supplementation to be effective. Lee et al. (2013) commented 
that the discrepancies in the results from n-3 PUFAs trials in older adults are mainly due to 
the extent of the cognitive impairment. Lee et al. further stated the participants in their trial 
were mildly impaired, with the results showing participants in their trial had a MMSE >25. Of 
the four MCI trials, Sinn et al. (2012) was the only trial to use a cut-off of 1.5 SDs for the 
cognitive deficit and Yacong et al. (2017) was the only trial to take into account ‘years of 
education’, but only in regard to the MMSE cut-off point. Research indicates that measuring 
pre-morbid functioning is more reliable than using years of education, as the quantity of 
education is not always an indication of the quality, as years of education can be influenced 
by many ‘non-cognitive factors’ such as gender, income and ethnicity (Ahl et al., 2013). 
There are major difficulties involved in recruiting participants, particularly older adults with 
mild cognitive impairments, which can result in the inclusion of a wide range of ‘mildly’ 
impaired participants. 
Two of the trials reviewed in this chapter were conducted in Germany using the 
same fish oil supplement (same brand and supplier), with the same daily dose (880 mg of 
DHA and 1320 mg of EPA) and with the same duration (26 weeks), but with different 
measures (Witte et al., 2013; Külzow et al., 2016). Both trials were focused on cognitively 





omega-3 index as a measure of change in n-3 PUFA levels. The trial by Witte et al. used a 
cognitive battery to assess all cognitive domains – Trail Making Test A & B, a verbal fluency 
test, a version of the Stroop Test and Digit Span Forwards and Backwards, whereas Külzow 
et al. used a visuospatial object location memory task called LOCATO containing a learning 
and a recall component. Witte et al. found that the fish oil group significantly improved on 
the executive composite score using the fluency, Trial Making versions B-A and Stroop Test, 
but only a trend for memory consolidation when the analysis focused on participants who 
responded best to the intervention, as measured by a change in the omega-3 index. Külzow 
et al. found that recall performance, but not learning, was significantly better in the fish oil 
group after controlling for dietary habits and APOE status. Interestingly, Witte et al. 
measured grey matter changes and found significant increases in left hippocampus volume 
in the fish oil group, and Külzow et al. noted that object location memory is dependent on 
proper hippocampal functioning. It is likely that the fish oil groups in both trials had changes 
in hippocampal activity, and that the different tests tapped into this activity in different 
ways. This highlights the importance of selecting measures with appropriate validity and 
sensitivity, including both memory and executive functioning measures, as well as 
commonly used measures to allow for comparison across trials.  
When reporting the results of clinical trials, there is a tendency to focus on the 
significant differences between the n-3 PUFA and placebo groups, but not the negative 
results or the significant differences in favour of the placebo. The meta-analysis by 
Mazereeuw et al. (2012) found that n-3 PUFAs improved verbal recall and attention in older 
adults with CIND, and an examination of the results for cognitively healthy older adults also 
showed that improvements tended to be in verbal recall and attention, as well as in verbal 





that they were in visuo-spatial/constructional tasks, speed and motor tasks, executive 
function tasks like spatial planning, block design and clock drawing, and most language tasks 
except for verbal fluency. Also, despite the randomisation element of RCTs, baseline 
differences between treatment and placebo groups do occur, as do differences between 
those who complete the trial and those who drop-out. For example, in the trial by Dangour 
et al. (2010) the authors noted that drop-outs had a lower baseline level of cognitive 
function as measured by the California Verbal Learning Test. The importance of reporting all 
results, and in particular how the differences were analysed, has recently been highlighted 
by the 2018 American Psychological Association guidelines (Appelbaum et al., 2018). 
Out of the 23 trials reviewed in this chapter, 15 trials used an n-3 PUFA supplement 
that contained only fish oil as the main ingredient, two trials used supplements containing 
fish oil in combination with lutein and zeaxanthin, one trial used fish oil in combination with 
a multi-vitamin/mineral complex, one used phosphatidylserine in combination with DHA, 
two used algal supplements, and two trials used combination supplements – one with the 
addition of the herbal extract Ginkgo biloba and one with the addition of phospholipids + 95 
mg of tryptophan + 5 mg of melatonin. The reason for using an algal supplement or a co-
factor such as a phospholipid/ phosphatidylserine or additional nutrients/extracts such as 
lutein or Ginkgo biloba is that they have the action of enhancing the biosynthesis of n-3 
PUFAs, making DHA more bio-available, or the ingredient has been independently shown to 
reduce cognitive decline. Strike et al. (2015) found a positive result in processing speed and 
verbal recognition memory using a commercial product from the company Efamol, which 
combined DHA + EPA + Ginkgo biloba + phosphatidylserine + vitamin E + folic acid + vitamin 





if the authors had also included a DHA + EPA capsule only this may have provided some 
insight into the issue. 
Nine trials used a higher daily amount of DHA than EPA, five trials used a higher daily 
amount of EPA than DHA, two used the same or similar amount of DHA and EPA, four used 
DHA only, one used DHA and ARA with no EPA, one used a ratio of DHA:EPA of 3:1, and one 
included two fish oil groups, one in which the EPA content was higher and one in which the 
DHA was higher. Yacong et al. (2017) suggested that the ratio of EPA to DHA of 3:2 is an 
important factor, and used a dose of 720 mg of EPA and 480 mg of DHA per day for 6-
months. Whether this ratio and dose were responsible for why Yacong et al. found a 
significant difference in three out of five subtests, rather than the population group, is 
unknown. One trial used a 5-week cross-over design (Nilsson et al., 2012) which may not be 
the most appropriate design for a fish oil trial when considering that n-3 PUFAs can be 
stored in the body for up to 2.5 years (Stonehouse et al., 2013). In contrast, the trial by 
Quinn et al. (2010) used an algal supplement, containing a daily dose 1000 mg of DHA with 
no EPA (or any other ingredients), in older adults with AD with low baseline levels of DHA. In 
this medium sized trial (402 participants started, 295 completed), DHA supplementation did 
not slow the rate cognitive or functional decline, except for a subgroup of non-ɛ4 carriers.  
van de Rest et al. (2008) and Dangour et al. (2010) both chose daily doses of DHA 
and EPA to reflect national dietary recommendations and what is ‘achievable’ through diet 
as opposed to a pharmacologic dose. Pharmacologic refers to a dose that is larger or more 
potent than what would occur naturally so as to have a different effect. In fact, van de Rest 
et al. included both a low (to reflect dietary recommendations) and high (pharmacologic) 





group, which is consistent with the finding by Mazereeuw et al. (2012) that dose was not 
related to treatment effect.  
APOE genotyping was included in five of the trials – Freund-Levi et al., 2008; van de 
Rest et al., 2008; Quinn et al., 2010; Külzow et al., 2016; and Danthiir et al., 2018. Freund-
Levi et al. found ɛ4 carriers showed a significant treatment effect in agitation, van de Rest et 
al. found a treatment effect in the attention domain for ɛ4 carriers and Quinn et al. found 
lower decline in the ADAS-cog for non-ɛ4 carriers. Külzow et al. found recall performance 
was significantly better in the fish oil group after controlling for dietary habits and APOE ɛ4 
carrier status, and Danthiir et al. 2018 found a greater improvement from fish oil in the 
domain of reasoning for ɛ4 carriers. Baseline RBC or plasma DHA and EPA levels were tested 
in the majority of the 23 trials, with the omega-3 index and 50th percentile used to 
determine low and high baseline levels of DHA. Most trials used this data to determine the 
change in DHA and EPA levels from baseline to end, as opposed to using baseline DHA levels 
as a covariate in the final analysis. 
 Several researchers have suggested that the different results between trials may be 
due to differences in DHA and EPA levels of participants at baseline. The results from the 
trial by Quinn et al. do not support this idea, although the authors quantified a ‘low’ 
baseline level using a 7-item FFQ as opposed to baseline RBC or plasma DHA levels. 
Confounding variables such as a healthy lifestyle and life circumstances, including socio-
economic and educational level, are associated with higher fish consumption and lower 
dementia risk, and may explain the positive findings in some trials. The evidence from 
epidemiological studies on the beneficial effects of fish consumption provides supports for 
this. Again, this highlights the importance of assessing the baseline levels of DHA in fish oil 





across studies from the cognitive measures to the sampling tissue (plasma vs. RBC) through 
to the reporting of p values as opposed to effect sizes contributes to a very confusing 
picture for those trying to decide whether taking a fish oil supplement is worthwhile or not. 
While the trials by Lee et al. (2013), Rondanelli et al. (2012) and Yacong et al. (2017) 
were not included in the meta-analysis by Mazereeuw et al. (2012), they provide further 
support for the beneficial effect of n-3 PUFAs in older adults with MCI. It appears that 
somewhere between cognitively healthy and dementia is where fish oil supplementation 
may be most benefical, although individual differences both genetically and in terms of 
previous intake of n-3 PUFAs, may also be important factors. Except for the two German 
trials (Witte et al., 2013; Külzow et al., 2016), the source of n-3 PUFAs, the dose and ratio of 
DHA and EPA, the inclusion of bio-factors and the duration of the trial varies widely between 









DESIGNING THE TRIAL 
 
Based on the results of the meta-analysis by Mazereeuw et al. (2012), the decision 
was made to investigate the cognitive effects of a fish oil supplement in older adults with 
Mild Cognitive Impairment (MCI) by replicating components of previous trials and with the 
inclusion of APOE genotyping. At the time of designing the trial, two fish oil trials were 
known to have specifically investigated the effects of a fish oil supplement in older adults 
with MCI – Sinn et al. (2012) and Lee et al. (2013). The decision was made to replicate these 
two trials by using a similar dose of DHA, with the inclusion of several of the same 
measures, and in the case of the trial by Lee et al., with the same trial duration. The decision 
was also made to extend these two trials by adding a 9-month testing time point and by 
including APOE genotyping.  
As part of designing the current RCT, many decisions had to be made regarding the 
type of fish oil supplement, the choice of placebo, the number of testing time points or 
sessions, what to test and how to measure it, as well as how to analyse and interpret the 
results. This chapter provides explanations for each of these design decisions as well as 
discussing other important parts of the research process including applying for funding, and 
correspondence with the supplement company and laboratories as part of the project 





6.1 Duration of the trial 
 The trial by Sinn et al. (2012) was based on a 6-month supplement period and found 
a significant difference between the DHA and placebo groups in one of the cognitive tasks, 
Initial Letter Fluency, and on the GDS at the 6-month mark. The trial by Lee et al. (2013) was 
based on a 12-month supplement period and found a significant difference between the fish 
oil and placebo groups in three of the cognitive tasks, Digit Span Backwards, Visual 
Reproduction I and Rey Auditory Verbal learning test, at the 12-month mark. Based on these 
results, it seemed that 6-months of supplementation may be a ‘minimum supplement 
period’, and therefore anything less would not be sufficient to see any significant changes in 
the cognitive outcomes. The decision was made to use a 12-month supplement period with 
a 6-month testing mark as well as a further testing point at the 9-month mark. This 9-month 
testing time point would be used to investigate any cognitive changes during the six month 
period between 6-months and 12-months of DHA supplementation. In particular, to explore 
the idea that there may be a plateau effect around the 9-month mark, with an improvement 
from baseline to 9-months, but with no further improvements from 9-months to 12-months. 
 
6.2 Capsules   
The DHA group in the Sinn et al. (2012) trial were given a daily dose of 1550 mg of 
DHA plus 400 mg of EPA for six months, and the fish oil group in the Lee et al. (2013) trial 
were given 1300 mg of DHA plus 450 mg of EPA per day for 12 months. The decision was 
made to use a fish oil supplement that contained a similar amount of DHA and EPA as these 
two trials. A major consideration when choosing a fish oil supplement for the trial was that 
participants were likely to be taking other tablets or capsules during the trial period. 





minimum number of capsules, and in a small capsule size. The decision was made to use an 
oblong shaped, size 20, 15 mm length, soft-gel capsule which is about the size of a standard 
oblong paracetamol tablet. This size of capsule can hold up to 1000 mg of oil per capsule, 
and so for a dose of three capsules per day, each capsule would need to contain at least 400 
mg of DHA. The advantage of a soft-gel capsule is that the rounded ends of the capsule can 
reduce swallowing difficulties. The only issue when using a soft-gel capsule is that if 
swallowed with a hot liquid they can start to dissolve while still in the mouth. To reduce the 
likelihood of this happening, participants would be asked to use room temperature or cold 
liquids when swallowing the capsules. Participants would also be asked to take the capsules 
after breakfast, as taking capsules after food reduces the chances of reflux. The capsule 
would also need to contain citrus oil to mask the flavour of the fish oil and to act as an 
emulsifier to assist with the digestion of fatty acids, and an anti-oxidant agent such as 
vitamin E.  
To further replicate the two trials by Sinn et al. (2012) and Lee et al. (2013), the 
decision was made to use a placebo that contained similar amounts of the n-6 PUFA Linoleic 
acid (LA). The placebo group in the trial by Sinn et al. were given a daily dose of 2200 mg of 
LA for six months by way of safflower oil, and the placebo group in Lee et al. were given 
1800 mg of LA per day for 12 months by way of corn oil. Despite the use of safflower and 
corn oil in these two trials, most other fish oil trials have used either olive oil or sunflower 
oil as the placebo oil. Olive oil is high in n-9 PUFAs, with very little n-3 PUFAs and n-6 PUFAs, 
and is often used to reduce and therefore control for the effects of the placebo on the ratio 
of n-3:n-6 (Danthiir, Burns, Nettelbeck, Wilson, & Wittert, 2011).  In an attempt to replicate 





1000 mg capsule would be equivalent to approximately 600 mg of LA (with no trace of DHA 
or EPA), and therefore three capsules per day would deliver approximately 1800 mg of LA. 
After researching the types of fish oil products that were available on the market and 
then contacting fish oil supplement manufacturers and suppliers within NZ to find a fish oil 
supplement with the above specifications, the possibility of asking a fish oil company to 
supply the capsules for the trial to reduce costs was explored. However, after further 
research, a supplement that would provide enough DHA and EPA in less than five capsules 
per day could not be found or would take over a year to arrange. Because a year was too 
long to wait, the decision was made to pay for the capsules. A pharmaceutical company 
based in Auckland NZ, GMP pharmaceuticals, eventually confirmed that they were able to 
provide a fish oil supplement with a DHA:EPA ratio of 5:1, equivalent to 500 mg of DHA and 
100 mg of EPA in a size 20, soft-gel capsule, meaning that three capsules per day would 
deliver approximately 1500 mg of DHA and 300 mg of EPA. GMP pharmaceuticals also 
confirmed they were able to provide a sunflower placebo capsule, identical in size, shape 
and composition except for the active oil. See Table 9 for the initial capsule composition 
specifications. 
Based on these specifications, this dose of DHA and EPA would be considered 
‘pharmacologic’, in that it is larger or more potent than what would be deemed ‘natural’ or 
‘normal’. This dose would be equivalent to eating approximately four to five portions of oily 





Table 9. Capsule composition (mg/per capsule) 
Ingredients     Per capsule 
Actives Oil 1000 
Excipients Vitamin E 1300 IU/g  1.15 
 Orange oil     10 
 Fill weight        1011.15 
Shell Gelatin 240 
 Glycerol  120 
 Caramel  2 
 Water – purified 38 
 Shell weight 400 
 Total weight 1411.15 
 
 
6.3 Medico-paks vs. opaque bottles 
As there was concern about capsule compliance during the long trial period, the use 
of Medico-paks was considered as a way of dispensing the capsules. Medico-paks are often 
used with older adults to help keep a record of whether capsules or tablets have been taken 
on a particular day or not. Douglas Pharmaceuticals Ltd, a supplier of the packs, was 
contacted regarding the possibility of using the packs for the trial. Medico-paks are typically 
packed by a pharmacist, however Douglas Pharmaceuticals could supply the packaging to be 
packed on site.  Medico-paks are not airtight, and therefore, for a supplement like fish oil 
which is sensitive to heat and light, they could only be inside a Medico-pak for maximum of 
one month. This meant that the capsules would need to be packaged every month, which 
would be both costly and difficult to orchestrate. Instead, it was decided to dispense the 
capsules in sealed, white, opaque bottles as they could be bottled by the manufacturer 
without labels but with an expiry date and batch number printed on the bottom. They 
would be labelled by a research assistant, and then easily stored in the refrigerator by the 





295. These batches numbers were removed by a research assistant once they had been 
labelled. 
 
6.4 APOE genotyping and RBC fatty acid profiles 
 The decision to include APOE genotyping and RBC fatty acid profiles was in line with 
the decision to extend and replicate the two fish oil trials. The decision was made to test 
APOE status at the end of the trial, so the lead researcher could remain blinded to APOE 
status until the end of testing and to minimise the cost from participant drop-outs due to 
high cost of APOE genotyping ($157 per sample). The main concern of the Health and 
Disability Ethics Committee (HDEC) was how the results of APOE genotyping results would 
be explained to participants. An expert in APOE genotyping advised that the key piece of 
information to convey to participants was that APOE genotyping is not a diagnostic genetic 
test; if a participant is found to carry a ɛ4 allele, it does not mean that this person will 
develop AD, rather it indicates an increased risk of developing AD. Further, it would be 
important to explain to ɛ4 carriers that many other factors contribute to the development 
of AD, while there are also other factors that offer protection from the disease. The HDEC 
were satisfied with this procedure as well as with the APOE factsheet that would be sent to 
ɛ4 carriers. The HDEC fully approved the trial on the 28th of October 2014.  
 
6.5 Participants 
A power analysis was performed using G*Power 3.1.9.2 (Faul, Erdfelder, Lang, & 
Buchner, 2007) to calculate the required number of participants. Based on the calculation of 
4 groups (Fish oil/APOE ɛ4, Fish oil/not APOE ɛ4, Placebo/APOE ɛ4 and Placebo/not APOE 





effect size of f = 0.40, to provide a statistical power equal to 0.8 and a α level of 0.05 (2-
tailed), the minimum total sample size required was 64, 16 participants in each of the four 
groups. 
The decision was made to focus the trial on participants with Mild Cognitive 
Impairment with an age range of 65 to 95 years of age, based on Statistics NZ’s (New 
Zealand’s official data agency) definition of older people as those aged 65+. This age range 
would allow comparison of statistical data, and because this is the age of retirement in NZ, 
would mean participants would be more likely to have time during the day to attend the 
testing sessions. However, due to a slowdown in recruitment, the decision was made to 
alter the age range from 65 to 60 years of age and from 95 to 90 years of age. The main 
issue with an age range of 60 to 95 years is that it would have spanned four decades, 
therefore the final decision was to reduce this to three decades and to use age as a 
covariate in the final analysis. 
Recruitment for the trial began in September 2015. Based on the inclusion and 
exclusion criteria, a screening questionnaire (see Appendix D) was developed to be 
administered via a 10-minute phone call. By January 2016, after four months of recruitment 
and screening, only 35 participants (the majority had been recruited from a previous 
memory study) had been enrolled so the decision was made to include 60 to 64 year olds. 
To increase participant numbers, advertisements, posters and leaflets were placed around 
Wellington. All advertisements and announcements specified that the study was looking for 
people who were interested in being involved in a PhD research project that looked at 
ageing and memory, who were over the age of 60 and who thought they might have a mild 
memory problem. See Appendix E for the trial leaflet and advertisement. See Appendix F for 





Older Persons and Rehabilitation Service of Hutt Valley Hospital, and the Neurology 
department at Capital Coast District Health Board also agreed to help recruit participants. As 
part of an email update sent through to participants in February 2016, participants were 
asked if they knew anyone who might be interested in taking part in the trial.  
 
6.6 Location 
 Because participants were to be tested at four time points, the decision was made to 
base the trial at the Massey Psychology Clinic in Mount Cook, Wellington. This ensured that 
participants would not be required to travel more than one hour (one way) to the clinic. 
Participants were given a map specifying the location of the clinic and the Wellington 
hospital outpatients unit (for blood sample collection) along with the information sheet and 
consent form. Two participants who expressed reservations about participating in the trial, 
one due to a recent injury and the other due to the time required for them to travel to the 
clinic, were tested at their homes. Another participant was tested in their home for the final 




The meta-analysis performed by Mazereeuw et al. (2012) found that the biggest 
improvement in cognitive performance from fish oil supplementation was in delayed verbal 
recall, immediate recall, attention and processing speed. As a result, the cognitive battery 
needed a heavy emphasis on measuring memory (allowing differentiation between memory 
tasks that depend on attention and processing speed and those which do not), along with 





function, and because of the participant characteristics, pre-morbid functioning. Research 
indicates that discriminating between MCI and cognitively healthy older adults requires both 
a word list recall test and an executive functioning task. The cognitive battery would also 
need to be brief and easy to administer. Sinn et al. (2012) used a cut-off point of 1.5 SDs for 
measuring the cognitive impairment, whereas Lee et al. (2013) used a cut-off point of 1 SD. 
Thus, the decision was made to use between 1 and 1.5 SDs in at least one cognitive domain. 
Four cognitive measures were considered – the Rivermead Behavioural Memory Test 
(Wilson, Cockburn, & Baddeley, 1991), Addenbrooke’s Cognitive Examination-Revised (ACE-
R; Mathuranath et al., 2000), the Montreal Cognitive Assessment (MoCA; Nasreddine et al., 
2005) and the RBANS (Randolph, 1998). The RBANS was chosen because of the availability 
of age norms, particularly for the 80 to 89 year age group, and because it had four alternate 
forms – RBANS A, B, C and D, which meant a different version could be used at each testing 
session. In addition, the RBANS is easy to administer, and each form of the RBANS involves 
two immediate memory and four delayed memory tasks resulting in both an immediate and 
delayed index score. Several of the participants were recruited from a previous memory 
study where the RAVLT had been used as the primary measure of memory, and therefore 
the RBANS provided an alternative version of a word list recall test to reduce any practice 
effects. 
The tasks in the RBANS are organised into five indexes – Immediate Memory, 
Visuospatial/Constructional, Language, Attention and Delayed Memory. According to the 
RBANS manual, reliability coefficients for the five indexes for the age groups 60 to 69, 70 to 
79 and 80 to 89 years of age respectively are: .85, .89 and .90 for Immediate Memory, .84, 
.81 and .78 for Visuospatial/Constructional, .85, .81 and .83 for Language, .83, .88 and .85 





reliability coefficients of the RBANS indexes are higher in older adults than in young age 
groups, perhaps due to the ceiling effects and reduced variability in younger controls. Also 
noted is that the reliability coefficients tend to be higher for the indexes than for the 
subtests. For example, the subtest coefficients for the age group 80 to 89 are: .84 for List 
learning, .84 for Story Memory, .54 for Figure Copy, .52 for Semantic Fluency, .83 for Digit 
span, .83 for Coding, .72 for Story Recall and .55 for Figure Recall. Although a closer 
inspection shows that this is probably only an issue for Figure Copy and Recall, and the 
Semantic Fluency tasks. In terms of validity, the total RBANS score correlates well with the 
Wechsler Memory Scale (WMS-R) Verbal Memory Index (r = .70), the Wechsler Adult 
Intelligence Scale (WAIS-R) FSIQ short form (r = .78) and the WMS-R Attention/ 
concentration index (r = .84) (Randolph, Mohr & Chase, 1993). The WMS-R 
Attention/concentration index also correlated well with the RBANS Attention index (r = .82) 
(Randolph, 2012). In terms of measuring executive functioning, the decision was made to 
include both the Trail Making Test and a version of the Stroop Test. The big issue with the 
RBANS as a cognitive battery is that adjustments for gender and education are not available, 
yet research has shown that both result in modest to large effects on RBANS scores (Beatty, 
Mold, & Gontkovsky, 2003). 
Measures of depression, anxiety and health-related quality of life were also included 
to allow comparison with other fish oil trials. The Geriatric Depression Scale (GDS; Sheikh, & 
Yesavage, 1986), the Geriatric Anxiety Inventory (GAI; Pachana, Byrne, Siddle, Koloski, 
Harley, & Arnold, 2007) and the 36-Item Short Form Health Survey Questionnaire (SF-36; 
Ware & Gandek, 1994) were selected because Sinn et al. (2012) used both the GDS and SF-
36, because the GDS and GAI are specifically developed to measure depression and anxiety 





made to only use a brief n-3 PUFA nutritional screening questionnaire at baseline because 
the RBC fatty acid profiles would provide a measure of changes in dietary fatty acids 
including n-3 PUFAs and n-6 PUFAs for the 12-month supplement period. Cardiovascular 
biomarkers by way of height and weight in order to calculate BMI, as well as systolic and 
diastolic blood pressure were included because of the link between cardiovascular disease 
and cognitive decline such as vascular dementia. The link between cognitive decline and 
weight is also of interest, as weight loss is considered a clinical expression of cognitive 
decline and dementia, and to worsen the clinical course of dementia.  
 A measure commonly used in clinical trials to improve compliance is a daily diary or 
charting system. Because participants in the trial were older adults, a traditional calendar 
style format was considered to be the most appropriate. This was confirmed after a small 
pilot study with a template revealed that it was easy to understand and use, and was 
something that people would consider putting up in the kitchen or somewhere likely to be 
seen every day. The calendar had a front page containing the short title of the study, the 
Massey University logo and a space for the participant’s name and ID number. The second 
page explained the purpose of the calendar along with details of how to use it. The 
following pages included one page for each month of the 12-month supplement period. As 
well as assisting with and assessing capsule compliance, the calendar would keep a record of 
fish consumption and any illnesses throughout the trial. See Appendix G for an example 
page.  A standard operating procedures document was also developed, outlining the test 
order along with descriptions and instructions for each measure to ensure consistency and 







6.8 Project management and administration 
In this section, the project management and administration components of the trial 
will be described, including applications for funding, training of research assistants as well as 
correspondence with the participants. The section will begin with two aspects of the project 
management and administration, both of which were very challenging at times – 
correspondence with GMP pharmaceuticals and correspondence with Wellington Regional 
hospital laboratory. See Figure 3 for a chart of the project management time frame. 
 
6.8.1. GMP pharmaceuticals and the capsules 
Communications with GMP pharmaceuticals began in July 2014 with monthly emails 
about capsule specifications and costing. Once the capsule specifications were decided on, it 
was calculated that each participant would need a total of 1,095 capsules for the 12-month 
supplement period. In addition, to ensure that participants never ran out of capsules and to 
accommodate any dropped or lost capsules, it was decided that each participant would be 
dispensed 1,200 capsules divided into 6 bottles, each containing 200 capsules. Based on the 
calculation that each participant would need 1,200 capsules, a total of 96,000 capsules 
would be needed for a sample size of 80. GMP Pharmaceuticals advised that capsules could 
be ordered in batches of 100,000 capsules, but because of the types of oils that had been 




















     










Figure 3. Chart outlining the time frame of project management and administration tasks 
  
 
April 2016 - July 2016 
 Dissemination of the first blood test results 
November 2017 
Dissemination of individual cognitive reports 
April - October 2018 
 Dissemination of grouped results and the final blood test results 
 
May 2014 - November 2017 
Funding applications 
June 2014 - October 2015 
Trial registration, ethical approval application and amendments 
July 2014 - October 2015  
Correspondence with GMP pharmaceuticals 
August 2014 - March 2018 
Correspondence with Wellington Hospital Laboratory,  
Southern Community Laboratories and Canterbury Health 
Laboratories 
March 2015 - November 2015 
 Purchase and preparation of materials for testing sessions 
November 2015 - May 2016 and November 2016 - March 2017 
 Correspondence and training with research assistants 
October 2015 - May 2017 
Recruitment, screening and booking testing session times 
 
January 2016 - June 2017 
Testing sessions 
March 2016 - May 2017 















The total cost for 200,000 capsules was set at $16,985.50. Because of the major 
delays already experienced in funding and recruitment, the decision was made to place the 
order, knowing that more funding would be needed to cover the expense. Further delays 
from GMP meant the trial start date was further delayed, and consequently materials such 
as the calendars needed to be reprinted. GMP finally confirmed a delivery date and so the 
trial start date was set. 
The capsules were independently tested in order to report the exact fatty acid 
composition. A sample of the two types of capsules was sent to the Nutrition laboratory at 
the Institute of Food, Nutrition and Human Health, Massey University in Palmerston North 
for fatty acid profile analysis. A report indicated that the levels of DHA and EPA were 10%  
below what had been initially agreed upon with GMP. Legal advice from two legal 
representatives at Massey University advised to seek compensation for the discrepancy. 
GMP replied to the legal action with test results, which contradicted those of the Nutrition 
laboratory.  The capsules were then re-tested by Cawthron Analytical Services, at the 
Cawthron Institute in Nelson. This time the results showed that the DHA and EPA levels 
were similar to both what GMP had originally specified, and to the test results GMP had 
provided. After correspondence with several laboratory technicians, it was probable that 
the discrepancy was a result of different analysis procedures. 
 
6.8.2 Correspondence with laboratories 
Communications with Wellington Regional Hospital began in August 2014, resulting 
in a meeting with the team leader of client services at the hospital laboratory in October 
2014. It was arranged that the laboratory would organise to collect, analyse and transport 





One of the major obstacles during this time was that the analysis needed for RBC fatty acid 
profiles was not a routine laboratory test. As a result technicians at the Wellington hospital 
laboratory and the Nutrition Laboratory at the Institute of Food, Nutrition and Human 
Health at Massey University had to work out what the analysis would involve, and which 
parts of the procedure each laboratory would do. A patient form was developed to include 
the details of the lead researcher (in case a Phlebotomist had any queries), the details of the 
trial, instructions for the Phlebotomist regarding the tubes required and the analysis to be 
performed. See Appendix H for the patient form.  
A major overhaul of the Wellington hospital laboratory and the incorporation of 
Southern Community Laboratories (SCL) took place the following year which caused two 
major changes. The first was an increase in cost, the second was access to collection centres 
other than at the outpatients unit of the Wellington Hospital. This meant that participants 
were able to have their blood samples taken at one of the SCL collection centres in and 
around Wellington. However, as a result of this restructuring, several samples went missing, 
or were not taken or stored properly, or in five cases destroyed due to an explosion in the 
main hospital laboratory. Several participants were asked to give repeat samples, and one 
participant had to have blood taken a total of five times (instead of twice) due to these 
issues. 
 
6.8.3 Funding, assistants and participant phone calls 
The two biggest expenses of the trial were the capsules and blood test collection and 
analysis. During the four years, over 30 scholarship and funding applications were 
submitted. Several were successful and the trial received $20,000 from the Oakley Mental 





$18,000 from the Hope-Selwyn Scholarship of Ageing Research and $9,490 from a Massey 
University Research Fund in January 2018.  
 Two post-graduate psychology students assisted with two different components of 
the trial. The first research assistant helped with the randomisation procedure and labelling 
of the capsule bottles, and the second assistant helped with testing participants during the 
3rd testing session.  For the randomisation procedure, a procedural document was 
developed explaining step-by-step the process of generating a list of random participant 
numbers, assigning the participant numbers to one of the two capsule groups, labelling the 
capsule bottles and then removing the batch numbers from the bottom of the bottles. The 
first assistant was the only person to know which group the participants had been allocated 
to – the lead researcher, supervisors and second assistant were not aware of the participant 
group allocations until after the final testing session. The first assistant was reimbursed with 
eight $20 supermarket vouchers.  
The second research assistant had completed a post-graduate course in clinical 
neuro-psychology and had some familiarity with psychometric tests. The assistant was first 
briefed, and then trained on administering and scoring the cognitive and well-being tasks. 
This involved two initial meetings, firstly outlining the trial design and the individual tests, 
and providing a copy of the standard operating procedures to read over, and secondly, a 
follow-up meeting where the testing schedule and availability were discussed. The research 
assistant then observed while the lead researcher administered the tests to a clinical 
psychology student and then administered the tests to the same clinical psychology student 
themselves. In total, the second assistant tested 45 of the final 60 participants, all with 





As well as the screening phone calls and testing sessions, the main form of 
communication with participants was via bi-monthly phone calls. During the first two of 
these phone calls, the aim was to ensure participants were not experiencing any serious side 
effects or problems with swallowing the capsules. If the side effect was deemed as too 
severe to continue, the participant was immediately withdrawn. If the side effect was less 
severe (e.g., minor reflux), suggestions were made in terms of changes in how and when the 
capsules were taken, which in most cases reduced the side effect. The blood test results 
were also given to participants via these bi-monthly phone calls. Later phone calls included 
updates on how the trial was progressing, when future testing sessions would take place, 
booking testing sessions as well as asking if the participant had noticed any physical or 
cognitive changes as a result of taking the capsules.  
 
6.9 Aims and hypotheses of the trial 
To conclude this chapter, the aims and hypotheses of the trial will be outlined again. 
The primary aim of the trial was to investigate the effects of a 12-month DHA fish oil 
supplement on cognitive performance in older adults with MCI. It was hypothesised that 
after 12 months of supplementation, participants in the DHA group would show higher 
scores in the immediate recall, delayed recall and working memory tasks than participants 
in the placebo group. The secondary aim of this trial was to investigate whether the APOE ɛ4 
allele has a moderating effect on the measures, as well as to examine the effect of the fish 
oil supplement on well-being, in particular depression. It was hypothesised that carriers of 
the APOE ɛ4 allele would benefit from (taking) the DHA supplement, and that the DHA 











7.1 Participants   
A total of 183 people were screened for the trial and 87 older adults were found to 
fit the eligibility criteria. Of the 87 older adults, 15 were excluded at baseline, which resulted 
in a final sample size of 72 participants. 
 
7.1.1 Recruitment 
Recruitment for the trial began in September 2015, and was completed at the end of 
May 2016. The first group of older adults was recruited from another study through the 
School of Psychology at Massey University in Wellington, which investigated memory 
complaints in adults over the age of 40 living in Wellington, NZ. Participants from this study 
were asked if they would be interested in participating in another research study, and if so 
their name and contact details were passed on to the lead researcher. The second group of 
older adults was recruited through advertisements in local newspapers, posters placed in 
libraries, hospitals and supermarkets around Wellington, leaflets and announcements 
through the Wellington City University of the Third Age (U3A), Probus, Grey Power, 
SeniorNet, Age Concern and the website ‘GrownUps’, as well as through Wellington District 





people came from the previous Massey University memory study, 40 from posters and 
leaflets around Wellington, 37 from word-of-mouth, 18 from newspaper advertisements, 14 
from U3A, eight from Probus, Grey Power, SeniorNet, Age Concern and GrownUps, and two 
from the Older Persons and Rehabilitation Service of Hutt Hospital.   
 
7.1.2 Screening 
Screening was conducted via a 10 to 15 minute phone call. During this phone call 
potential participants were given a brief description of the trial which included an 
explanation of the time-frame as well as the randomisation and double-blind elements of 
the study, and then asked if they would be willing to take three capsules per day for a 12-
month period and attend four testing sessions at the psychology clinic at Massey University 
over the course of a 15-month period. If participants answered ‘yes’, they were asked if they 
were between 60 and 90 years of age, if they had regularly taken any fish oil supplements 
over the previous 6-month period, if they consumed more than two servings of fish per 
week and if they were willing not to start taking fish oil supplements of their own during the 
study.  
Participants were then asked whether they would be away from Wellington for any 
period of time during the next 15 months, if they were willing to have two blood samples 
taken throughout the trial and whether they lived independently in their own homes. 
Participants were asked whether they had any major medical conditions including head 
injury or any recent or upcoming major surgery, about current medications in particular 
whether they were taking the blood-thinner medication warfarin, whether there were any 
problems with swallowing soft-gel capsules or an allergy to any type of fish or seafood. 





in change in their memory or cognition in the last six to 12 months. If participants answered 
‘no’, they were excluded and were told the reason why, if answered ‘yes’, they were asked 
to explain further.  
Participants were sent the information sheet and consent form in the post, and then 
phoned approximately two weeks later to discuss and answer any questions about the trial. 
Participants then completed the consent form and returned it using a postage-paid 
envelope. From the 183 people screened, 96 were excluded – 34 people regularly took fish 
oil supplements, 11 reported no subjective memory or cognition complaints, eight were on 
contraindicated medications, seven ate more than two servings of fish per week, five were 
vegetarian or vegan, five had travel plans during testing times, five felt their health was too 
poor to participate, four wanted to start taking a fish oil supplement of their own, four did 
not want to swallow capsules, three had heavy work commitments, three felt the trial was 
too long to commit to, two had sustained head injuries, two were older than 90 or younger 
than 60 years of age, two lived outside of Wellington and one person did not want to be 
involved in the trial for other reasons. See Figure 4 for a flowchart outlining the process of 























Figure 4. Participant recruitment and screening 
  
Potential participants were recruited between September 2015 and May 2016 from:  
- A previous Massey University memory study (n = 64) 
- Posters around Wellington city (n = 40) 
- Word of mouth (n = 37) 
- Newspaper advertisements (n = 18) 
- University of the Third Age (n = 14) 
- Probus, Grey Power, SeniorNet, Age Concern and GrownUps (n = 8)  







87 participants assessed at baseline  
Excluded (n = 15) 
- Did not fit the criteria for MCI (n = 13) 




Excluded (n = 96) 
- Regularly took fish oil supplements (n = 34)      - No subjective memory complaint (n = 11)    
- Taking contraindicated medications (n = 8)       - Ate > 2 servings of fish per week (n = 7)             
- Had travel plans during testing times (n = 5)     - Vegetarian/vegan (n = 5)                                  
- Felt their health was too poor (n = 5)                  - Did not want to swallow capsules (n = 4)                               
- Wanted to take a fish oil supplement (n = 4)     - Had heavy work commitments (n = 3)                             
- Felt the trial was too long to commit (n = 3)      - Had sustained head injuries (n = 2)                 
- Lived outside of Wellington (n = 2)                      - Age >90 or <60  (n = 2)                                         
- Did not want to be in the study (n = 1) 










7.2 Classification of Mild Cognitive Impairment  
 Participants were classified as having Mild Cognitive Impairment (MCI) based on the 
following criteria by Petersen (2004): 1. Presence of a memory complaint. 2. Evidence of 
cognitive impairment in at least one cognitive domain as assessed as a score or scores 
between 1 to 1.5 standard deviations below the mean for age. 3. Preserved general 
cognition i.e., normal IQ. 4. Ability to perform everyday activities without the assistance of 
another person. 5. Not demented.  
 At the baseline testing session a total of 87 older adults were tested. Fifteen were 
excluded – 13 because they did not fit the criteria for MCI based on criteria 2, and two were 
excluded because after completing the nutritional questionnaire it was found that their 
seafood intake was more than two servings per week. 
 
7.3 Trial registration and ethical approval 
 The trial was registered with the Australian New Zealand Clinical Trials Registry 
ACNTRN12614000874617 on the 14th of August 2014 with updates made on the 2nd of 
November 2015 and 6th of October 2016. Ethical approval for the trial was obtained by the 
Central Health and Disability Ethics Committee on the 28th of October 2014. Ethics 
Reference: 14/CEN/148. Minor amendments were made to the trial design after peer 
review and these changes were approved by the Central Health and Disability Ethics 
Committee on the 30th of April 2015 and 30th of October 2015. Ethics References: 
14/CEN/148/AMO1 and 14/CEN/148/AMO2. See Appendix I. Annual ethics progress reports 







7.4 Study design 
A 12-month parallel, randomised, double-blind, placebo-controlled, interventional 
study design was used. The participants were divided into two groups to assist with 
administration and testing. For the first group the 12-month supplement period began on 
the 1st of March 2016 and finished on the 28th of February 2017, and for the second group 
the 12-month supplement period began on the 1st of June 2016 and finished on the 31st of 
May 2017. The cognitive tasks and well-being measures were assessed at four time points – 
at baseline, then after 6-months, 9-months and 12-months of taking the capsules. These 
testing sessions were also referred to as the baseline, 2nd, 3rd and final testing sessions.  
 
7.5 Intervention 
The DHA group were given three capsules per day, each capsule contained 1000 mg 
of fish oil equivalent to 497 mg of DHA, 117 mg of EPA, 1.15 mg of Vitamin E 1300 IU/g and 
10 mg of orange oil, equating to a total daily dosage of 1491 mg of DHA and 351 mg of EPA. 
The placebo group were also given 3 capsules per day, each capsule contained 1000 mg of 
sunflower oil equivalent to 619 mg of LA, 1.15 mg of Vitamin E 1300 IU/g and 10 mg of 
orange oil, equating to a total daily dose of 1857 mg of LA per day. Both types of capsules 
contained vitamin E as an anti-oxidant, and orange oil to help mask the taste of the fish and 
sunflower oils. Table 10 shows the fatty acid composition of each capsule type by way of 
grams per 3000 mg daily dosage. Both types of capsules were supplied by GMP 
Pharmaceuticals Ltd and were independently tested by Cawthron Analytical Services, at the 
Cawthron Institute in Nelson. The dose of DHA and EPA was based on the two trials by Sinn 
et al. (2012) and Lee et al. (2013) and was equivalent to eating approximately 4-5 portions 






Table 10. Fatty acid composition of DHA and placebo capsules (g/3000 mg daily dosage) 
Fatty acids DHA capsules Placebo capsules 
Palmitic acid (C16:0) 0.022 0.174 
Stearic acid (C18:0) 0.022 0.088 
Oleic acid (C18:1n-9) 0.045 0.866 
Linoleic acid (C18:2n-6) <0.01 1.857 
Alpha-linolenic acid (C18:3n-3) <0.01 <0.01 
Eicosenoic acid (C20:1n-9) 0.047 <0.01 
Arachidonic acid (C20:4n-6) 0.036 <0.01 
Eicosapentaenoic acid (C20:5n-3) 0.351 <0.01 
Docosapentaenoic acid (C22:5n-3) 0.107 <0.01 
Nervonic acid (C24:1n-9) 0.057 <0.01 
Docosahexaenoic acid (C22:6n-3) 1.491 <0.01 
 
 
The two types of capsules were identical in size, colour and shape. Participants were 
asked to take the three capsules every day after breakfast with water for the course of the 
12-month supplement period. The capsules were dispensed in white opaque plastic bottles, 
with each bottle containing 200 capsules. Each participant received six bottles in 
total. Each bottle was labelled with the participant’s name, participant number, the required 
dose and directions, storage instructions, the batch number and expiry date. The first four 
bottles were given to the participant at the end of the baseline testing session, the fifth 
bottle at the end of the 2nd testing session and the sixth bottle at the end of the 3rd testing 
session. Participants were asked to store the bottles in the refrigerator, and to bring any 
unopened or partially full bottles to the following testing session for counting as part of the 
compliance assessment. 
Participants were randomly allocated to one of the two capsule groups using a 
randomly generated list of numbers from Random.org. A paid research assistant generated 
the list of random participant numbers, assigned the participant numbers to one of the two 





7.6 Cognitive measures 
The battery of cognitive tasks used to assess cognitive performance were the 
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS; Randolph, 
1998), the National Adult Reading Test (NART; Nelson, 1982), the Coin Rotation Task (CRT; 
Mendoza, Apostolos, Humphreys, Hanna-Pladdy, & O'bryant, 2009), the California Older 
Adult Stroop Test (COAST; Pachana, Thompson, Marcopulos, & Yoash-Gantz, 2004), the Trail 
Making Test A and B (TMT; Army Individual Test Battery, 1944) and the Digit Span 
Backwards Test (DSBT) from the Wechsler Adult Intelligence Scale 3 (WAIS-III; Wechsler, 
1997). This battery of tasks focused on assessing all cognitive domains including attention, 
memory, language, visuo-spatial, executive functioning, information processing speed, 
motor function and pre-morbid ability, with an emphasis on the main types of memory, 
especially those that are affected by early age-related cognitive decline such as episodic 
memory.  
 
7.6.1 Repeatable Battery for the Assessment of Neuropsychological Status – RBANS 
The RBANS is a neurocognitive battery with four alternate forms – RBANS A, B, C and 
D. Form A was used at the baseline testing session, form B at the 2nd testing session, form C 
at the 3rd testing session and form D at the final testing session. Each alternate form consists 
of 12 subtests divided into five indexes – Immediate Memory, Visuospatial/Constructional, 
Language, Attention and Delayed Memory.  
The Immediate Memory index consists of two subtests – List Learning and Story 
Memory. In List Learning participants were read a list of 10 unrelated words and then asked 
to recall as many words as they could. This list of words was repeated three more times. The 





to 40. In Story Memory participants were read a story with 12 core components and then 
asked to retell the story from memory. This was repeated once more with the same story. 
The raw score was the total number of recalled components of the story from both trials 
with a score range of 0 to 24. 
The Visuospatial/Constructional index consists of two subtests – Figure Copy and 
Line Orientation. In Figure Copy participants were shown a geometric figure and asked to 
copy it while the figure remained in front of them with a maximum of four minutes to 
complete the task. The raw score was the total number of correctly drawn and positioned 
parts of the figure with a score range of 0 to 20. In Line Orientation participants were 
presented with 10 drawings, each drawing consisted of 13 lines radiating from a single point 
in a semi-circular shape. These lines were numbered from 1 to 13. Below the drawing were 
two lines which matched two of the lines in the drawing. Participants were asked to identify 
the two numbers. Participants had a maximum of 20 seconds to name the two numbers for 
each drawing. The raw score was the total number of correct responses from all 10 
drawings with a score range of 0 to 20. 
The Language index consists of two subtests – Picture Naming and Semantic Fluency. 
In Picture Naming participants were presented with drawings of 10 objects and asked to 
name each one. Participants were given a semantic clue if the drawing was misidentified. 
The raw score was the total number of correctly identified drawings with a score range of 0 
to 10. In Semantic Fluency participants were asked to name as many examples as possible 
from a given semantic category such as different kinds of fruits and vegetables or animals 
found in a zoo. The raw score was the total number of correct responses within 60 seconds 
with a score range of 0 to 40 for form A, a score range of 4 to 40 for form B and C and a 





made to accommodate the level of difficultly of forms B and C (animals you would find in a 
zoo and musical instruments) by adding four additional points to the raw scores and form D 
(articles of clothing) by adding two additional points to the raw score. 
The Attention index consists of two subtests – Digit Span and Coding. In Digit Span 
participants were read a string of numbers and then asked to repeat it back. The string of 
numbers increased by one digit for each trial. The raw score was the total number of correct 
strings with a score range of 0 to 16. In Coding participants were presented with the back 
page of the record form which contained rows of boxes with nine different geometric 
shapes in a random sequence above each box. At the top of the page was a key that 
consisted of two rows, one row with the nine geometric shapes and the row below with the 
numbers 1 to 9. Using this key, participants were asked to fill in the number that matched 
each of the geometric figures. The raw score was the total number of items correctly coded 
within 90 seconds with a score range of 0 to 89. 
The Delayed Memory index consists of four subtests – List Recall, List Recognition, 
Story Memory and Figure Recall. In List Recall participants were asked to recall words from 
the 10 words learned in the List Learning subtest. The raw score was the total number of 
recalled words with a score range of 0 to 10. In List Recognition participants were read 20 
words, 10 of which were from the List Learning subtest and 10 were distractor words. After 
each word was read, participants were asked to indicate whether the word was on the 
original word list or not. The raw score was the total number of correctly identified words 
with a score range of 0 to 20. In Story Memory participants were asked to retell the story 
from the Story Memory subtest. The raw score was the total number of recalled 





asked to draw from memory the figure from Figure Copy. The raw score was the total 
number of correctly drawn and positioned parts of the figure with a score range of 0 to 20.  
A standardised total RBANS score, five index scores and 12 subtest scores for each 
form were calculated based on age norms (Randolph, 2012). 
 
7.6.2 National Adult Reading Test – NART 
The NART is a test of pre-morbid functioning and was administered only at the 
baseline testing session. It required participants to read aloud 50 irregular words such as 
‘Heir’ and ‘Zealot’, printed in two columns. The raw score was the total number of words 
correctly pronounced. The number of words incorrectly pronounced/number of errors was 
used to calculate a predicted IQ score: Predicted IQ score = 128 - 0.83 x number of errors. 
         
7.6.3 Coin Rotation Task – CRT 
 The CRT is a test of fine motor coordination. Participants were asked to position a NZ 
20 cent coin in between their middle and index fingers on their dominant hand, and then to 
flip the coin as many times as they could in 20 seconds. Participants were asked to repeat 
this task three times and the final raw score was an average of the three trials. Raw scores 
were converted to z-scores based on age and gender norms (Thornton & Leathem, 2013). 
 
7.6.4 California Older Adult Stroop Test – COAST 
 The COAST is a test of attention and executive function, specifically the ability to 
inhibit information. There are three parts in this version of the Stroop, in each part 
participants were given a laminated A4 sheet to read off. In part one, the page contained 





of colours that were arranged on the page in 10 rows of five blocks. Participants were asked 
to name each block of colours by reading left to right from the top to the bottom of the 
page as quickly as they could. In part two, the page contained the words of the colours (e.g., 
RED, GREEN, YELLOW) printed in black ink, again in a 10 by five format. Participants were 
asked to read the words from top to bottom as quickly as they could. In part three, the page 
contained the words RED, GREEN and YELLOW printed in either red, green or yellow ink, 
with the ink colour incongruent to the meaning of the word. Participants were asked to 
name the colour of the ink that the word was printed in as opposed to reading the word. 
The main raw score was the time taken to complete part three of the task. The time taken 
to complete the other two parts of the test as well as the number of self-corrected and non-
corrected errors was also measured. Raw scores were converted to z-scores (Pachana et al., 
2004).  
  
7.6.5 Trail Making Test A and B – TMT 
 The TMT is a test of attention and mental flexibility. This test contained two parts, A 
& B. In part A, participants were presented with an A4 page that contained the numbers 1 to 
25 inside small circles which were randomly distributed among the page. Participants were 
told to join up the numbers in numerical order using a pencil.  In part B, participants were 
presented with an A4 page that contained the numbers 1 to 13 and the letters A through to 
L, again inside small circles randomly distributed among the page. Participants were told to 
join up the numbers and letters in an alternating sequence using a pencil.  Before each part 
was administered, a small practice sample was completed to ensure participants 
understood the task. Participants were told to complete the task as quickly as they could. 





errors. Raw scores were converted to percentiles based on norms by age and gender (Shirk 
et al., 2011). 
 
7.6.6 Digit Span Backward Test – DSBT 
The DSBT is a test of working memory. Participants were read a string of digits and 
were asked to repeat the digits in a backwards sequence. Two string lengths of the digit 
string were presented and was increased by one extra digit with each trial. The raw score 
was the total number of correct strings. Raw scores were scaled (Wechsler, 1997) based on 
age and then converted to percentiles based on norms by age and gender (Shirk et al., 
2011). Raw scores from the Digit Span Backward Test and the Digit Span Forward (Digit span 
from RBANS) were scaled based on age (Wechsler, 1997) to produce both a Digit Span 
Forward score (DSF) and a Digit Span Total score (DSTot). 
 
7.7 Well-being measures 
The well-being measures used were the Geriatric Depression Scale (GDS; Sheikh, & 
Yesavage, 1986), the Geriatric Anxiety Inventory (GAI; Pachana et al., 2007) and 36-Item 
Short Form Health Survey Questionnaire (SF-36; Ware & Gandek, 1994).  
 
7.7.1 Geriatric Depression Scale – GDS 
 The GDS is a self-reported measure of depression. Participants were given an A4 
page with 15 yes or no questions. Participants were asked to read each question and then 
circle ‘Yes’ or ‘No’ to describe whether they felt this way or not over the past week. An 
example question was ‘Do you feel that your life is empty?’. The raw score was the total 





suggested no indication of depression, a score between 5 to 9 suggested some indication of 
depression, and 10 or more suggested an indication of depression.  
 
7.7.2 Geriatric Anxiety Inventory – GAI 
 The GAI is a self-reported measure of anxiety. Participants were given an A4 page 
with 20 statements. Participants were asked to read each statement and then tick the 
‘Agree’ or ‘Disagree’ column to reflect how they felt over the past week. An example 
statement was ‘I often feel nervous’. The raw score was the total number of positive 
responses, with a score range of 0 to 20. A GAI score between 0 to 8 indicated an absence of 
anxiety and a score of 9 or more indicated the presence of anxiety. 
 
7.7.3 36-Item Short Form Health Survey Questionnaire – SF-36 
 The SF-36 is a self-reported measure of health and quality of life. The survey consists 
of 36 questions, with 26 of the questions on a 5-point Likert scale and 10 questions on a 3-
point Likert scale. The survey is divided into eight domains and scores: physical functioning, 
role physical (limitation in usual role due to physical health problems), bodily pain, general 
health, vitality, social functioning, role emotional (limitation in usual role due to emotional 
problems) and mental health. Scores were standardised and were based on age norms. A 
total physical and mental score were also calculated. 
 
7.8 Anthropometric measurements 
Weight was measured using a dial scale, and height using a wall-mounted 
stadiometer. Body mass index (BMI) was calculated by dividing participants’ weight in 





on the non-dominant arm and after the participant had been seated for at least 15 minutes, 
using an automated sphygmomanometer (Sure Signs VM4; Philips Medical Systems, 
Andover, MA).  
 
7.9 Biochemical analysis 
Participants had two fasting blood samples taken throughout the trial. The first 
sample was taken after the baseline testing session and was analysed for red blood cell 
(RBC) fatty acid profile status, vitamin B12 and ferritin levels. The second sample was taken 
after the final testing session and was analysed for RBC fatty acid profile status and APOE 
genotyping. Blood samples were taken in one of the Southern Community Laboratories 
(SCL) collection centres in and around Wellington, including a collection point at the 
outpatients area of the Wellington Regional Hospital. The Wellington Hospital laboratory 
prepared, stored and transported the blood samples to the Nutrition Laboratory at the 
Institute of Food, Nutrition and Human Health, Massey University in Palmerston North for 
RBC fatty acid status, and Canterbury Health Laboratories (CHL) in Christchurch for APOE 
genotyping. Wellington regional hospital laboratories ran the analysis for vitamin B12 and 
ferritin status. All three laboratories have International accreditation. All blood samples 
were destroyed once analysed.  
 
7.9.1 Red blood cell fatty acid profile status 
 This test measured erythrocyte or RBC levels of 38 fatty acids including LA, ALA, ARA, 
EPA, DPA and DHA with a unit measure of mg/mL as well as total % fatty acids. Values of the 





DHA / total % fatty acids. Values were also used to calculate two n-6:n-3 ratios – ARA:EPA 
and ARA:DHA.  
Blood samples were collected in 5 mL lithium/heparin tubes and centrifuged at 3000 
x g for 10 minutes. The RBCs were then transferred to a cryotube and 1.7 mL butylated 
hydroxytoluene/methanol was added. The sample was then agitated until homogenous and 
stored at -80°C. Per 50 uL RBCs, 200 uL of internal standard working solution was added. 
The internal standard (IS) stock solution consisted of 22.5 mg +/-0.5 mg of heptadecanoic 
acid dissolved in 100 mL of methanol. The IS solution was diluted further to 22.5 ug/mL by 
adding 2500 uL to 25 mL of methanol. Per 50 uL RBCs, 1000 uL of 3N methanolic 
hydrochloric acid was added to each sample tube. The samples were incubated for 4 hours 
at 90˚C with occasional mixing, and then left to cool to room temperature. Samples were 
transferred into kimax tubes and per 50 uL RBCs a further 2000 uL of hexane was added to 
each sample. Samples were shaken manually for 10 seconds, vortexed for 1 minute and 
then centrifuged at 2000 rpm and 20˚C for 3 minutes. The top layer was removed and 
transferred to round bottom flask. Samples were dried with a rotary evaporator at 38˚C. 
Samples were dissolved by adding 100 uL of hexane per 50 uL RBCs to each tube, using 
a calibrated pipette. Samples were then transferred to gas chromatography vials. Fatty acid 
analysis was run using a gas chromatograph (Shimadzu G-2010 plus). The concentration of 
fatty acid of each sample was calculated by comparing the average area of the sample to 
the concentration and area of the international standard in the standard solution. 
 
7.9.2 Vitamin B12 and Ferritin  
 Low levels of vitamin B12 and ferritin have been associated with cognitive decline in 





levels were measured to rule out the effect of a deficiency or a secondary cause for any 
cognitive impairment (Blennow et al., 2006). Vitamin B12 was measured by pmol/L units 
with a reference range of between 170 and 800 pmol/L. Ferritin was measured by µg/L units 
with a reference range of 20 and 350 µg/L. 
 
7.9.3 APOE genotyping 
 APOE genotyping was performed using a Polymerase Chain Reaction in a DNA 
Thermal Cycler (Perkin Elmer Cetus) using the method described by Hixson and Vernier 
(1990). The results of the APOE test comprised of two APOE alleles/numbers (e.g., 
Apolipoprotein E genotype: E3/4) for each participant. 
 
7.10 Questionnaire 
A list of the participant’s medications and supplements, existing health conditions 
including any vision or hearing impairments and family history of dementia or memory 
problems was compiled at the baseline session along with general demographic information 
including date of birth, country of birth, relationship status, ethnicity, employment status, 
occupation (including prior occupation if retired), income level, years of education, highest 
qualification obtained, number of languages spoken, left or right handed, frequency of 
computer use, and other health related behaviours such as cigarette smoking – both current 
and past, weekly alcohol consumption, average number of hours sleep per night and 
amount of weekly exercise and weekly mental engagement. At the 2nd and 3rd testing 
sessions, participants were asked about changes in medication and supplement use, the 
number of hours sleep per night, weekly exercise and mental engagement. At the final 





given during the trial, and also whether they thought their memory and cognition had 
improved, declined or remained the same throughout the trial. 
 
7.11 Nutritional status questionnaire 
Participants completed a nutritional screening questionnaire during the baseline 
testing session. This questionnaire was designed to screen out participants who consumed 
more than two servings of fish and other seafood per week. See Appendix J for the 
nutritional screening questionnaire. The first question asked whether the participant 
consumed any type of fish or seafood. If the answer was ‘yes’ the participant was asked how 
many servings of fish and seafood were consumed per week and then asked to specify how 
often they consumed certain types of fish and seafood. Participants were asked to limit 
consumption of fish and seafood to two servings per week, and to maintain their usual diet 
throughout the course of the trial. 
 
7.12 Calendar 
 Participants were given a 12-month calendar at the end of the baseline testing 
session and were asked to answer three daily ‘Yes’ or ‘No’ questions on the calendar during 
the 12-month supplement period. Each day participants were asked to circle ‘Y’ or ‘N’ for 
the following three questions: Taken pills Y/N, Ate fish Y/N, Felt unwell Y/N. If participants 
circled ‘Y’ for ‘Ate fish’ they were asked to write down on the calendar what type of fish 









Participants completed the anthropometric, cognitive and well-being measures for 
all four testing session in the same order. All testing sessions, except the sessions for three 
participants, took place at the Massey University Psychology Clinic at 24 King Street, Mount 
Cook, Wellington. For two of the three participants, all four testing sessions took place in 
the participant’s home and for the fourth participant the first three testing sessions took 
place at the Psychology clinic and the final testing session in the participant’s home. 
Participants were reimbursed for participating in this study with a $20 supermarket voucher 
for each testing session. 
 
7.13.1 Baseline testing session 
 The first testing session was divided into four parts. The first part involved explaining 
the time frame of the trial, giving the participant a copy of the signed consent form, 
administering the baseline questionnaire, and then measuring blood pressure, weight and 
height. This took between 30 and 45 minutes. The second part involved the cognitive 
measures in the following order: NART, RBANS version A, CRT, COAST, DSBT and TMT. This 
took between 45 minutes to 1 hour. Participants were then given a 15-minute break. During 
the break participants had a refreshment of a hot or cold drink and biscuit/cookie, and then 
took a toilet break. In the third part participants completed the GDS, GAI, SF-36 and the 
Nutritional Screening Questionnaire. This took approximately 20 minutes. The fourth part 
involved explaining the first blood test and the patient form, dispensing the first four bottles 
of capsules and explaining how and when to take the capsules, explaining how to use the 






7.13.2 Second testing session 
 The second testing session was divided into four parts. The first part involved the 
questionnaire, and then measuring blood pressure, weight and height. This took 
approximately 20 minutes. The second part involved the cognitive measures in the following 
order: RBANS version B, CRT, COAST, DSBT and TMT. This took between 40 minutes and 1 
hour. Participants were then given a 5-minute break. In the third part participants 
completed the GDS, GAI and SF-36. This took approximately 15 minutes. The fourth part 
involved counting the returned capsules, and handing over the 5th bottle of capsules and 
supermarket voucher. This took approximately 10 minutes. 
 
7.13.3 Third testing session 
 The third testing session was divided into four parts. The first part involved the 
questionnaire, then measuring weight and height. This took approximately 15 minutes. The 
second part involved the cognitive measures in the following order: RBANS version C, CRT, 
COAST, DSBT and TMT. This took between 40 minutes and 1 hour. Participants were then 
given a 5-minute break. In the third part participants completed the GDS, GAI and SF-36. 
This took approximately 15 minutes. The fourth part involved counting the returned 
capsules, handing over the 6th bottle of capsules and the supermarket voucher. This took 
approximately 10 minutes. 
 
7.13.4 Final testing session 
 The final testing session was also divided into four parts. The first part involved the 
final questionnaire, and then measuring blood pressure, weight and height. This took 





order: RBANS version D, CRT, COAST, DSBT and TMT. This took between 45 minutes and 1 
hour. Participants were then given a 5-minute break. In the third part participants 
completed the GDS, GAI and SF-36. This took approximately 20 minutes. The fourth part 
involved counting the returned capsules, completing the final summary questionnaire, 
explaining the dissemination of the results and the handing out the final supermarket 
voucher. This took approximately 15 minutes. 
 
7.14 Storage of information and participant feedback 
All participant information collected during and after the trial was stored in a locked 
filing cabinet and on a password-locked computer.   
All participants answered ‘Yes’ to receiving individual and grouped cognitive results 
and so at the conclusion of the trial all participants were sent both an individual results 
report and grouped results summary page. See Appendix K and L. Results of the vitamin 
B12, ferritin and RBC fatty acid profiles were given over the phone. Copies of the results 
were forwarded if requested. If a participant indicated on the consent form that they 
wanted to know the results of the APOE genotyping test, the individual report as provided 
by CHL was sent to the participant via the post. If the participant was an APOE ɛ4 allele 
carrier, they were also sent a copy of the APOE fact sheet (see Appendix M). If a participant 
then requested further information about any of the biochemical tests, they were advised 
to contact their nurse or General Practitioner.  
 
7.15 Data analysis 
Differences between participant completers and drop-outs, and between the two 





square tests. ANCOVAs were used to test for treatment effects on the measures, with 
treatment group as the main factor and with age, gender, and years of education as 
covariates.  All assumptions were met for the linear model analyses including Levene’s test 
of equality of error variances. Bonferroni corrections were used for multiple analyses. The 
alpha was set at 0.05 for all analyses, all of which were performed using IBM SPSS statistics 







from an effect size calculator, where an effect size of 0.2 was considered small, 0.5 was 
medium and 0.8 was large (Lakens, 2013). Eta squared effect sizes were calculated with 
SPSS using the formula ƞ2  = SS effect / SS total, where .01 was considered small, .09 was 












8.1 Participant completers and drop-outs  
Seventy-two participants were enrolled in the 12-month RCT. Participants were 
randomly assigned to receive either the DHA supplement (n = 37) or a placebo (n = 35). Of 
the 72 participants, 12 withdrew (seven from the DHA group and five from the placebo 
group). One participant died (placebo) between the 2nd and 3rd testing sessions due to a pre-
existing health condition, but otherwise all participant drop-outs occurred voluntarily 
between the baseline and 2nd testing sessions. See Figure 5 for a flow diagram showing 
participant drop-outs and completers. The 12 participant drop-outs resulted in an attrition 
rate of 17%. There were no demographic, cognitive or well-being differences between 
participants who dropped out and completed the trial. The final analysis was performed 
with a total of 60 participants – 30 participants in each group. 
 
8.2 Baseline characteristics of the participants 
The baseline characteristics of participants in the DHA and placebo groups are 
summarised in Table 11. There were no differences between the two groups in any of the 















            











Figure 5. Participant drop-outs and completers 
  
Completed 2nd testing session (n = 30) 
     Completed 3rd testing session (n = 30) 
Completed 2nd testing session (n = 31) 
Completed 3rd testing session (n = 30) 
Completed final testing session (n = 30) 
Dropped out (n = 1) 
- Died  
 Participants randomly assigned at baseline (n = 72) 
Assigned to DHA group (n = 37) Assigned to placebo group (n = 35) 
 
Dropped out (n = 7) 
- Loose bowels (n = 2) 
- Reflux (n = 1) 
- Pneumonia (n = 1) 
- Second stroke (n = 2) 








Dropped out (n = 4) 
- Loose bowels (n = 1) 
- Personal reason (n = 1) 
- Too many capsules (n = 1) 
- Started a fish oil supplement (n = 1) 
 
 





The NART predicted IQ scores were more than 1 SD above standardised average IQ, 
indicating that the participant group was above average in IQ and met the MCI criteria for 
preserved general cognition/IQ. The only significant difference between the two groups at 
baseline was in ARA levels, with a significantly higher baseline ARA level for the placebo 
group (M = 19.99, SD = 1.83) compared to the DHA group (M = 18.87, SD = 1.64), t(58) = 
2.49, p = .02, d = 0.63. 
At baseline, women (M = 56.18, SD = 6.81) scored significantly higher than men on 
the SF-36 general health score (M = 52.06, SD = 7.65), t(58) = -2.19, p = .03, d = 0.57 and had 
significantly higher EPA (women M = 1.10, SD = 0.51; men M = 0.86, SD = 0.37), t(58) = -2.03, 
p = .04, d = 0.53 and DHA levels (women M = 4.35, SD = 0.83; men M = 3.73, SD = 1.07), t(58) 
= -2.52, p = .02, d = 0.63. At baseline there was also a trend towards men (M = 0.05,             
SD = 1.31) scoring higher than women (M = -0.54, SD = 1.00), t(58) = 1.97, p = .05, d = 0.52 
on the Coin Rotation Task.  
Of the 60 participants, 30% were carriers of APOE ɛ4 (5 ɛ2/ɛ4, 12 ɛ3/ɛ4 and 1 ɛ4/ɛ4) 
and 27% were carriers of APOE ɛ2 (0 ɛ2/ɛ2 carriers, 11 ɛ2/ ɛ3 and 5 ɛ2/ɛ4). APOE ɛ4 carriers 
had significantly higher baseline GDS scores (M = 3.00, SD = 2.17) than non-ɛ4 carriers        
(M = 1.67, SD = 2.07), t(58) = -2.26, p = .03, d = 0.62, and higher baseline GAI scores            
(M = 3.61, SD = 4.34) than non-ɛ4 carriers (M = 1.90, SD = 2.68), t(58) = -1.86, p = .07,            
d = 0.53. APOE ɛ4 carriers had lower baseline SF-36 Role physical scores (M = 47.68,            
SD = 7.45) than non-ɛ4 carriers (M = 51.34, SD = 5.93), t(58) = 2.03, p = .05, d = 0.56, and 
lower baseline SF-36 Physical functioning scores (M = 47.68, SD = 8.45) than non-ɛ4 carriers 
(M = 51.93, SD = 4.95), t(58) = 2.44, p = .02, d = 0.68. There were no differences between ɛ4 





Table 11. Baseline characteristics of DHA and placebo groups 
Characteristic DHA group  Placebo group  p d 
 (n = 30) (n = 30)   
Age (years) 72.33 (6.16) 1 73.40 (6.96) .53 0.16 
Gender (Male/Female) 14/16 11/19 .43  
NZ born – Euro/Pakeha (%) 73 83 .67  
Handed (L/R) 3/27 7/23 .16  
Married (%) 47 37 .09  
Education (years) 15.56 (2.83) 14.30 (3.19) .11 0.39 
NART predicted IQ score 119.72 (4.76) 119.02 (5.03) .58 0.14 
BMI score (kg/m2) 27.54 (4.16) 26.01 (3.94) .15 0.42 
Systolic BP (mmHg) 145.90 (15.98) 140.23 (21.91) .26 0.29 
Diastolic BP (mmHg) 83.67 (11.87) 80.07 (13.77) .28 0.28 
Current smoker (Y/N) 0/30 2/28 .15  
Alcohol (drinks/week) 5.36 (5.87) 4.88 (4.47) .72 0.08 
Sleep (hrs/night) 7.11 (0.96) 6.70 (1.16) .13 0.38 
Exercise (days/week) 4.17 (1.39) 4.53 (1.17) .28 0.28 
Number of med (per day) 2.26 (1.62) 2.0 (1.52) .46 0.19 
Hypertension med (Y/N) 16/14 17/13 .80  
APOE ɛ4 carriers (n/%)  10/33 8/27 .58  
APOE ɛ2 carriers (n/%)  7/23 9/30 .57  
LA (%/TFA) 7.96 (1.03) 7.95 (1.32) .94 0.01 
ARA (%/TFA)       18.87 (1.64)         19.99 (1.83) .02* 0.64 
EPA (%/TFA) 1.00 (0.50) 0.99 (0.44) .95 0.02 
DPA (%/TFA) 1.9 (0.35) 1.85 (0.31) .48 0.15 
DHA (%/TFA) 4.1 (1.01) 4.06 (0.96) .84 0.04 
Omega-3 index 5.12 (1.29)  5.06 (1.11)  .94 0.02 
Vitamin B12 (pmol/L)     284.67 (112.08)      325.86 (232.08) .39 0.22 
Ferritin (µg/L)     182.40 (152.36)      150.30 (115.03) .36 0.24 
Note. NZ = New Zealand, Euro = European, NART = National adult reading test, BMI = Body 
mass index, BP = Blood pressure, med = medication, APOE = Apolipoprotein,                
LA = Linoleic acid, TFA = total % fatty acid, ARA = Arachidonic acid,                                
EPA = Eicosapentaenoic acid, DPA = Docosapentaenoic acid, DHA = Docosahexaenoic 
acid, Omega-3 index = EPA + DHA / total % fatty acid.  





8.3 Primary outcome measures 
The primary outcome was a change in the cognitive, well-being and anthropometric 
measures from baseline to 12 months. Table 12 shows that the only significant treatment 
effect was on systolic blood pressure, where systolic blood pressure increased more in the 
placebo group (Mdiff = 10.70, SD = 14.53) over the 12-month period than in the DHA group 
(Mdiff = 1.83, SD = 16.23) F(1, 55) = 4.97, p = .03, ƞ2= .08. The change in scores from baseline 
to 6-months in the cognitive, well-being and anthropometric measures were also analysed 
but showed no treatment effects. See Appendix N for the mean scores of the two groups at 
baseline, 6-months and 12-months and Appendix O for change in measures by group from 
baseline to 6 months. The data from the 9-month testing session was excluded because 
several participants were unavailable for testing due to unforeseen circumstances (e.g., 
illness, work commitments, and need to travel overseas for family reasons). 
 
8.4 Secondary outcome measures 
The secondary outcome was the treatment x APOE interaction effect on the change 
in cognitive, well-being and anthropometric measures. There was a significant effect for 
APOE ɛ4 x treatment on GDS and GAI scores, see Figures 6 and 7. GDS scores significantly 
improved in ɛ4 carriers in the DHA group compared to ɛ4 carriers in the placebo group F(1, 
53) = 4.16, p = .04, ƞ2= .07, and GAI scores significantly improved in ɛ4 carriers in the DHA 
group compared to ɛ4 carriers in the placebo group F(1, 53) = 5.41, p = .02, ƞ2 = .09. GDS and 





Table 12. Change in cognitive, well-being and anthropometric measures by group from baseline to 12 months 
 
                           DHA group (n = 30)                        Placebo group (n = 30)  DHA compared  to Placebo 
 Baseline 12 months Change  Baseline 12 months Change  Difference Treatment effect  APOE ɛ4 x treatment 
          p ƞ2  p ƞ2 
               
RTot 101.9 (11.9)1 108.4 (12.8) 6.5 (5.8)  100.3 (11.9) 105.5 (11.2) 5.2 (7.4)  1.3 (-4.7, 2.1)2  .373 .02  .64 .00 
RIM 104.8 (16.2) 110 (13.6) 5.2 (8.7)  105.3 (13.9) 109.9(13.8) 4.5 (12.3)  0.6 (-6.1, 4.8) .68 .01  .66 .00 
RVC 96.6 (9.6) 98.4 (8.8) 1.7 (9.1)  92.9 (12.6) 91.4 (11.8) -1.4 (13.1)  3.1 (-9.0, 2.7) .28 .02  .99 .00 
RL 103.9 (13.8) 107.0 (101.1) 3.06 (13.1)  103.2 (12.8) 106.7 (7.8) 3.5 (11.7  -0.4 (-5.9, 6.8) .86 .00  .83 .00 
RA 103.7 (13.8) 110.4 (15.3) 6.7 (8.1)  102.9 (13.3) 109.8 (13.9) 6.9 (10.5)  -0.2 (-4.6, 5.0) .93 .00  .73 .00 
RDM 98.2 (11.3) 104.6 (11.9) 6.3 (7.9)  98.3 (12.7) 102.8 (12.9) 4.5 (10.3)  1.8 (-6.5, 2.9) .45 .01  .38 .01 
CRT -0.33 (1.2) -0.003 (1.4) 0.33 (0.7)  -0.25 (1.2) -0.12 (1.5) 0.13 (0.96)  0.1 (-0.6, 0.24) .38 .01  .50 .01 
COA 57.8 (22.9) 65.2 (21.5) 7.4 (16.5)  53.7 (22.8) 64.8 (22.4) 11.1 (13.3)  -3.6 (-4.1, 11.4) .35 .02  .23 .03 
DSF 75.4 (24.3) 84.5 (19.1) 9.1 (20.9)  63.2 (26) 77.1 (22.1) 13.9 (24)  -4.7 (-6.8, 16.4) .42 .01  .58 .01 
DSBT 56.1 (32.5) 63.6 (31.1) 7.6 (17.3)  49.5 (30.5) 51.4 (30.1) 1.86 (24.5)  5.7 (-16.6, 5.3) .30 .02  .56 .01 
DSTot 12.4 (3.4) 13.6 (3.4) 1.2 (2.3)  11.2 (3.2) 12.1 (3) 0.9 (2.2)  0.3 (-1.4, 0.8) .60 .01  .40 .01 
TMTB 41.9 (30.4) 48.0 (31.1) 6.1 (26.2)  49.8 (31.6) 56.8 (32.3) 6.9 (37)  -0.8 (-15.7, 17.4) .91 .00  .81 .00 
GDS 1.97 (2) 1.97 (2.7) 0.0 (1.4)  2.2 (2.4) 2.1 (2.2) 0.03 (2.3)  -0.03 (-0.9, 1.0) .95 .00    .04* .07 
GAI 2.2 (3.0) 1.83 (3.1) 0.4 (2.4)  2.6 (3.6) 1.9 (2.4) 0.7 (2.6)  -0.3 (-0.9, 1.6) .64 .00     .02* .09 
SF36PF 50.0 (6.9) 50.0 (6.6) 0.03 (2.9)  51.3 (5.9) 49.8 (6.4) -1.5 (4)  1.5 (-0.2,3.3) .09 .05  .83 .00 
SF36BP 50.5 (7.7) 52.1 (7.4) 1.6 (8.9)  52.6 (8.8) 49.9 (8.1) -2.6 (11.1)  4.2 (-0.95, 9.5) .09 .05  .58 .01 
SF36SF 52.3 (6.7) 53.5 (5.7) 1.17 (6.3)  51.6 (6) 49.9 (9.3) -1.5 (9.6)  2.6 (-1.5, 6.8) .21 .03  .71 .00 
SBP 145.9 (15.9) 147.7 (16.7) 1.8 (16.2)  140.2 (21.9) 150.9 (25.1) 10.7 (14.5)  8.8 (-0.9, 16.8)   .03* .08  .47 .01 
DBP 83.6 (11.9) 84 (12.9) 0.3 (10.9)  80.1 (13.7) 81.9 (12.1) 1.83 (10)  1.5 (-3.9, 6.9) .57 .01  .35 .02 
               
Note.   RTot = RBANS Total score, RIM = RBANS Immediate Memory, RVC = RBANS Visuospatial/Constructional, RL = RBANS Language, RA = RBANS Attention, RDM = RBANS 
Delayed Memory, CRT = Coin Rotation Task, COA = COAST incongruent score, DSF = Digit Span Forward, DSBT = Digit Span Backward Test, DSTot = Digit Span Total, 
TMTB = Trial Making Test B, GDS = Geriatric Depression Scale, GAI = Geriatric Anxiety Inventory, SF36PF = SF-36 Physical functioning, SF36BP = SF-36 Bodily pain, 
SF36SF = SF-36 Social functioning, SBP = Systolic blood pressure, DBP = Diastolic blood pressure 
1 Values are means; SDs in parentheses   2 Values are means; 95% CIs in parentheses   3P values were derived by using ANCOVA (adjusted for age, gender and years of 
education) with APOE as an independent variable to test APOE ɛ4 x treatment interaction. None of the analyses violated Levene’s test of equality of error variances.              







Figure 6. Mean change in GDS scores from baseline to 12-months in APOE ɛ4 carriers and 
non-ɛ4 carriers   






Figure 7. Mean change in GAI scores from baseline to 12-months in APOE ɛ4 carriers and 
non-ɛ4 carriers  






There were no other APOE ɛ4 x treatment effects on the cognitive and well-being 
measures. There was a significant effect for APOE ɛ2 x treatment on RBANS Total scores, in 
that RBANS Total scores were significantly improved in APOE ɛ2 carriers in the placebo 
group (Mdiff = 9.57, SD = 10.29) compared to APOE ɛ2 carriers in the DHA group (Mdiff = 
4.00, SD = 6.32) F(1, 52) = 7.04, p = .01, ƞ2= .12. There were no gender x treatment effects, 
nor any age x treatment effects in any of the cognitive or well-being measures. Overall, 
RBANS immediate memory scores improved significantly more in non-ɛ4 carriers (M = 6.90, 
SD = 10.55) than in ɛ4 carriers (Mdiff = 0.11, SD = 9.26), F(1, 55) = 5.18, p = .03, ƞ2= .09, and 
RBANS delayed memory score improved significantly more in non-ɛ4 carriers (Mdiff = 7.33, 
SD = 8.37) than in ɛ4 carriers (Mdiff = 0.88, SD = 9.54), F(1, 55) = 6.49, p = .01, ƞ2= .11. There 
were no other differences between ɛ4 carriers and non-ɛ4 carriers in any of the measures. 
 
8.5 Compliance, seafood consumption and fatty acid levels 
Compliance rates at the end of the trial were on average 93% across the groups, with 
no significant difference between the DHA group (M = 92.51, SD = 8.14) and the placebo 
group (M = 94.79, SD = 5.25), t(58) = 1.27, p = .21, d = 0.32. This compliance was confirmed 
by changes in RBC fatty acids levels (see Table 13). RBC fatty acid levels of EPA (d = 1.00), 
DHA (d = 1.76) and total n-3 (d = 1.39) increased in the DHA group compared to the placebo 
group (all p < .01), and both the ARA:EPA (d = 1.07) and ARA:DHA (d = 1.68) ratios decreased 





Table 13. Change in PUFA levels of DHA and placebo groups from baseline to 12 months 
 DHA group (n = 30)  Placebo group (n = 30)  Difference     
PUFA Baseline 12 months Change  Baseline 12 months Change  DHA  to Placebo     P d  
             
LA  7.97 (1.06) 1   7.41 (1.04) -0.55 (0.87)  7.95 (1.32)  7.78 (1.53)  -0.16 (0.99)  -0.39 (-0.87, -0.09)2   .12 0.42  
ALA   0.00   0.00    0.00  0.08 (0.21)  0.00 -0.08 (0.21)   0.08 (0.004, 0.15)3     
ARA 18.87 (1.64) 13.32 (2.88) -5.55 (2.91)  19.99 (1.83) 15.21 (3.78) -4.78 (3.81)   -0.77 (-0.98, 2.52)   .38 0.20  
NA   4.44 (0.84) 5.54 (0.77)   1.09 (1.02)  4.40 (0.96)  5.51 (0.70)   1.11 (0.92)  0.02 (-0.48, 0.52)   .94 0.19  
EPA   1.00 (0.50) 1.10 (0.49)    0.09 (0.61)  0.99 (0.44)  0.56 (0.32) -0.44 (0.47)  0.54 (0.26, 0.82) <.01** 1.00  
DPA   1.92 (0.35) 1.44 (0.43) -0.48 (0.50)  1.85 (0.31)  1.54 (0.53) -0.32 (0.65)  -0.16 (-1.14, 0.46)   .29 0.28  
DHA   4.11 (1.01) 6.24 (1.78) 2.13 (1.87)  4.06 (0.96)  3.4 (1.36) -0.66 (1.19)  2.79 (1.97, 3.59) <.01** 1.76  
ARA:EPA 22.87 (9.47) 12.59 (5.37) -8.95 (10.30)  24.07 (10.18) 26.41 (7.95)  2.32 (10.57)  -11.25 (-16.8, -5.73) <.01** 1.07  
ARA:DHA   4.81 (1.04) 2.27 (0.70) -2.54 (1.15)  5.21 (1.40)   5.03 (1.92) -0.17 (1.63)  -2.33 (-3.09, -1.63) <.01** 1.68  
Omega-3   5.12 (1.29)  7.34 (2.20)  2.22 (2.29)    5.06 (1.11)    3.96 (1.56)  -1.10 (1.47)    3.38 (2.39, 4.37)  <.01**  1.72   
Total n-3   7.04 (1.29) 8.78 (2.50) 1.74 (2.61)  7.00 (1.22)   5.50 (2.01) -1.49 (1.98)  3.24 (2.05, 4.44) <.01** 1.39  
Note. LA = Linoleic acid, ALA = Alpha-linolenic acid, ARA = Arachidonic acid, NA = Nervonic acid, EPA = Eicosapentaenoic acid,                                    
DPA = Docosapentaenoic acid, DHA = Docosahexaenoic acid, ARA:EPA = Ratio of Arachidonic acid to Eicosapentaenoic acid, ARA:DHA = Ratio 
of Arachidonic acid to Docosahexaenoic acid, Omega-3 = EPA + DHA / total % fatty acid, Total n-3 = ALA + EPA + DPA + DHA / total % fatty 
acid. 
1 Values are means (as percentage of fatty acids); SDs in parentheses 
2 Values are means; 95% CIs in parentheses 
3 Unable to calculate p value due to zero values 





APOE ɛ4 carriers had a higher baseline DPA level (M = 2.02, SD = 0.32) than non-ɛ4 
carriers (M = 1.83, SD = 0.32), t(58) = -2.16, p = .04, d = 0.63. There were no other 
differences between ɛ4 carriers and non-carriers in any of the baseline RBC fatty acid levels 
or in any changes in fatty acid levels. During the course of the 12-month period seafood 
consumption was on average 1.14 servings per week across the groups (0.24 servings/week 
from oily fish) with no significant differences between the DHA group (M = 1.08, SD = 0.49) 
and the placebo group (M = 1.19, SD = 0.57), t(58) = 0.75, p = .45, d = 0.21. Increased 
baseline levels of DHA (r = .33, p < .05) and the omega-3 index (r = .32, p < .05) were 
associated with baseline weekly fish consumption. Decreased baseline levels of ARA:DHA 
ratios (r = -.39, p < .01) were associated with baseline weekly fish consumption. 
 
8.6 Blinding and adverse effects 
Over 75% of participants stated they had ‘no idea’ which type of capsule they had 
been given during the 12-month supplement period, 66.6% (n = 20) from the DHA group and 
86.6% (n = 26) from the placebo group. In the DHA group 23.3% (n = 7) of participants 
correctly guessed they had been given the DHA capsule, and in the placebo group 10%        
(n = 3) correctly guessed they had been given the placebo capsule. Two participants 
reported tasting an orange flavour (one DHA, one placebo). The capsules were well 











The research described in this thesis aimed to answer four questions: Can a high 
DHA fish oil supplement improve cognitive performance in older adults with Mild Cognitive 
Impairment (MCI)? Does the APOE ɛ4 allele have a moderating effect on cognition and well-
being? How popular are fish oil supplements within New Zealand (NZ)? What health 
behaviours are associated with fish oil supplement use? The first two questions were 
answered by way of a randomised controlled trial (RCT), and the other two questions 
through an online cross-sectional survey. This chapter will discuss the results of the RCT and 
survey as well as implications for the use of fish oil supplements and for dietary intake of n-3 
PUFAs in preventing cognitive decline in older adults. The chapter will end by discussing the 
strengths and limitations of the research, and future recommendations.  
  
9.1 The randomised controlled trial 
 The results of the RCT found that a high DHA fish oil supplement did not improve 
cognitive performance in older adults with MCI compared to a placebo of sunflower oil. This 
is the first fish oil supplement trial in older adults with MCI that did not find a significant 





an improvement in the cognitive measures, despite a significant increase in DHA and EPA 
levels in the DHA group compared to the placebo group. 
The current RCT did find a treatment effect on systolic blood pressure after 12 
months. Systolic blood pressure increased by only 1.83 mmHg units in the DHA group 
compared to an increase of 10.7 mmHg units in the placebo group, indicating that the DHA 
group showed a significantly smaller increase (a stabilising effect) in systolic blood pressure 
over the 12-month period. Systolic blood pressure refers to the amount of pressure within 
the arteries while the heart is contracting, and an increase is related to an increase in artery 
stiffness which is common with age. Systolic blood pressure in older adults is often used as 
an indication of the risk of having a stroke or a heart attack. The proposed mechanisms by 
which n-3 PUFAs, EPA and DHA reduce blood pressure are via prostaglandins that cause 
vasodilation, anti-platelet aggregation and control sodium and water retention (Das, 2001). 
The link between diet and hypertension is well established (e.g., Schwingshackl & Hoffmann, 
2015), which has led to recommendations of eating a diet high in vegetables and fruit, 
whole grains and starchy vegetables, with legumes, eggs and oily fish as the preferred forms 
of protein along with regular physical activity and not smoking (Heart foundation, 2016). 
A meta-analysis of 31 fish oil RCTs specifically investigating the effects on blood 
pressure found that reduction in blood pressure was dose-responsive and was strongest in 
those with hypertension (Morris, Sacks, & Rosner, 1993). The mean systolic blood pressure 
of the participants in the current RCT at baseline was 143 (indicative of high blood pressure), 
whereas the average diastolic blood pressure was 81 (normal blood pressure), which backs 
these findings. This positive effect on blood pressure supports the two fish oil trials by 
Nilsson et al. (2012) that found a significant reduction in systolic blood pressure in 





and by Witte et al. (2013) who found a significant reduction in diastolic blood pressure in 
participants with an average diastolic blood pressure of 87.5 and an average systolic blood 
pressure of 140. The omega-3 index has been used to indicate risk for coronary heart 
disease with scores less than ‘4’ indicating a high risk, ‘4-8’ indicating an intermediate risk 
and scores above ‘8’ a low risk (Harris, 2008). The participant group showed a mean baseline 
omega-3 index score of 5.09 indicating an intermediate risk of heart disease, and after 12-
months of supplementation the DHA group was still below a score of ‘8’. This indicates that 
a longer period or higher dose of supplementation may have been required to reach the 
highest level of cardio-protection. 
Eighty percent of participants in the current RCT took prescription medications on a 
daily basis, and 55% of participants were taking at least one type of hypertension 
medication. The trial by Yurko-Mauro et al. (2010) found that 50% of participants were 
taking hypertensive medications, and although there was no treatment effect on blood 
pressure, the DHA group had a significant decrease in heart rate at 24-weeks compared to 
baseline. There is debate as to whether nutritional supplementation can be beneficial 
alongside pharmaceutical treatments. The fact that over half of the participants in the 
current RCT were taking hypertension medication, and that those who took the DHA had a 
smaller increase in systolic blood pressure over the 12-month period, suggests that fish oil 
may provide additional benefit. Similarly, Freund-Levi et al. (2008) reported that 40% of 
participants in their trial were being treated with anti-depressant medication, and yet they 
found depression scores improved in non-ɛ4 carriers in the fish oil group. 
The current RCT also found an APOE ɛ4 x treatment interaction with two of the well-
being measures, the Geriatric Depression Scale (GDS) and the Geriatric Anxiety Inventory 





whereas GDS and GAI scores increased in ɛ4 carriers in the placebo group. The result 
indicates that ɛ4 carriers may benefit from a DHA supplement with alleviating depression 
and anxiety symptoms. This may be partially explained by higher scores on the GDS and GAI 
in ɛ4 carriers at baseline. In contrast to this finding, the trial by Freund-Levi et al. (2008) 
found that in older adults with AD depression scores improved in non-ɛ4 carriers in the fish 
oil group, whereas ɛ4 carriers showed a positive treatment effect for agitation. These 
findings indicate that both non-ɛ4 carriers and ɛ4 carriers benefited from taking a fish oil 
supplement in terms of an improvement in well-being in AD. The link between genetics, and 
both depression and anxiety is well established (e.g., Sullivan, Neale, & Kendler, 2000). 
Depression and carrying the ɛ4 allele are both associated with higher levels of inflammation, 
and therefore it is possible that the fish oil was able to improve depression scores due to the 
interaction of these two factors. It is likely there is a mediating factor linking depression and 
the APOE ɛ4 allele, perhaps a personality trait, stress or dysfunction within the brain such as 
decreased activation of the frontal lobes (Carr & McNulty, 2016).  
The results of the current RCT showed that there were no significant differences in 
the cognitive measures at baseline between ɛ4 and non-ɛ4 carriers, but that overall non-ɛ4 
carriers improved more over the 12-month period than ɛ4 carriers in immediate memory, 
delayed memory, and total RBANS scores. However, this difference is not due to the 
treatment as the results showed no significant APOE ɛ4 x treatment effects for any of the 
cognitive measures. The lack of an APOE ɛ4 x treatment effect on cognition is in contrast to 
the trial by van de Rest et al. (2008a), which found ɛ4 carriers in both the low and high fish 
oil groups improved in an attention domain score, and the trial by Danthiir et al. (2018) 
where ɛ4 carriers improved significantly on several reasoning tasks. The total percentage of 





RCT by Stonehouse et al. (2013), who found a total of 31% ɛ4 carriers in a sample of healthy 
adults (18 to 45 years of age). Both percentages are lower than those in the RCT by Quinn et 
al. (2010), where 57.7% of AD participants were found to be ɛ4 allele carriers. This is 
probably due to the increased risk for AD from carrying the ɛ4 allele. It is still unclear how 
the ɛ4 allele affects cognition with age, although the APOE ɛ2 x treatment effect on the 
RBANS total score indicates that carrying the ɛ2 allele may be a factor.  
The current RCT was designed to replicate the trials by Sinn et al. (2012) and Lee et 
al. (2013). Sinn et al. found a significant improvement in scores on the GDS after 6-months, 
which the current RCT failed to replicate, although it did find a moderating effect from the 
ɛ4 allele. The participants in the trial by Sinn et al. showed higher scores at baseline than 
participants in the current RCT, which could partially explain the discrepancy. Lee et al. 
found that participants in the fish oil group improved significantly after 12-months of 
supplementation on several memory scores, but found no treatment effect on GDS. Both 
Sinn et al. and Lee et al. used the same cognitive measures at each testing time-point, which 
Lee et al. observed might have resulted in a practice effect, contributing to higher scores at 
the end of the trial. The current RCT tried to eliminate practice effects with the use of 
alternate forms of the RBANS, which could explain the discrepancy in this finding. 
Lee et al. noted that participants from the trial were from a low socioeconomic 
background where the consumption of foods high in n-3 PUFAs was low due to financial 
constraints. Participants in Lee et al.’s trial began with DHA and EPA levels that were 
approximately half the baseline DHA and EPA levels of participants in the current RCT. This 
supports the idea that participants with lower levels at baseline may benefit more from 
taking a nutritional supplement. Levels of LA, EPA and DHA in the trial by Lee et al. were 





this may also explain why mean baseline levels of LA in the fish oil group in trial by Lee et al. 
were lower than in the current RCT. This may also be a reflection of the Western-style diet 
of New Zealanders where consumption of n-6 PUFAs is higher than in Asian countries like 
Malaysia, where the trial by Lee et al. was based. 
 Lee et al. observed that participants were ‘mildly impaired’ but not ‘in a more 
progressive stage’, implying that the positive results were possibly due to the level of 
cognitive impairment. This raises the question about whether the participants in the current 
RCT were not sufficiently cognitively impaired, and therefore were less likely to benefit from 
a nutritional intervention. The participants had a higher than average pre-morbid 
functioning level, so it is also possible that a participant group with a lower pre-morbid 
functioning level may have benefited more from the fish oil supplement. The fact that mean 
IQ scores were 119, yet the baseline scores for the RBANS indexes were close to a quotient 
of 100 and mean TMT B percentile scores were below the 50th percentile, indicates that the 
group was cognitively impaired, but it is not clear whether a higher cognitive reserve 
prevented a treatment effect.  
Although years of education was included as a covariate, education norms were not 
available, and therefore, not used to score the cognitive measures. This is a major limitation 
of the RBANS as a primary cognitive battery. The MMSE was used in the two trials by 
Rondanelli et al. (2012) and Lee et al. with scores of between 26 to 27 at baseline 
(considered to be ‘normal’ cognition), and both found a significant treatment effect. The 
supplement group in Rondanelli et al. improved by over one point on the MMSE and the 
placebo group decreased by over two points resulting in a significant effect, whereas in the 
trial by Lee et al. the fish oil group had improved by 0.2 of a point and the placebo group by 





these participants were. Considering the variations in MCI criteria, it may be more useful to 
include a pre-morbid functioning task rather than a global scale such as the MMSE to gauge 
the baseline level of functioning of participants. 
It is unclear whether the types of cognitive measures used in the current RCT 
contributed to the negative results. The current RCT used several similar cognitive measures 
as Sinn et al. and Lee et al. including Digit Span Forwards, Digit Span Backwards, Trail 
Making Test A and B and a version of the Stroop Test. One noteworthy difference from the 
current RCT was that Sinn et al. found a treatment effect for Initial Letter Fluency. In the 
current RCT Semantic Fluency was measured, and was combined with Picture Naming into 
an RBANS Language quotient score. Because reliability coefficients are higher for indexes 
than for subtests, the RBANS subtest scores are not usually reported; however, the analysis 
showed no differences between the two groups on scaled Semantic Fluency subtests scores 
at all-time points. Lee et al. found a significant effect using Digit Span Total, which was not 
replicated in the current RCT. There is support for the use of the RBANS as a tool for 
measuring cognitive change, particularly in older adults at risk for decline and with AD (e.g., 
Duff et al., 2005), although less so in amnestic MCI (Duff, Hobson, Beglinger, & O'Bryant, 
2010). Participants in the current RCT were a combination of amnestic and non-amnestic 
MCI due to low numbers, so including only one MCI subgroup should be considered in 
future fish oil trials. 
 The inclusion criteria for the trial involved a dietary intake of fish and seafood below 
two servings per week, and self-reported fish consumption from calendar records indicated 
that participants consumed on average 1.14 servings per week. The significant positive 
correlations between baseline levels of DHA and the omega-3 index with baseline weekly 





method of assessing fish consumption was reliable. The only difference between the DHA 
and placebo groups at baseline was in ARA levels, but both groups showed a similar 
decrease in ARA levels over the 12-month period. It is unclear why ARA levels decreased in 
the placebo group, especially since LA is the precursor to ARA and in the current RCT the 
placebo group was given 1857 mg of LA per day compared to less than 0.01 mg in the DHA 
group. Despite the high dose of LA in the current RCT, the placebo group showed a decrease 
in LA levels over the 12-month period, which suggests that LA may have been converted to 
fatty acids other than ARA. The influence of LA and ARA on cognition is not yet fully 
understood, although research shows that ARA levels tend to decrease with age, and that 
these levels are heavily influenced by EPA and DHA intake.  
Nervonic acid levels increased by a similar amount in both groups, which could 
possibly explain the improvement found on the cognitive measures in both groups. Nervonic 
acid is an n-9 PUFA found in white matter, primarily in the myelin sheath of nerve fibres, 
and low levels have been implicated in attention-deficit hyperactivity disorder and psychosis 
(Chen Hsu, Hsu, Hwang, & Yang, 2004; Amminger et al., 2012). Nervonic acid is considered 
an important nutrient for neuronal growth and is typically found in maternal milk as well as 
in oily fish and seeds, although it can also be produced from oleic acid. The fish oil 
supplement in the current RCT contained nervonic acid (0.057 g/day), but it was only 
present in trace amounts in the placebo capsule (<0.01 g/day). The increase in nervonic acid 
levels in the placebo group could be due to an increased conversion rate from the oleic acid, 








9.2 The cross-sectional survey 
The results of the cross-sectional survey showed that over 21% of NZ respondents 
used fish oil supplements, and that those who took fish oil supplements were more likely to 
regularly consume oily fish. It appears that fish oil is becoming a popular choice of 
nutritional supplementation, yet questions remain about current dietary recommendations 
as well as quality and sustainability issues. The current survey also found that only 6.8% of 
fish oil users stored their fish oil supplements in the refrigerator, and approximately 26% of 
fish oil users were taking a daily dose of fish oil that would meet the National Heart 
Foundation daily recommendations of 400 to 600 mg DHA and EPA. Dietary 
recommendations for ALA, EPA, DHA and total n-3 PUFAs and n-6 PUFAs have been very 
difficult to set, and consequently, recommendations for these nutrients vary widely around 
the world. Reasons for this difficulty include a lack of information about set dose-response 
relationships, uncertainty over conversion rates and the difficulty with differentiating the 
requirements of each fatty acid individually (Capra et al., 2006).  
Since n-3 PUFAs and n-6 PUFAs compete for conversion enzymes, several dietary 
organisations decided to set n-3 PUFA:n-6 PUFA ratios of between 1:5 to 1:10, with a ratio 
over 1:10 indicating the need to consume more n-3 PUFAs. Some experts disagreed with this 
as a dietary recommendation, and instead suggested it may be helpful to set 
recommendations for plant and marine sources of n-3 PUFAs and n-6 PUFAs separately due 
to their different effects, and also because decreasing n-6 PUFAs does not produce the same 
effect as increasing n-3 PUFAs (de Deckere, Korver, Verschuren, & Katan, 1998). This led to 
the development of separate recommendations for LA, ALA, EPA and DHA based on the 
different physiological effects. Recommendations for PUFAs are often expressed as an 





and RCTs. Currently in NZ the daily AI levels for women over 19 years of age are 8 g of LA, 
800 mg of ALA and 90 mg of combined DHA + EPA; for men, 13 g of LA, 1300 mg of ALA and 
160 mg of combined DHA + EPA. These equate to an n-3 PUFA to n-6 PUFA ratio of 
approximately 1:10. The suggested dietary target (SDT) or upper level at the 90th percentile 
is a level of intake that provides a ‘potential benefit while still at a safe level’. In comparison 
to the AI, the SDT is set at 430 mg/day combined DHA + EPA for women and 610 mg/day for 
men, with an upper level of intake of combined EPA, DPA and DHA set at 3000 mg/day 
(Capra et al., 2006).  
There is minimal information about the consumption of individual fatty acids by New 
Zealanders. The 2008/9 National Adult Nutrition Survey found that older adults between 51 
and 70 years of age had a median intake of total PUFAs of 10.5 g/day, contrasted with 8.85 
g/day for older adults over the age of 71, and a median intake of 11.35 g/day for all age 
groups combined. A review published in 2000 estimated that PUFA intake of adult New 
Zealanders was high, sitting at 15 g/day for LA, 1000 mg/day of ALA and slightly less than 
200 mg/day of DHA + EPA (Eyres, 2000). Based on recommended AIs these figures are 
sufficient; however, they are not sufficient when based on SDTs. The question of whether 
the dietary intake of n-3 PUFAs and n-6 PUFAs in older adults in NZ is contributing to the 
increasing incidence of dementia is worthy of further research. 
The ethics and sustainability of using fish to produce n-3 PUFA supplements is a very 
topical issue, especially in light of the high numbers of oxidised fish oil supplements. There 
has been a decline in wild marine fish stocks, partially due to the increased demand for fish 
and fishmeal due to population growth and rising disposable incomes. This is especially the 
case for fish high in n-3 PUFAs such as salmon, where the salmon available to consumers 





Sneddon, Sprague, Horgan, & Brouwer, 2017).  A 2017 paper on the health properties of 
farmed fish found that the content of EPA and DHA has halved within farmed salmon in the 
last decade, which will no doubt hinder people from meeting their requirements from this 
food source (de Roos et al., 2017). Part of the reason for this decline is the type of food 
salmon are fed. In the wild, salmon typically eat other fish, squid, eels and plankton (all 
sources of EPA and DHA), whereas farmed salmon are typically fed soya or corn-based feed, 
lacking in n-3 PUFAs or even rapeseed oil, which contains ALA as opposed to EPA and DHA.  
The source of n-3 PUFAs for fish oil supplements in RCTs is often unknown and varies 
among the trials. In the current RCT, the source of the n-3 PUFAs was sardines, a small 
short-lived wild fish, and therefore had no detectable levels of mercury. Due to declining 
fish stocks as well as the decline in n-3 PUFA content of certain types of fish, marine algae or 
seaweed is increasingly used as an alternative source of EPA and DHA. Algae oil 
supplements have been shown to significantly increase DHA levels and are also a source of 
other important nutrients including iodine and magnesium, and plant pigments such as 
chlorophyll. Two of the RCTs reviewed in Chapter 5 used an algae-based n-3 PUFA 
supplement – Quinn et al. (2010) and Vakhapova et al. (2010). The algae supplement used 
by Quinn et al. contained only DHA whereas the supplement used by Vakhapova et al. 
contained EPA, DHA and phosphatidylserine, a phospholipid found in plasma membranes 
that plays a crucial role in neuronal signal transduction. Quinn et al. found a lower decline in 
mean change in the ADAS-cog for non-ɛ4 carriers and Vakhapova et al. found an 
improvement in immediate recall. Quinn et al. found that plasma phospholipid levels and 
cerebrospinal fluid levels of DHA increased substantially from the algae supplement. Five 
participants who were screened for the current RCT were either vegetarian or vegan, and 





The survey also contained a question aimed to see how willing people were to have 
a blood sample taken as part of a research study. The reason for including this question in 
the survey was due to the main supervisor’s concerns that this would be a deterrent to 
participation. It turned out that 70% of respondents answered ‘Yes’ to this question, 
indicating that the majority of respondents would not be deterred from participating in a 
trial if a blood sample was required. Considering the importance of measuring RBC levels of 
fatty acids to analyse compliance and treatment effects as well as the need for APOE status, 




The results of the current RCT add to an already confusing picture about whether 
EPA and DHA from fish oil can help older adults with cognitive difficulties. Exactly why the 
results from these trials have been inconsistent is of significant interest, especially when 
epidemiological and nutritional-based research is relatively strong. Until now, it appeared 
that somewhere between cognitively healthy and dementia was where fish oil 
supplementation might be most beneficial. The fact that in the current RCT the only 
significant treatment effect detected was in systolic blood pressure may indicate that DHA 
works via homeostatic mechanisms, and therefore the EPA and DHA were used to correct a 
dysfunction within the cardiovascular system as opposed to within the neuronal system. The 
results show that overall, the mean cognitive scores were higher in the DHA group 
compared to the placebo group at the 12-month mark, but the difference did not reach 
statistical significance. Whether a longer supplement period (e.g., between 18 and 24 





year supplement period and Dangour et al. (2010) a 2-year period in cognitively healthy 
older adults, and yet neither study found a treatment effect. Whether these negative results 
were due to the lack of cognitive impairment is unclear, although Chew et al. found that 
lower cognitive function at baseline was associated with a lower education level, 
hypertension and stroke, highlighting the multifactorial nature of cognition in older adults.  
 The effects of supplementing with a nutrient can be very difficult to measure, 
especially in comparison to a substance such as a pharmaceutical agent, which typically 
targets a single receptor or type of tissue. Nutrients such as DHA and EPA as well as minerals 
and vitamins, can support multiple different functions within the body and exactly what the 
body does with these nutrients depends on several factors. These factors include current 
levels of the nutrient and its co-factors, current levels of disease and stress, and in the case 
of DHA, previous intake as well as current (and previous) intake of n-6 PUFAs and other n-3 
PUFAs. This makes it very difficult to know what to measure (or control for) at a particular 
point in time without knowing a particular person’s physiological and homeostatic state.  
 Another critical factor is that not all participants begin an RCT in the same 
physiological state. RCTs have typically measured demographic and cognitive states at 
baseline, but it is costly and time consuming to measure all components of a person’s 
health. Efforts to measure baseline levels of DHA, EPA and other fatty acids in n-3 PUFA 
trials has made progress in this regard, but this type of analysis does not give any insight 
into exactly how the fatty acids will be used or stored in the body. Both EPA and DHA 
contribute significantly to the production of anti-inflammatory mediators, to a reduction in 
vaso-constriction, to thrombosis production within the vascular system, to protecting and 





energy production. Future trials may need to measure these effects to rule out reasons why 
DHA and EPA may not be contributing to an improvement in cognition.  
The inconsistencies in the results from RCTs for other nutrients have been similarly 
problematic. For example, vitamin C has received considerable attention over the years, 
specifically in preventing the common cold, and yet vitamin C is involved in over eight major 
enzyme-dependent reactions within the body as an anti-oxidant agent, a lipid protector and 
in collagen, gastric juice and hormone production (Capra et al., 2006). Vitamin C also aids 
the absorption and stabilisation of other nutrients like iron, copper, vitamin A and folate. 
Therefore, how the body chooses to use the vitamin C when ingested depends on the 
current state of health within the body. For example, the turnover of vitamin C is markedly 
higher in smokers and consequently the RDA is higher in smokers (100 mg/day) than for 
non-smokers (between 30 to 60 mg/day) (Schectman, Byrd, & Hoffmann, 1991).  
The trial by Witte et al. (2013) used MRI and found that in healthy older adults a fish 
oil supplement resulted in significant increases in fractional anisotropy, mean diffusivity and 
radial diffusivity, an indication of superior white matter structural integrity. The trial also 
found that the fish oil supplement increased grey matter regional volume in the left 
hippocampus, precuneus, superior temporal, inferior parietal and postcentral gyri, and right 
middle temporal gyrus. In contrast, Quinn et al. (2010) found no changes in total brain 
volume using MRI between two treatment groups of participants with AD. This suggests that 
fish oil supplementation may result in structural and functional changes within the neuronal 
system, but only at the pre-pathological stage. It is possible that a regular intake of n-3 
PUFAs over the course of a lifetime could help to strengthen neuronal pathways from 
normal wear and tear, but not for severely damaged neuronal pathways. It is clear that 





unclear as to whether EPA and DHA improve cognitive outcomes via genes, by targeting 
specific areas of the brain (and specific cognitive domains), or via broad-spectrum 
mechanisms such as reducing inflammation and oxidation (e.g., the decrease in 
inflammatory mediators in Yacong et al., 2017) and by improving synaptic transmission and 
cerebral flow – or all of the above. Understanding exactly how n-3 PUFAs, EPA and DHA 
work to improve cognition (or to prevent cognitive decline) needs to be explored further to 
understand who may benefit the most from taking a fish oil supplement.  
The current survey found that over half of fish oil users take fish oils to ‘improve 
brain functioning’, and yet the results from the current RCT and the 23 RCTs reviewed in 
Chapter 5 suggest that the evidence for the use of fish oil supplementation in improving 
brain functioning in older adults (regardless of the level of impairment) is still not clear. 
Discrepancies between the evidence for fish consumption, the evidence for n-3 PUFA, EPA 
and DHA intake, the evidence for RBC and plasma n-3 PUFA levels, and results from RCTs 
suggests that the protective effect of fish consumption on cognition may be from more than 
just the n-3 PUFA content (Dacks et al., 2013). Fish contains other dietary and nutritional 
factors including vitamin D, calcium, zinc, selenium and protein, which in older adults have 
been shown to help with improving bone density, well-being, tissue strength, mobility and 
energy levels. The role and impact of culture and food habits on fish consumption is also an 
important factor (Gillette-Guyonnet et al., 2007). A RCT carried out in Japan used an n-3 
PUFA enriched fish product in the form of a fish sausage as opposed to a capsulated product 
as the source of EPA and DHA (Hashimoto et al., 2012). The sausages contained a daily dose 
of 1720 mg of DHA and 407 mg of EPA and the trial found positive results in language 
copying from the MMSE and conflicting instructions from the Frontal Assessment Battery. 





them being a traditional way of consuming fish as a form of snack for children in Japan. Fish 
is not only seen as a source of nutrients; foods from the sea (or from a river) play a very 
significant role in certain food cultures. 
Fish is also typically part of an overall healthier diet, for example in the 
Mediterranean diet, and diets from Scandinavian and Northern Asian countries such as 
Japan. In contrast, the Western-style diet is typically simultaneously low in fish consumption 
and high in red meat, processed foods and n-6 PUFAs from fried foods and margarine, 
resulting in a lower ratio of n-3 PUFAs to n-6 PUFAs. The 2008/2009 New Zealand Adult 
Nutrition Survey showed that the primary food sources of protein of New Zealanders are 
from bread (11%), poultry (9%), milk (9%), beef and veal (8%), grains and pasta (7%), bread-
based dishes (7%), fish and seafood (7%) and pork (5%), and that very little fat comes from 
fish and seafood (only 3.8%) compared to butter and margarine (9.3%) which are typically 
high in saturated fatty acids and n-6 PUFAs (New Zealand Adult Nutrition Survey, 2011). The 
National Adult Nutrition survey does not specify what types of fish and seafood New 
Zealanders eat. Fish and seafood are consumed less than other types of meat due to the 
smell and taste, to the high cost compared to other forms of protein, and because it spoils 
more quickly than other forms of protein like eggs and beef. Fish and seafood sources of n-3 
PUFAs tend to be those that people like the least, including sardines, anchovies, tuna and 
herring, because of their strong or ‘full-flavoured’ taste. In addition to this, there are very 
few other food sources of n-3 PUFAs apart from fish and seafood in the Western diet.  
The NZ diet, especially in older adults, is still based mainly on the old UK diet of 
‘meat and three vege’. When fish is consumed, it is typically in the form of ‘fish and chips’, 
which usually consists of a white fish (therefore with lower levels of n-3 PUFAs) along with 





or so, NZ’s food culture has adopted several non-meat sources of n-3 PUFAs from other 
cultures as can be seen in the consumption of seaweed in sushi and chia seeds in certain 
cereals and bread. The traditional Māori diet on the other hand contains a significant 
number of foods from the sea or from rivers, a lot of them high in n-3 PUFAs such as eel, 
muttonbird, and shellfish such as paua and kina or sea urchin. It could be that the traditional 
Māori diet is not necessarily higher in fish and seafood in terms of quantity, but may include 
a wider range of types of seafood, and in particular, types that are high in n-3 PUFAs. Even 
though salmon is more likely to be part of a Western-style diet than a Polynesian diet, 
intensive farming means the PUFA content might be lower than in non-farmed n-3 PUFA 
foods like kina.  
The current survey also found that fish oil supplement use was least likely in 
respondents who regularly eat nuts and seeds. Plant sources of n-3 PUFAs such as ALA are 
seen in most traditional diets around the world – linseeds in the Indian Ayurvedic tradition, 
leafy vegetables including Perilla from traditional Korean and Japanese food cultures, 
Portulaca (purslane) from both the Mediterranean and Central Europe, hemp seed from 
China, chia seeds from Central and South America, berries such as lingonberry from Nordic 
countries, gooseberry from China and rosehip berries from the indigenous people of North 
American as well as the Mayans. Both DHA and EPA can be synthesised from ALA, but due to 
limited conversion rates, most dietary organisations recommend eating fish and seafood to 
obtain sufficient amounts of DHA and EPA. However, there is still a need to promote the 
consumption of plant food sources of n-3 PUFAs as well, especially considering that the 
number of people opting for a vegetarian or vegan diet is increasing. Seaweed and algae 
hold promise, as certain strains of algae contain LA, ALA, EPA and DHA, providing a 





friendly, have a low carbon footprint, contain other important and often commonly 
deficient minerals such as iron, zinc and iodine alongside many other phytonutrients. The 
fatty acids in algae are stable, unlike the fatty acids in fish oil and are less likely to become 
oxidised (easier to manufacture and store), making them an attractive commercial product 
for capsulation. Like mussels, seaweed and algae can be farmed sustainably without causing 
detrimental effects to the environment.  
As some nutritional experts have suggested, increasing foods high in n-3 PUFAs is 
more efficacious than decreasing foods high in n-6 PUFAs. This does not mean that efforts 
to reduce foods high in n-6 PUFAs are not worthwhile. Foods high in n-6 PUFAs that are 
likely targets are certain types of margarines, fried foods, processed biscuits and breads, 
pastries, crackers and cakes – all of which pose significant other concerns including the high 
sugar content and low overall nutritional content including fibre, and the high content of 
saturated and trans-fatty acids. These nutritional factors contribute to obesity, diabetes and 
other major chronic health conditions, all of which also increase the risk of cognitive decline 
and dementia. The idea of combining fish oil supplementation with other lifestyle 
interventions to reduce cognitive decline has led to the development of multi-domain 
interventional programs such as Multi-domain Alzheimer Preventive Trial, but so far with 
limited results (Chhetri et al., 2018).  The best prevention approaches for cognitive decline 
in older adults are most likely to be multifactorial with multiple benefits; however, this 
design methodology poses a range of challenges for researchers. 
 
9.4 Strengths and limitations of the trial 
 The main strength of the current RCT is that it was designed to replicate components 





measures. Considering the ever-increasing number of fish oil RCTs (with widely varied 
design details and consequently varied results), it may be time to start replicating key design 
components to bring some order to the current confusion.  
The current RCT had several limitations. The lack of educational norms for the 
RBANS was a major limitation, particularly given that the participant group was highly 
educated and showed high pre-morbid functioning. As a result, it was difficult to gauge the 
exact level of cognitive impairment of the participant group, which is important as it has 
been suggested that the negative results from trials could be due to participants not being 
impaired enough or having a high cognitive reserve. Participants in the trial were a mix of a 
community sample and those recruited from a memory clinic, whereas most other RCTs 
have been one or the other. At least four of the participants began the trial with pre-existing 
conditions (one reflux, two previous stroke, one bowel irregularities), which in hindsight 
should have excluded them from the trial, primarily for their safety and comfort. There is 
increasing evidence to suggest that a higher dose of EPA than used in the current RCT is 
required to see a noticeable change in depression scores, therefore future trials should 
consider using a supplement high in both DHA and EPA. The small sample size (and low 
power) restricted analysis, mainly concerning the APOE x treatment effects. The 12 
participants who dropped out of the trial were not followed up, and therefore this data was 
missing. The decision was made not to perform an intention-to-treat analysis, as the small 
sample size with the high proportion of participant drop-outs would risk underestimating 









 The current RCT aimed to investigate whether a 12-month course of a high DHA fish 
oil supplement could improve scores on cognitive and well-being measures in older adults 
with MCI. The trial found no evidence of a treatment effect on the cognitive measures, 
although a positive result was found for systolic blood pressure in favour of the DHA fish oil 
supplement. The trial also aimed to investigate the moderating effect of the APOE ɛ4 allele 
on the treatment, which was shown for scores on both the GDS and GAI in the DHA group. 
Despite the lack of treatment effect on the cognitive and well-being measures, the positive 
result for APOE ɛ4 carriers and on systolic blood pressure justifies further RCTs. 
 A poor diet underlies the main risk factors for dementia including obesity, diabetes, 
hypertension and depression, and is associated with the major health behaviours associated 
with cognitive decline, including physical inactivity, smoking and low educational 
attainment. A recent meta-analysis of 15 cohort studies involving over one million 
participants found that a DASH-like diet (low in salt and high in vegetables, fruit, nuts and 
legumes) significantly reduces the risk for cardiovascular disease, cancer and type 2 
diabetes, but not neurodegenerative diseases such as dementia (Schwingshackl & 
Hoffmann, 2015). Therefore, it could be that diet may provide a beneficial effect on 
cognitive decline via effects on the cardiovascular, digestive and endocrine systems. It could 
be that measuring the cumulative effects of diet on cognitive decline independently of these 
factors is difficult to do with a RCT methodology. The inconsistencies from RCTs is of 
concern, especially for consumers who amid conflicting media reports, try to decide 
whether taking a fish oil supplement or purchasing salmon is worth the time and expense. It 





factors, for example, those that control LA and ALA intake and metabolism, and without 
being able to control and measure what the body does with the DHA and EPA.  
There is no doubt that n-3 PUFAs play a significant role in the neuronal system as 
well as in the homeostatic mechanisms used to control inflammation, vasodilation and 
tissue regeneration. There is also no question about how crucial DHA is to the development 
of the nervous system, but it is still unclear exactly what role it plays within the neuronal 
system in the later years. Epidemiological research indicates that fish consumption is part of 
a diet that protects older adults from a whole range of age-related chronic diseases, but the 
exact role it plays in reducing or preventing severe forms of cognitive decline is still unclear. 
Diminishing fish stocks highlight the need to promote plant sources of n-3 PUFAs, in 
particular marine algae, which would ensure a sufficient intake of EPA and DHA alongside 
other important nutrients.  
Efforts by researchers to test the efficacy of EPA and DHA by way of RCTs has 
resulted in painting a very confusing picture. Trying to decipher the details of these RCTs has 
researchers questioning the impact of dose, duration and measures, together with baseline 
demographic factors like lifestyle and health status. Whether any of these factors can 
explain the inconsistencies in the results is yet to be determined. What remains is evidence 
that suggests that what we eat is an important part of the dementia puzzle, alongside the 
quality of our social connections, our educational attainment, the amount of physical 
activity we do, and our general health, in particular the health of the vascular and 
cardiovascular systems as well as our mental health. We must of course consider the cohort 
and generational nature of the older adults we have tested and collected data on so far. The 
new generations are faced with a new world, with different eating patterns, different forms 
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Appendix C. Supplement survey  
 
Section 1 – Consent 
 
Thank you for participating in this questionnaire. Your participation implies consent. You have the right to 
decline to answer any particular question. 
 
I have read and understood the information sheet for this study and consent to collection of my responses. 
o Yes 
o No                                            
 
Section 2 – Demographics 
 
1. What is your current age? 
 
o 18-29 years old 
o 30-39 years old 
o 40-49 years old 
o 50-64 years old 
o 65-85 years old 
o 86 years and older 
 















o Palmerston North 








4. Which ethnic groups do you belong to? 
 
o New Zealand European/Pakeha 
o New Zealand Maori 
o Pacific Islander 
o Chinese 
o Indian 
o Other (please specify) 
 
5. What is the highest qualification you have achieved? 
 
o High school attendance 
o School certificate or NCEA Level 1 
o University Entrance, Bursary or NCEA 
level 3 
o Tertiary certificate or diploma (not a 
degree) 
o Bachelor’s degree – For example: BA, BSc 
o Postgraduate – For example: Honours, 
Masters, PhD or postgraduate diploma 
 
6. What is your annual salary? 
 
o 0 – $14,999 per year 
o $15,000 – $24,999 per year 
o $25,000 – $44,999 per year 
o $45,000 – $64,999 per year 
 
o $65,000 – $84,999 per year 
o $85,000 – $104,999 per year 
o $105,000 – $149,999 per year 





7. Are you currently taking any medications prescribed by a GP/Medical doctor/Physician? 
 
o Yes o No 
 







9. What is your current height? 
Please use either metric or imperial measures (eg. 183cm or 6’3”) 
Open 
 
10. What is your current weight? 
Please use either metric or imperial measures (eg. 70kg or 154 pounds or 11 stones 3lbs) 
Open 
 
11. Do you smoke tobacco cigarettes? 
o Yes o No 
 
 
12. Would you be willing to have a blood sample taken if you were part of a research study? 
o Yes o No 
 
 
Section 3 – Fish oils 
 
1. Do you take fish oil supplements?  
o Yes o No 
 
2. How often do you take fish oil supplements? 
o Every day 
o 4-6 times per week 
o 1-3 times per week 
o Several times a month 
o About once a month 
o Less than once a month
 
3. How long have you been taking fish oil supplements? 
o Less than 3 months 
o Between 3 to 6 months 
o Between 6 to 12 months 
o More than 12 months 
 
4. Why did you first start taking fish oil supplements? 
o General well-being 
o To improve brain functioning 
o For joint pain and/or inflammation 
o To lower cholesterol levels 
o Dietary insufficiency 
o Other 
o Recommended to take them by a health 
professional e.g. GP, nutritionist, 
naturopath 
o Heard about them on the radio/TV 
o Read about them in a magazine 
o Read about them on the internet 
o Was told about them by a friend or family  
 
5. Have you ever taken a break from taking fish oil supplements for more than 1 month? 






6. What brand of fish oil supplements are you currently taking?       Open 
7. What dose of fish oil supplements are you currently taking? 
e.g. 2 capsules containing 300 mg of DHA and 120 mg of EPA 
Open    
8. Where do you store your fish oil supplements? 
 
o On my bench top 
o In the pantry/food cupboard 
o In the refrigerator 
o Other 
 
9. Have you noticed any good or bad health effects from taking fish oil supplements? 
 
o Yes     o No 
 
10. Do you feel you know enough about fish oil products and their use? 
 
o Yes     o No 
 
 
Section 4 – Supplement use 
 
1. Do you take any other types of supplements? 
o Multi-vitamins and minerals 
o Single vitamins e.g. Vitamin C 
o Single minerals e.g. Calcium, Magnesium, 
Iron 
o Probiotics e.g., Acidophilus 
o Herbal remedies e.g., Ginkgo, Echinacea, 




o I don’t take any supplements 
 
 
2. How often do you take these supplements? 
o Every day 
o 4-6 times per week 
o 1-3 times per week 
o Several times a month 
o About once a month 
o Less than once a month 
 
3. Why do you take these supplements? 
o For a particular medical condition   
o General well-being  
o Dietary insufficiency 
o Recommended to take them by a health 
professional e.g. GP, nutritionist, 
naturopath 
o Heard about them on the radio/TV 
o Read about them in a magazine 
o Read about them on the internet 




4. Where do you purchase your supplements?    Tick all that apply 
o Pharmacy 
o Specialty health store e.g. Health 2000 
o Supermarket 
o Online 
o Phone/Mail order 
o Other
 
5. What influences your decision when selecting your supplements?  
o Brand 
o On sale/special price 
o Availability 







6. Have you ever told your GP/Medical doctor/Physician that you take supplementation? 
 
o Yes o No  Why not? Open 
 
 
Section 5 – Your diet and exercise habits 
 





o Once a month 
o Once a fortnight 
o Once a week 
o 1-2 times per week 
o More than 2 times per week 
 
 
2. How often do you eat white fish or seafood including shellfish and crustaceans such as prawns/shrimps? 




o Once a month 
o Once a fortnight 
o Once a week 
o 1-2 times per week 
o More than 2 times per week 
 
 
3. How often do you eat nuts and seeds such as walnuts, almonds, sunflower seeds, pumpkin seeds, 




o Once a month 
o Once a fortnight 
o Once a week 
o 1-2 times per week 
o More than 2 times per week 
 




o Once a month 
o Once a week 
o 1-2 times per week 
o More than 2 times per week 
 
5. How many portions of fresh fruits and vegetables do you eat per day? One portion is equal to one handful 
 
o On average, less than 1 portion per day 
o About 1 portion per day 
o 2-3 portions per day 
o 4-5 portions per day 
o 6-7 portions per day 
o 8+ portions per day 
 




o Once a month 
o Once a week 
o 1-2 times per week 
o 3-4 times per week 





Appendix D.  Screening questionnaire 
 
Participant Screening questionnaire    Assigned ID number   ____________ 
     
Name  __________________________________________    Date of phone call    _____________________    
 
Stated would be willing to be part of the study?     No / Yes    Why not?  _____________________________ 
 
Do you fit between the age of 60 and 90?      Y / N           How old are you?   ________________       
 
Have you taken any fish oil capsules over the last 6 months?    Yes  /  No    _______________________ 
 
Are you willing to not take a fish oil supplement of your own during the trial?   Yes /  No 
 
Do you eat 2 or more servings of oily fish per week?   Yes  /  No 
 
Do you have any allergies to any type of fish or seafood?  Yes  /  No 
 
So are you willing to have two blood samples taken?  Yes  /  No 
 
Any major medical conditions including head injury, recent or expected major surgery? 
Yes  /  No   ____________________________________________________________________ 
 
Do you take any medications? ____________________________________________________________ 
 
Are you planning on being away for any period of time during the next 15 months?    Yes /No 
 






Can you attend four testing sessions at the psychology clinic at Massey University?    Yes / No 
 
Are you fluent in English?  Yes /  No 
 





Do you live independently of a carer or home help?  Y  /  N 
 
Fits the inclusion criteria    Yes  /   No  
 
Great, you fit the project criteria, would you be willing to participate in the trial?    Y  /  N 
 




Sent Information sheet and Consent form                         
 
2 week call                                                                              
 
Arrange first testing session date and time       







Appendix E. Trial leaflet and newspaper advertisement 
 
                               
                        
Researcher/PhD student: Alexia Mengelberg         This project has been reviewed and approved by the 
School of Psychology, Massey University Wellington          Central Health and Disability Ethics Committee 








Appendix F. Participant information sheet and consent form
 
Participant Information Sheet 
 
Study Title: Investigating the effects of fish oil supplements on cognitive performance 
Locality: Psychology Clinic at Massey University of Wellington  
Address: 24 King Street, Mount Cook (near the Basin Reserve)  
Lead researcher: Alexia Mengelberg 
Contact phone number: (04) or (021) 
Ethics Committee reference number: 14/CEN/148/AMO1 
 
You are invited to take part in a study on omega-3 fish oil supplements and cognition.  Whether or not 
you take part is your choice.  If you do not want to take part, you do not have to give a reason, and it 
will not affect the care you receive.  If you do want to take part now, but change your mind later, you 
can pull out of the study at any time.   
 
This document is 6 pages long, including a participant information sheet and a consent form.   The 
participant information sheet will help you decide if you would like to take part in the study.  It explains 
why we are doing the study, what your participation would involve, what the benefits and risks to you 
might be, and what would happen after the study ends.  You do not have to decide today whether or 
not you will participate in this study. Before you decide you may want to talk about the study with 
other people, such as family, whānau, friends, or healthcare providers.  Feel free to do this. 
 
Please make sure you have read and understood all the pages. You will receive a phone call once you 
have had time to read the information. This will give you a chance to ask any questions you might have 
about the study. If you agree to take part in this study, you will be asked to sign the consent form and 
return it using the self-addressed envelope enclosed. You can keep the participant information sheet. 
You will receive a copy of the signed consent form at the first testing session. 
  
WHAT IS THE PURPOSE OF THE STUDY? 
The aim of this study is to look at whether omega-3 fish oil supplements can improve thinking and 
reasoning abilities in older adults between the age of 60 and 90. The research concerning omega-3 
fish oil supplementation for improving memory is very positive. It is hoped that the current study will 
contribute to a clearer understanding of the benefits of omega-3 fish oils for the prevention of 





School of Psychology 





You have been chosen to participate in this study because you have a mild memory problem and it 
seems you might benefit from taking an omega-3 fish oil supplement.  It is important that you do not 
have an allergy to seafood or have any difficulty swallowing soft-gel capsules. Please talk the lead 
researcher if you have any further questions about this.  
This study will be placebo-controlled, double-blind and randomised. ‘Placebo-controlled’ means that 
half of the participants in this study will be given fish oil capsules and half of the participants will be 
given placebo capsules containing sunflower oil. ‘Double-blind’ means that neither you nor the lead 
researcher will know which capsules you will be given until the end of the study. This double-blind 
procedure ensures that we do not bias the results. ‘Randomised’ is ensures that there is an equal 
chance that you will be given the fish oil capsules or the placebo capsules. 
 
WHAT WILL MY PARTICIPATION IN THE STUDY INVOLVE? 
 
This study will begin in December 2015 and will finish in March 2017.  
 
During the study there will be four testing sessions. All testing sessions will take place at the 
Psychology clinic at Massey University, 24 King Street, Mount Cook (near the Basin Reserve). It is 
important that you attend all four testing sessions. 
 
The first testing session will take place sometime between December 2015 and February 2016. This 
will be called the baseline testing session and will take place before you start taking the capsules. The 
baseline testing session will take 2 hours to complete. It will involve 15 minutes to collect demographic 
information, 60 minutes of psychological tests then a 15 minute refreshment break, followed by 30 
minutes of questions about your diet and general well-being.  
 
You will be required to take the capsules for a 12-month period from the 1st of March 2016 until the 
28th of February 2017. During these 12 months you will need to take 3 capsules per day after breakfast 
with water. Please store the capsules in the fridge. You will be given your first 4 bottles of supplements 
at the end of the baseline testing session. At the end of each month, I will contact you via telephone 
to answer any questions you may have about taking the capsules or about the study. You will also be 
asked to record on a monthly calendar your daily consumption of fish and seafood.  
 
You will be required to have two lots of blood samples taken during the course of this study. The first 
sample will be after the baseline testing session and the second sample will be after the fourth testing 
session at the end of the study. You will need to go to the outpatients area at Wellington Regional 
Hospital on Riddiford Street in Newtown to have the blood samples taken. Please find enclosed a map 
of both the outpatients area at the Wellington Regional Hospital as well as the Psychology Clinic at 
Massey University. You will be given further information about the blood testing part of this study at 
the baseline testing session.  
 
The second testing session will take place in September 2016. This second testing session will take 1 
and ¼ hours to complete and will include 45 minutes of psychological tests and 30 minutes of 
questions about your well-being. Please remember to return your finished bottles of capsules at this 
session time along with any unused capsules. 
 
The third testing session will take place in December 2016. This third testing session will take 1 and ¼ 
hours to complete. It will include 45 minutes of psychological tests and 30 minutes of questions about 







The fourth testing session will take place in March 2017. This follow-up testing session will take 1 and 
½ hours to complete. It will involve 45 minutes of psychological tests, followed by 45 minutes of 
questions about your diet and general well-being.  Once the fourth testing session is over your 
participation in this study is complete. Again, please remember to return your bottle of capsules at 
this session time along with any unused capsules. Please return the calendar at this session too. 
 
WHAT ARE THE POSSIBLE BENEFITS AND RISKS OF THIS STUDY? 
 
Clinical research has shown that omega-3 fish oils can improve your ability to remember information 
faster. You may experience this effect during the trial or you may experience no effect at all. 
 
The potential adverse effects or side effects from the capsules are minimal. If you experience any 
discomfort from swallowing the capsules or digestive problems such as nausea of reflux after taking 
the capsules please contact the lead researcher as soon as possible.  
 
This study has been approved by the Central Health and Disability Ethics Committee and has been 
funded by the Massey University Postgraduate Research Fund, the Oakley Mental Health Foundation, 
a small project grant from the Neurological Foundation and the Hope-Selwyn Foundation Scholarship 
in Ageing. 
 
WHAT IS A GENETIC TEST? 
 
As part of this study, we will test to see if you carry a particular genetic allele in your blood. You can 
choose whether or not you would like to be told the results of this test. 
 
We are all different in terms of our genetic make-up. This study is interested in a particular gene called 
the APOE4 allele. Research has also shown that people who have the APOE4 allele are more likely to 
benefit from a diet rich in omega-3 fish oils. Research has also shown that people who have the APOE4 
allele are slightly more likely to develop Alzheimer’s disease later in life than those who do not. 
 
If you do carry the APOE4 allele this may have implications for your life or health insurance and for 
your family, as there is a small chance that it may have been passed onto your children and 
grandchildren. Please ask the lead researcher if you have any further questions about this.  
 
WHO PAYS FOR THE STUDY? 
 
You will be reimbursed for participating in this study with a $20 supermarket voucher for each testing 
session you attend. You will not be expected to pay any money to participate in this study.  
 
WHAT IF SOMETHING GOES WRONG? 
 
If you were injured in this study, which is unlikely, you may be eligible for compensation from ACC just 
as you would be if you were injured in an accident at work or at home. You will have to lodge a claim 
with ACC, which may take some time to assess. If your claim is accepted, you will receive funding to 
assist in your recovery.   
 
If you have private health or life insurance, you may wish to check with your insurer that taking part 






WHAT ARE MY RIGHTS? 
 
Your participation in this study is entirely voluntary. You are free to decline to participate. If you do 
agree to participate in this study, you may withdraw at any time without being penalized for doing so. 
You have the right to access information collected about you as part of the study. Please contact the 
lead researcher directly if you would like to do so. 
 
You will be informed of any new information that becomes available during the study during the 
monthly phone calls. 
 
WHAT HAPPENS AFTER THE STUDY? 
 
You can choose to be sent an information sheet with the results of the study. These results will be 
summarized and will be in the form of grouped test results. No individual results will be identifiable. 
 
Research findings will not be associated with the names of the participants, and all records will be 
stored securely and then destroyed after ten years. Blood samples will be destroyed once they have 
been analysed. 
 
WHO DO I CONTACT FOR MORE INFORMATION OR IF I HAVE CONCERNS? 
 
If you have any questions, concerns or complaints about the study at any stage, you can contact the 
lead researcher:  
 
 Alexia Mengelberg, PhD student  
 (04) or (021)  
  @gmail.com 
 
If you want to talk to someone who isn’t involved with the study, you can contact an independent 
health and disability advocate on: 
 
Phone:   0800 555 050 
Fax:   0800 2 SUPPORT (0800 2787 7678) 
Email:   advocacy@hdc.org.nz 
 
You can also contact the Central Health and Disability Ethics Committee (HDEC) that approved this 
study on: 
 
 Phone:  0800 4 ETHICS 
 Email:  hdecs@moh.govt.nz 
 
For Maori health support, please contact Te Roopu Awhina: 
Phone:   









Please tick to indicate you consent to the following 
 
I have read, or have had read to me in my first language, and I understand 
the Participant Information Sheet.   
Yes  No  
I have been given sufficient time to consider whether or not to participate in 
this study. 
Yes  No  
I have had the opportunity to use a legal representative, whanau/ family 
support or a friend to help me ask questions and understand the study. 
Yes  No  
I am satisfied with the answers I have been given regarding the study and I 
have a copy of this consent form and information sheet. 
Yes  No  
I understand that taking part in this study is voluntary (my choice) and that I 
may withdraw from the study at any time without this affecting my medical 
care. 
Yes  No  
I consent to the research staff collecting and processing my information, 
including information about my health. 
Yes  No  
If I decide to withdraw from the study, I agree that the information collected 
about me up to the point when I withdraw may continue to be processed. 
Yes  No  
I agree to my blood samples being disposed of using established guidelines 
for discarding biohazard waste. 
Yes  No  
I agree to an approved auditor appointed by the New Zealand Health and 
Disability Ethic Committees, or any relevant regulatory authority or their 
approved representative reviewing my relevant medical records for the sole 
purpose of checking the accuracy of the information recorded for the study. 
Yes  No  
I understand that my participation in this study is confidential and that no 
material, which could identify me personally, will be used in any reports on 
this study. 
Yes  No  
I understand the compensation provisions in case of injury during the study. Yes  No  
I know who to contact if I have any questions about the study in general. Yes  No  
 
I understand my responsibilities as a study participant. 
 
     Yes       No  






I wish to receive the results of the genetic testing. 
 
 
     Yes  
 
    No  
 
I wish to receive a summary of the results from the study. 
Yes  No  
   ________________________________________________________________________________ 
 
 
Declaration by participant: 
 







Declaration by member of research team: 
 
I have given a verbal explanation of the research project to the participant, and have answered the 
participant’s questions about it.   
 






































Appendix J. Nutritional Screening Questionnaire 
 





a. Do you consume any type of fish or seafood?                  
 
Yes □ No □ 
 
If yes, on average, how many servings of fish and seafood do you consume per week? 
 
Consider all types e.g. fresh, frozen or tinned?  (Please mark one only) 
 
(A ‘serving’ = 100 – 120 g of fish or seafood (the size of an adults hand palm) 
E.g. 1 small tin of fish = 1 serving per week 
 
Per Week 
□ None   □ < 1 serving  □ 1-3 servings 
□ 4-6 servings  
 
























Fish fried in batter (from fish 
& chips shop)                 
Albacore tuna, salmon, 
sardines, warehou, herring, 
kahawai, swordfish, carp, 
dogfish, gemfish, Alfonsino, 
rudderfish, anchovies                 
Mackerel, snapper, oreo, 
barracouta, trevally, dory, 
trout, eel         
Tuna (canned), hoki, dory, 
gurnard, hake, kingfish, cod, 





























Crumbed fish Patties /Cakes 
/ Fingers/ Nuggets/ Portions                 
Green mussels, Squid         
Shellfish: Cockles, kina, 
oysters, paua, scallops, 
shrimp/prawn, pipi, roe          








Omega 3 enriched products 
 
Omega 3 enriched milk or 
soy milk e.g. Vital or  
Essential          
Omega 3 enriched bread 
e.g. Goodness Omega 3         
























Please find below a summary of the individual results of the cognitive screening tests that you 
underwent as part of the fish oil supplement and cognition trial.  As you are aware the tests 
were conducted for a specific research purpose and so not what would normally be conducted 
for a clinical purpose.   
 
The tests administered and your results are shown below: 
 
Testing session (TS)  1st TS 2nd TS 3rd TS 4th TS 
Test Administered Measures Quotient1    
Repeatable Battery of  
Neuropsychological Status (RBANS) 
 
Immediate memory 109 85 94 94 
Visuospatial/Construction 100 72 72 75 
Language 99 88 92 92 
Attention 132 112 128 115 
Delayed memory 107 75 98 71 
TOTAL 113 82 95 85 
Coin rotation task Fine motor speed 88 71 79 65 
Stroop colour-word test Divided attention 116 113 102 114 
Digit span backwards Working memory 113 108 113 108 
Trial making test B Mental flexibility 125 70 124 113 
1 Average is 100, average range is between 90-110. Scores between 80-89 are low average, 70-79 are well below 
average. Scores between 110-119 are high average. 
 
Test Administered Measures Score2,3    
Geriatric Depression Scale GDS Depression 1 1 1 2 
Geriatric Anxiety Inventory GAI Anxiety 0 0 0 0 
2 GDS score – 0-4=No indication of depression, 5-9=Some indication of depression, >10=Indication of depression 
3 GAI score – 0-8=Absence of anxiety, >9=Presence of anxiety 
 
Test Administered Measures Score4    
SF-36 Physical Self-reported physical health 44.07 56.76 45.74 41.7 
SF-36 Mental Self-reported mental health 61.46 53 60.63 64.45 
4 Average is 50, average range is generally between 40-60 
 
The grouped results which will show any differences between the fish oil and placebo groups 
will also be forwarded to you. If you have any queries about these test results, please contact 
me directly on (04) or via email: @gmail.com  
 




PhD candidate and lead researcher 












Please find below a summary of the grouped results from the omega-3 fish oil trial that you 
were part of within the School of Psychology at Massey University in Wellington.  
 
I want to thank you again for your contribution to the trial. The trial was a great success, and 
this is largely due to your time and effort. 
 
The aim of the omega-3 fish oil trial was to answer two main questions:  
1. Can an omega-3 fish oil supplement improve memory and cognition in older adults? 
2. How does the APOE ɛ4 allele affect cognition and well-being in older adults? 
 
The results of the trial found that the fish oil supplement had no effect on memory and 
cognition. This result is based on the finding that there were no differences between the fish 
oil group and the placebo group on the scores of the cognitive tests.  
 
The trial found that the fish oil supplement had a significant effect on systolic blood 
pressure. Systolic blood pressure is the ‘top’ number of a blood pressure reading e.g., the 
number 140 of a blood pressure reading of 140/80. Systolic blood pressure refers to the 
amount of pressure within the arteries while the heart is contracting, and an increase in 
blood pressure is related to an increase in artery stiffness, which is common with age. The 
trial found that systolic blood pressure increased by 1.83 mmHg units in the fish oil group 
compared to a much bigger increase of 10.7 mmHg units in the placebo group. This finding 
indicates that the fish oil supplement resulted in a smaller increase in systolic blood 
pressure over the 12-month supplement period.  
 
The trial also found that depression and anxiety scores were improved in APOE ɛ4 carriers 
from taking a fish oil supplement. We were interested in the APOE gene because previous 
research has shown that people who carry the APOE ɛ4 allele have an increased risk of 
developing Alzheimer’s disease, and also that people with the APOE ɛ4 allele may benefit 
from taking a fish oil supplement. The results from the trial show that APOE ɛ4 carriers may 
benefit from taking a fish oil supplement because it can alleviate symptoms associated with 
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The results of this trial will make a significant contribution to our understanding of how 
omega-3 fatty acids and fish oil supplements can help improve health and well-being in 
older adults. Due to the success of the trial, the results will be complied into a journal  
manuscript and submitted to an international journal for publication. The results in the 
paper will be grouped results, so no individual results will be identifiable. 
 
Lastly, I would like to apologise for the delay in getting these grouped results to you – I really 
do appreciate your patience. If you have any queries about the trial or these results, please 









PhD candidate and lead researcher 
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Appendix M. APOE fact sheet 
 
APOE genetic test – Fact sheet 
 
Here are some important facts to know about the APOE genetic test 
 
What is APOE? 
 APOE is the short name for a protein called Apolipoprotein E which is found in the liver and brain 
 APOE’s main role is to process and carry cholesterol and fats around the body. 
 There are 3 alleles or types of the APOE protein – APOE2, APOE3 and APOE4. Each one has a slightly 
different role in the body. 
 We each have two of the three types of APOE – we get one from each of our parents. We can either 
have two of the same type e.g., APOE3 and APOE3 or two which are different e.g., APOE3 and APOE4. 
 We can test which two types of the APOE protein you have from a blood sample. 
 If someone has APOE3 and APOE4, the results of the test will look like this –  
              Apolipoprotein E genotype: E3/4 
 Approximately 10% of people have at least one APOE2, 75% have APOE3 and 15% have APOE4. 
 
Why did we test for the APOE protein? 
 Research has shown that people who have one or two APOE4 types have a small increased risk of 
developing Alzheimer’s disease and also that people with the APOE4 type can benefit from taking a 
fish oil supplement.  
 
What does this mean for me? 
 It is important to remember that having an APOE4 type does not mean you will develop Alzheimer’s 
disease; it simply means you have a slightly higher chance than if you didn’t have the APOE4 type. 
There are many other factors which will affect your chance of developing dementia such as your diet, 
how much exercise you do, your cardiovascular health and how often you engage in mental or brain 
activities such as word puzzles, playing a musical instrument or reading. 
 
Want to know more information? 
 Try the internet – http://en.wikipedia.org/wiki/Apolipoprotein_E 
 Or ask your nurse or GP or a registered genetic counsellor 
___________________________________________________________________________ 
Study Title: Investigating the effects of fish oil supplements on cognitive performance 
Lead researcher: Alexia Mengelberg   Email: @gmail.com 
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Appendix N. Data from baseline, 6- and 12-months 
 
Table N1. Data for cognitive measures at baseline and at 6- and 12-month follow-up  
Treatment  Baseline 1 6 months 12 months  
 RBANS Total quotient score   
DHA 101.90 (11.87) 104.00 (11.90) 108.40 (12.77)  
Placebo 100.30 (11.89) 104.73 (11.47) 105.47 (11.20)  
 RBANS Immediate Memory quotient score 
DHA 104.83 (16.19) 108.57 (16.88) 110.03 (13.59) 
Placebo 105.33 (13.89) 109.43 (10.71) 109.87 (13.79) 
 RBANS Visuospatial/Constructional quotient score 
DHA 96.63 (9.66) 95.73 (8.96) 98.37 (8.85) 
Placebo 92.87 (12.67) 94.63 (9.80) 91.43 (11.79) 
 RBANS Language quotient score 
DHA 103.97 (13.76) 100.40 (10.24) 107.03 (10.07) 
Placebo 103.17 (12.79) 104.17 (8.15) 106.70 (7.76) 
 RBANS Attention quotient score  
DHA 103.67 (13.79) 105.20 (13.79) 110.37 (15.24) 
Placebo 102.90 (13.32) 106.63 (15.59) 109.80 (13.85)  
 RBANS Delayed Memory quotient score 
DHA 98.20 (11.26) 105.47 (10.28) 104.50 (11.95) 
Placebo 98.33 (12.66) 103.13 (13.71) 102.87 (12.87) 
 Coin Rotation Task z-score  
DHA -0.33 (1.17) -0.24 (1.45) -0.003 (1.44) 
Placebo -0.25 (1.18) -0.45 (1.47) -0.12 (1.46)  
 COAST incongruent percentile score 
DHA 57.80 (22.99) 61.52 (22.65) 65.24 (21.54) 
Placebo 53.68 (22.80) 62.59 (24.76) 64.75 (22.44) 
 Digit Span Forward percentile score 
DHA 75.40 (24.31) 74.96 (27.67) 84.51 (19.14) 
Placebo 63.25 (26.02) 73.26 (25.78) 77.12 (22.11) 
 Digit Span Backward Test percentile score 
DHA 56.08 (32.45) 55.99 (34.53) 63.63 (31.08) 
Placebo 49.53 (30.53) 47.51 (30.27) 51.39 (30.15) 
 Digit Span Total scaled score  
DHA 12.36 (3.37) 12.37 (3.52) 13.6 (3.42) 
Placebo 11.20 (3.17) 12.10 (3.53) 12.13 (3.00)  
 Trial Making Test B percentile score 
DHA 41.95 (30.44) 41.47 (32.16) 48.01 (31.13)  
Placebo 49.88 (31.57) 48.40 (31.62) 56.79 (32.30)  







Table N2. Data for well-being/anthropometric measures at baseline, 6- and 12-months 
 
Treatment group Baseline1 6 months 12 months 
 Geriatric Depression Scale (GDS) score2  
DHA 1.97 (2.01) 2.13 (2.38) 1.97 (2.74) 
Placebo 2.17 (2.35) 2.43 (2.35) 2.13 (2.24) 
 Geriatric Anxiety Inventory (GAI) score3 
DHA 2.23 (3.02) 2.53 (3.67) 1.83 (3.13) 
Placebo 2.60 (3.64) 3.37 (4.19) 1.90 (2.36) 
 SF-36 Physical functioning4   
DHA 50.04 (6.98) 49.31 (6.63) 50.07 (6.56) 
Placebo 51.27 (5.90) 49.57 (6.34) 49.75 (6.42) 
 SF-36 Role physical  
DHA 50.44 (6.85) 49.89 (6.89) 49.97 (7.33) 
Placebo 50.04 (6.41) 50.49 (6.50) 48.99 (6.84) 
 SF-36 Bodily pain 
DHA 50.48 (7.67) 49.90 (7.73) 52.12 (7.35) 
Placebo 52.58 (8.87) 53.85 (6.24) 49.97 (8.10) 
 SF-36 General health  
DHA 54.62 (6.82) 55.50 (5.47) 54.77 (6.73) 
Placebo 54.31 (8.05) 54.42 (5.94) 54.91 (7.74) 
 SF-36 Vitality  
DHA 56.06 (6.04) 54.98 (5.69) 56.46 (7.15) 
Placebo 53.19 (5.59) 53.39 (8.47) 53.29 (9.01) 
 SF-36 Social functioning  
DHA 52.32 (6.71) 53.33 (5.49) 53.49 (5.69) 
Placebo 51.49 (6.04) 54.66 (4.31) 49.99 (9.29) 
 SF-36 Role emotional  
DHA 51.06 (7.91) 50.83 (7.13) 51.99 (7.04) 
Placebo 50.07 (7.74) 49.32 (7.84) 50.36 (7.83) 
 SF-36 Mental health  
DHA 55.09 (7.59) 55.23 (6.35) 55.23 (7.72) 
Placebo 53.31 (6.76) 54.36 (7.22) 54.09 (5.98) 
 Systolic blood pressure (mmHg) 
DHA 145.90 (15.89) 144.47 (16.77) 147.73 (16.69) 
Placebo 140.23 (21.91) 139.33 (31.75) 150.93 (25.06) 
 Diastolic blood pressure (mmHg) 
DHA 83.67 (11.88) 82.00 (13.89) 84.00 (12.92) 
Placebo 80.07 (13.77) 79.03 (12.98) 81.90 (12.13) 
 Body Mass Index  
DHA 27.55 (4.16) 27.77 (4.45) 27.57 (4.42) 
Placebo 26.01 (3.94) 26.31 (3.98) 26.05 (3.99) 
Note.  1 Values are means; SDs in parentheses 
                2,3  Lower GDS and GAI scores indicate an improvement 






Appendix O. Change in measures from baseline to 6 months 
 
                     Table O. Change in cognitive, well-being and anthropometric measures by group from baseline to 6 months 
 
                           DHA group (n = 30)                        Placebo group (n = 30)                DHA compared  to Placebo 
    Baseline 6 months  Change  Baseline 6 months Change  Difference Treatment effect  
          p ƞ2  
             
RTot1 101.9 (11.9) 104.0 (11.9) 2.1 (7.2)  100.3 (11.9) 104.73 (11.5) 4.4 (7.3)  -2.3 (-6.1, 1.4)2      .26 3 .02  
RIM 104.8 (16.2) 108.6 (16.8) 3.7 (13.3)  105.3 (13.9) 109.4 (10.7) 4.1 (10.5)  -0.4 (-6.5, 5.8) .96 .00  
RVC 96.6 (9.6) 95.7 (8.9) -0.9 (9.1)  92.9 (12.6) 94.6 (9.8) 1.7 (10.3)  -2.6 (-7.6, 2.4) .21 .03  
RL 103.9 (13.8) 100.4 (10.3) -3.5 (13.3)  103.2 (12.8) 104.2 (8.2) 1.0 (12.5)  -4.5 (-11.2, 2.0) .22 .03  
RA 103.7 (13.8) 105.2 (13.8) 1.5 (10.2)  102.9 (13.3) 106.6 (15.6) 3.7 (11.0)  -2.2 (-7.6, 3.3) .46 .01  
RDM 98.2 (11.3) 105.5 (10.3) 7.3 (8.9)  98.3 (12.7) 103.1 (13.7) 4.8 (9.9)  2.5 (-2.4, 7.3) .29 .02  
CRT -0.33 (1.2) -0.24 (1.5) 0.09 (0.8)  -0.25 (1.2) -0.45 (1.5) -0.2 (0.9)  0.3 (-0.1, 0.8) .14 .04  
COA 57.8 (22.9) 61.5 (22.6) 3.7 (15.2)  53.7 (22.8)  62.6 (24.7) 8.9 (12.7)  -5.1 (-12.4, 2.0) .25 .02  
DSF 75.4 (24.3) 74.9 (27.7) -0.4 (25.0)  63.2 (26) 73.3 (25.8) 10.0 (26.8)  -4.7 (-16.4, 6.8) .13 .04  
DSBT 56.1 (32.5) 56.0 (34.5) -0.08 (20.9)  49.5 (30.5) 47.5 (30.3) -2.0 (19.6)  1.9 (-8.5, 12.4) .92 .00  
DSTot 12.4 (3.4) 12.4 (3.5) 0.0 (2.6)  11.2 (3.2) 12.1 (3.5) 0.9 (2.5)  -0.9 (-2.2, 0.4) .15 .04  
TMTB 41.9 (30.4) 41.5 (32.2) -0.4 (22.5)  49.8 (31.6) 48.4 (31.6) -1.5 (38.1)  1.0 (-15.2, 17.2) .86 .00  
GDS 1.97 (2) 2.1 (2.4) 0.2 (1.7)  2.2 (2.4) 2.4 (2.4) 0.2 (1.8)  0.1 (-1.0, 0.82) .87 .00  
GAI 2.2 (3.02) 2.5 (3.7) 0.3 (2.2)  2.6 (3.6) 3.4 (4.2) 0.8 (4.3)  -0.5 (-2.3, 1.3) .66 .00  
SF36PF 50.0 (6.9) 49.3 (6.6) -0.7 (5.6)  51.3 (5.9) 49.6 (6.3) -1.7 (4.5)  0.9 (-1.6, 3.5) .51 .00  
SF36BP 50.5 (7.7) 49.9 (7.7) -0.6 (8.7)  52.6 (8.8) 53.8 (6.2) 1.2 (7.9)  -1.8 (-6.2, 2.4) .43 .01  
SF36GH 54.6 (6.8) 55.5 (5.5) 0.9 (5.1)  54.3 (8.1) 54.4 (5.9) 0.1 (8.1)  0.8 (-2.7, 4.2) .90 .00  
SBP 145.9 (15.9) 144.4 (16.7) -1.4 (15.6)  140.2 (21.9) 139.3 (31.8) -0.9 (22.0)  0.5 (-9.3, 10.4) .93 .00  
DBP 83.6 (11.9) 82.0 (13.9) -1.6 (11.7)  80.1 (13.7) 79.0 (12.9) -1.0 (10.6)  0.6 (-5.1, 6.4) .96 .00  
             
Note.      RTot = RBANS Total score,  RIM = RBANS Immediate Memory, RVC = RBANS Visuospatial/Constructional, RL = RBANS Language, RA = RBANS Attention,              
RDM = RBANS Delayed Memory, CRT = Coin Rotation Task, COA = COAST incongruent score, DSF = Digit Span Forward, DSBT = Digit Span Backward Test,        
DSTot = Digit Span Total, TMTB = Trial Making Test B, GDS = Geriatric Depression Scale, GAI = Geriatric Anxiety Inventory, SF36PF = SF-36 Physical functioning, 
SF36BP = SF-36 Bodily pain, SF36GH = SF-36 General health, SBP = Systolic blood pressure, DBP = Diastolic blood pressure   
1 Values are means; SDs in parentheses   2 Values are means; 95% CIs in parentheses   3P values were derived by using ANCOVA (adjusted for age, gender and 





             
